|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
increases expression decreases expression multiple interactions |
ISO EXP |
Lovastatin results in increased expression of ABCA1 mRNA lovastatin decreases expression of ABCA1 mRNA in HepG2 cells [Dietary Fats co-treated with Lovastatin] affects the expression of ABCA1 mRNA Lovastatin results in decreased expression of ABCA1 mRNA |
CTD RGD |
PMID:19260826 PMID:29852127 PMID:27765770 |
RGD:18936994 |
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions decreases activity |
ISO |
Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Lovastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 PMID:24014644 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
increases transport decreases activity multiple interactions |
ISO |
ABCB1 protein results in increased transport of Lovastatin; ABCB1 protein results in increased transport of Lovastatin analog Lovastatin analog results in decreased activity of ABCB1 protein Lovastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] |
CTD |
PMID:15616150 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
decreases activity multiple interactions |
EXP |
Lovastatin results in decreased activity of ABCC1 protein [Lovastatin results in decreased activity of ABCC1 protein] which results in increased susceptibility to Antimony Sodium Gluconate; Doxorubicin inhibits the reaction [Lovastatin results in increased expression of ABCC1 mRNA] |
CTD |
PMID:18056276 PMID:22712078 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
multiple interactions increases expression decreases activity |
ISO |
ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Lovastatin results in increased expression of ABCC2 mRNA Lovastatin analog results in decreased activity of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]; Lovastatin promotes the reaction [Cisplatin results in decreased expression of ABCC2 mRNA] |
CTD |
PMID:15616150 PMID:23562342 PMID:26739623 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
affects expression multiple interactions |
EXP |
Lovastatin affects the expression of ABCG5 mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of ABCG5 mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
affects expression |
EXP |
Lovastatin affects the expression of ABCG8 mRNA |
CTD |
PMID:27208389 |
|
NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACACA mRNA |
CTD |
PMID:29852127 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACOX1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACSS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 2:155,359,963...155,404,663
Ensembl chr 2:155,359,868...155,427,644
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions decreases expression |
ISO |
Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] Lovastatin results in decreased expression of ACTA2 protein |
CTD |
PMID:22129737 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Actb |
actin, beta |
decreases expression increases expression |
EXP |
Lovastatin results in decreased expression of ACTB mRNA Lovastatin results in increased expression of ACTB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509
|
|
G |
Actr3 |
ARP3 actin-related protein 3 |
increases expression |
EXP |
Lovastatin results in increased expression of ACTR3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:125,320,642...125,363,464
Ensembl chr 1:125,320,642...125,363,464
|
|
G |
Adam10 |
a disintegrin and metallopeptidase domain 10 |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of ADAM10 protein [Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein |
CTD |
PMID:29341888 |
|
NCBI chr 9:70,586,133...70,687,511
Ensembl chr 9:70,586,279...70,687,511
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
affects expression multiple interactions |
EXP |
Lovastatin affects the expression of ADIPOQ mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of ADIPOQ mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Ahcy |
S-adenosylhomocysteine hydrolase |
decreases expression |
EXP |
Lovastatin results in decreased expression of AHCY mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:154,901,230...154,916,417
Ensembl chr 2:154,901,230...154,916,417
|
|
G |
Akap7 |
A kinase anchor protein 7 |
decreases response to substance |
ISO |
AKAP7 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr10:25,044,988...25,175,115
Ensembl chr10:25,044,988...25,183,768
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions decreases phosphorylation |
ISO |
Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of AKT1 protein] Lovastatin results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16425225 PMID:17472962 PMID:19760159 PMID:20578043 PMID:35734936 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased activity of ALOX15 protein] |
CTD |
PMID:35734936 |
|
NCBI chr11:70,234,973...70,279,465
Ensembl chr11:70,234,978...70,242,857
|
|
G |
Ank2 |
ankyrin 2, brain |
decreases response to substance |
ISO |
ANK2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 3:126,715,256...127,293,996
Ensembl chr 3:126,715,261...127,292,999
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
EXP |
Lovastatin results in decreased expression of ANXA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:86,713,822...86,770,616
Ensembl chr 6:86,713,822...86,770,566
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
EXP |
Lovastatin results in decreased expression of ANXA5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:36,503,072...36,530,036
Ensembl chr 3:36,503,072...36,530,043
|
|
G |
Apoa1 |
apolipoprotein A-I |
multiple interactions |
ISO |
[Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein; [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein |
CTD |
PMID:12633795 PMID:17319473 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Apob |
apolipoprotein B |
multiple interactions decreases secretion |
ISO |
[Niacin co-treated with Lovastatin] results in decreased expression of APOB protein Lovastatin results in decreased secretion of APOB protein |
CTD |
PMID:11728391 PMID:12633795 |
|
NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835
|
|
G |
Apoe |
apolipoprotein E |
affects expression multiple interactions |
EXP |
Lovastatin affects the expression of APOE mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of APOE mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases cleavage increases secretion |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; TAPI-2 inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; U 0126 inhibits the reaction [Lovastatin results in increased secretion of APP protein] [APP protein co-treated with Lovastatin] results in increased secretion of APP protein; [Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein; [Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein; [Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein; [Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[APP protein co-treated with Lovastatin] results in increased secretion of APP protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein] Lovastatin results in increased cleavage of APP protein Lovastatin results in increased secretion of APP protein; Lovastatin results in increased secretion of APP protein modified form |
CTD |
PMID:19741129 PMID:29341888 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
EXP |
Lovastatin results in increased expression of ARHGDIA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:120,468,925...120,472,450
Ensembl chr11:120,468,930...120,472,450
|
|
G |
Atm |
ataxia telangiectasia mutated |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATM protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040
|
|
G |
Atr |
ataxia telangiectasia and Rad3 related |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATR protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr 9:95,739,655...95,834,813
Ensembl chr 9:95,739,650...95,833,834
|
|
G |
Bace1 |
beta-site APP cleaving enzyme 1 |
multiple interactions decreases expression |
ISO |
[Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein Lovastatin results in decreased expression of BACE1 protein |
CTD |
PMID:29341888 |
|
NCBI chr 9:45,749,878...45,775,694
Ensembl chr 9:45,749,878...45,775,697
|
|
G |
Bace2 |
beta-site APP-cleaving enzyme 2 |
multiple interactions increases expression |
ISO |
[Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein Lovastatin results in increased expression of BACE2 protein |
CTD |
PMID:29341888 |
|
NCBI chr16:97,157,928...97,244,136
Ensembl chr16:97,157,942...97,244,136
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions affects localization |
ISO EXP |
Lovastatin results in increased expression of BAX protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BAX protein]; Lovastatin promotes the reaction [Cisplatin results in increased expression of BAX mRNA] Lovastatin affects the localization of BAX protein |
CTD |
PMID:10473109 PMID:15180944 PMID:26739623 PMID:35734936 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcar1 |
breast cancer anti-estrogen resistance 1 |
increases cleavage multiple interactions |
ISO |
Lovastatin results in increased cleavage of BCAR1 protein Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of BCAR1 protein] |
CTD |
PMID:16367743 |
|
NCBI chr 8:112,437,106...112,470,481
Ensembl chr 8:112,437,106...112,470,441
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression multiple interactions |
ISO |
Lovastatin results in decreased expression of BCL2 protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of BCL2 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] |
CTD |
PMID:10473109 PMID:11178870 PMID:12094262 PMID:35734936 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression multiple interactions |
ISO |
Lovastatin results in decreased expression of BCL2L1 protein Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2L1 protein] |
CTD |
PMID:11178870 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions increases expression |
ISO |
pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BCL2L11 protein] |
CTD |
PMID:18766339 PMID:35734936 |
|
NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein] |
CTD |
PMID:24718106 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
farnesyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein] |
CTD |
PMID:17472962 PMID:18815881 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Brca2 |
breast cancer 2, early onset |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of BRCA2 mRNA] |
CTD |
PMID:22712078 |
|
NCBI chr 5:150,445,759...150,493,612
Ensembl chr 5:150,446,095...150,493,794
|
|
G |
C1qbp |
complement component 1, q subcomponent binding protein |
increases expression |
EXP |
Lovastatin results in increased expression of C1QBP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:70,868,672...70,873,852
Ensembl chr11:70,868,662...70,873,852
|
|
G |
Calr |
calreticulin |
increases expression |
EXP |
Lovastatin results in increased expression of CALR mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II, beta |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr11:5,919,642...6,016,401
Ensembl chr11:5,919,644...6,016,362
|
|
G |
Casp2 |
caspase 2 |
increases activity multiple interactions |
ISO EXP |
Lovastatin results in increased activity of CASP2 protein Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein] |
CTD |
PMID:12933658 PMID:16234849 |
|
NCBI chr 6:42,241,942...42,259,442
Ensembl chr 6:42,241,919...42,259,442
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity decreases expression |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein] Lovastatin analog results in increased cleavage of CASP3 protein Lovastatin results in increased activity of CASP3 protein Lovastatin results in decreased expression of CASP3 mRNA Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CASP3 protein]; Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein] |
CTD |
PMID:11720884 PMID:12933658 PMID:15180944 PMID:16367743 PMID:18034278 PMID:18766339 PMID:20493250 PMID:26863638 PMID:35734936 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp6 |
caspase 6 |
increases activity |
ISO |
Lovastatin results in increased activity of CASP6 protein |
CTD |
PMID:11720884 |
|
NCBI chr 3:129,695,064...129,707,761
Ensembl chr 3:129,695,074...129,707,752
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO EXP |
Lovastatin results in increased activity of CASP8 protein |
CTD |
PMID:15180944 PMID:15705602 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
EXP ISO |
Lovastatin results in increased activity of CASP9 protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of CASP9 protein] |
CTD |
PMID:12933658 PMID:15180944 PMID:15705602 PMID:35734936 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased activity of CAT protein] |
CTD |
PMID:35734936 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]; Lovastatin inhibits the reaction [Epirubicin results in increased expression of CCN2 mRNA] |
CTD |
PMID:22712078 PMID:28710503 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of CCND1 protein Lovastatin results in increased expression of CCND1 mRNA; Lovastatin results in increased expression of CCND1 protein |
CTD |
PMID:18034278 PMID:20578043 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CCND3 protein |
CTD |
PMID:10502407 |
|
NCBI chr17:47,815,976...47,910,614
Ensembl chr17:47,815,976...47,910,616
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
increases expression |
EXP |
Lovastatin results in increased expression of CCT5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:31,590,946...31,601,992
Ensembl chr15:31,590,946...31,601,950
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
increases expression |
EXP |
Lovastatin results in increased expression of CCT6A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:129,864,420...129,875,284
Ensembl chr 5:129,864,062...129,875,212
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
decreases expression |
EXP |
Lovastatin results in decreased expression of CCT8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr16:87,280,213...87,292,757
Ensembl chr16:87,280,214...87,292,761
|
|
G |
Cd40 |
CD40 antigen |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868
|
|
G |
Cd44 |
CD44 antigen |
decreases expression |
ISO |
Lovastatin results in decreased expression of CD44 mRNA; Lovastatin results in decreased expression of CD44 protein |
CTD |
PMID:21199873 |
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression decreases expression |
ISO EXP |
Lovastatin results in increased expression of CDC42 protein Lovastatin results in decreased expression of CDC42 mRNA |
CTD |
PMID:18766339 PMID:20493250 |
|
NCBI chr 4:137,047,011...137,085,007
Ensembl chr 4:137,047,007...137,085,031
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity |
ISO |
Lovastatin results in decreased activity of CDK2 protein |
CTD |
PMID:10502407 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdk4 |
cyclin dependent kinase 4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CDK4 mRNA; Lovastatin results in decreased expression of CDK4 protein |
CTD |
PMID:20578043 |
|
NCBI chr10:126,899,404...126,903,157
Ensembl chr10:126,899,403...126,903,789
|
|
G |
Cdk5 |
cyclin dependent kinase 5 |
decreases cleavage |
ISO |
Lovastatin results in decreased cleavage of CDK5 protein |
CTD |
PMID:19741129 |
|
NCBI chr 5:24,612,595...24,628,737
Ensembl chr 5:24,623,239...24,628,528
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO EXP |
Lovastatin results in increased expression of CDKN1A protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA] |
CTD |
PMID:18034278 PMID:22712078 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
increases expression |
ISO |
Lovastatin results in increased expression of CDKN1B mRNA; Lovastatin results in increased expression of CDKN1B protein |
CTD |
PMID:9848777 PMID:10502407 PMID:15118409 PMID:18034278 PMID:20578043 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn3 |
cyclin dependent kinase inhibitor 3 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of CDKN3 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr14:46,997,912...47,008,987
Ensembl chr14:46,997,998...47,009,126
|
|
G |
Cenpf |
centromere protein F |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of CENPF protein Lovastatin promotes the reaction [Paclitaxel results in increased expression of CENPF protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of CENPF protein] |
CTD |
PMID:12467231 |
|
NCBI chr 1:189,372,803...189,420,302
Ensembl chr 1:189,372,803...189,420,283
|
|
G |
Cfl1 |
cofilin 1, non-muscle |
decreases phosphorylation |
ISO |
Lovastatin results in decreased phosphorylation of CFL1 protein |
CTD |
PMID:20578043 |
|
NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of CHEK1 protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of CHEK1 protein] Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK1 protein modified form] |
CTD |
PMID:17088865 PMID:21356574 PMID:26739623 |
|
NCBI chr 9:36,619,935...36,637,897
Ensembl chr 9:36,619,778...36,638,361
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK2 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr 5:110,987,668...111,022,006
Ensembl chr 5:110,987,845...111,022,011
|
|
G |
Chrna7 |
cholinergic receptor, nicotinic, alpha polypeptide 7 |
multiple interactions increases expression |
ISO |
[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein] Lovastatin results in increased expression of CHRNA7 mRNA; Lovastatin results in increased expression of CHRNA7 protein U 0126 inhibits the reaction [Lovastatin results in increased expression of CHRNA7 protein] |
CTD |
PMID:29341888 |
|
NCBI chr 7:62,748,440...62,862,274
Ensembl chr 7:62,748,440...62,862,317
|
|
G |
Clic1 |
chloride intracellular channel 1 |
decreases expression |
EXP |
Lovastatin results in decreased expression of CLIC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:35,269,219...35,277,695
Ensembl chr17:35,268,942...35,277,725
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
increases expression |
EXP |
Lovastatin results in increased expression of COX5A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:57,423,012...57,439,710
Ensembl chr 9:57,428,557...57,439,709
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CP protein] |
CTD |
PMID:35734936 |
|
NCBI chr 3:20,011,097...20,063,914
Ensembl chr 3:20,011,218...20,063,309
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crk |
v-crk avian sarcoma virus CT10 oncogene homolog |
increases expression |
EXP |
Lovastatin results in increased expression of CRK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:75,570,020...75,599,254
Ensembl chr11:75,570,085...75,597,734
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CRP protein] |
CTD |
PMID:35734936 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases degradation increases expression multiple interactions |
ISO EXP |
Lovastatin results in decreased degradation of CTNNB1 protein Lovastatin results in increased expression of CTNNB1 mRNA Lovastatin affects the localization of and results in increased expression of CTNNB1 protein |
CTD |
PMID:17234346 PMID:19741129 PMID:24742230 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CYP1A1 mRNA]; Lovastatin results in increased expression of and results in increased activity of CYP1A1 protein Lovastatin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:1311272 PMID:22712078 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Lovastatin results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp2c29 |
cytochrome P450, family 2, subfamily c, polypeptide 29 |
decreases activity |
ISO |
Lovastatin results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157
|
|
G |
Dctn2 |
dynactin 2 |
decreases expression |
EXP |
Lovastatin results in decreased expression of DCTN2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:127,102,131...127,117,828
Ensembl chr10:127,102,237...127,117,819
|
|
G |
Ddt |
D-dopachrome tautomerase |
decreases expression |
EXP |
Lovastatin results in decreased expression of DDT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:75,607,067...75,609,208
Ensembl chr10:75,607,064...75,609,248
|
|
G |
Dlg3 |
discs large MAGUK scaffold protein 3 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein] |
CTD |
PMID:24718106 |
|
NCBI chr X:99,811,200...99,862,016
Ensembl chr X:99,811,328...99,862,016
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
decreases expression |
EXP |
Lovastatin results in decreased expression of DLST mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:85,157,597...85,180,865
Ensembl chr12:85,157,607...85,181,619
|
|
G |
Dock7 |
dedicator of cytokinesis 7 |
increases expression |
EXP |
Lovastatin results in increased expression of DOCK7 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:98,824,669...99,019,190
Ensembl chr 4:98,824,908...99,009,152
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
EXP |
Lovastatin results in increased expression of DPYSL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:67,040,313...67,148,490
Ensembl chr14:67,040,313...67,106,137
|
|
G |
Dstn |
destrin |
decreases expression |
EXP |
Lovastatin results in decreased expression of DSTN mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:143,757,251...143,785,244
Ensembl chr 2:143,757,240...143,785,244
|
|
G |
Eaf2 |
ELL associated factor 2 |
decreases response to substance |
ISO |
EAF2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr16:36,613,246...36,695,275
Ensembl chr16:36,613,246...36,695,365
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
EXP |
Lovastatin results in decreased expression of EEF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:81,012,465...81,018,343
Ensembl chr10:81,012,465...81,018,332
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:12942316 PMID:19760159 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:12942316 PMID:19760159 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Eif3i |
eukaryotic translation initiation factor 3, subunit I |
decreases expression |
EXP |
Lovastatin results in decreased expression of EIF3I mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:129,485,767...129,494,441
Ensembl chr 4:129,485,753...129,494,441
|
|
G |
Ercc1 |
excision repair cross-complementing rodent repair deficiency, complementation group 1 |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of ERCC1 mRNA Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC1 mRNA] |
CTD |
PMID:26739623 |
|
NCBI chr 7:19,079,016...19,090,449
Ensembl chr 7:19,078,703...19,090,449
|
|
G |
Ercc5 |
excision repair cross-complementing rodent repair deficiency, complementation group 5 |
multiple interactions increases expression |
ISO |
Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC5 mRNA] Lovastatin results in increased expression of ERCC5 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 1:44,184,084...44,220,399
Ensembl chr 1:44,186,904...44,220,420
|
|
G |
Ercc6 |
excision repair cross-complementing rodent repair deficiency, complementation group 6 |
increases expression |
ISO |
Lovastatin results in increased expression of ERCC6 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr14:32,235,248...32,302,947
Ensembl chr14:32,235,478...32,302,947
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
decreases expression |
EXP |
Lovastatin results in decreased expression of ERP29 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:121,582,816...121,590,537
Ensembl chr 5:121,566,653...121,590,569
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of FADS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FAS mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of FAS protein] |
CTD |
PMID:17088865 PMID:35734936 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fasl |
Fas ligand |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FASLG mRNA] |
CTD |
PMID:17088865 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Lovastatin results in increased expression of FASN mRNA |
CTD |
PMID:11728391 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions increases expression |
EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein]; Lovastatin promotes the reaction [Fenofibrate results in increased expression of FBXO32 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein] Lovastatin results in increased expression of FBXO32 mRNA; Lovastatin results in increased expression of FBXO32 protein |
CTD |
PMID:19406843 PMID:33408297 |
|
NCBI chr15:58,039,275...58,078,288
Ensembl chr15:58,039,275...58,078,328
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases activity |
ISO |
Lovastatin results in increased activity of FDFT1 protein |
CTD |
PMID:8517861 |
|
NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027
|
|
G |
Fdps |
farnesyl diphosphate synthetase |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of FDPS mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 3:89,000,895...89,009,274
Ensembl chr 3:89,000,895...89,009,266
|
|
G |
Flot1 |
flotillin 1 |
decreases expression |
EXP |
Lovastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr17:36,134,243...36,143,674
Ensembl chr17:36,134,122...36,143,683
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
affects expression multiple interactions decreases expression |
ISO EXP |
Lovastatin affects the expression of FOS protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FOS mRNA] Lovastatin results in decreased expression of FOS |
CTD |
PMID:10412747 PMID:12392621 PMID:22712078 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Fosb |
FBJ osteosarcoma oncogene B |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased expression of FOSB protein] |
CTD |
PMID:18434508 |
|
NCBI chr 7:19,036,621...19,043,970
Ensembl chr 7:19,036,621...19,043,976
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions decreases phosphorylation |
EXP |
Lovastatin promotes the reaction [Fenofibrate results in increased expression of FOXO1 protein] Lovastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 PMID:33408297 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
decreases expression |
EXP |
Lovastatin results in decreased expression of FSCN1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:142,946,110...142,958,944
Ensembl chr 5:142,946,098...142,958,940
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
increases expression |
EXP |
Lovastatin results in increased expression of G3BP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:55,360,521...55,391,722
Ensembl chr11:55,360,511...55,395,664
|
|
G |
G6pdx |
glucose-6-phosphate dehydrogenase X-linked |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of G6PD mRNA |
CTD |
PMID:29852127 |
|
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
|
|
G |
Gale |
galactose-4-epimerase, UDP |
decreases expression |
EXP |
Lovastatin results in decreased expression of GALE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:135,690,550...135,695,489
Ensembl chr 4:135,691,038...135,695,489
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
EXP ISO |
Lovastatin results in increased expression of GAP43 protein |
CTD |
PMID:20694854 |
|
NCBI chr16:42,068,915...42,161,014
Ensembl chr16:42,068,805...42,161,014
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
increases expression |
EXP |
Lovastatin results in increased expression of GDI2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr13:3,588,075...3,616,261
Ensembl chr13:3,588,063...3,617,871
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of GK mRNA |
CTD |
PMID:29852127 |
|
NCBI chr X:84,745,543...84,820,425
Ensembl chr X:84,745,543...84,820,425
|
|
G |
Gmps |
guanine monophosphate synthetase |
increases expression |
EXP |
Lovastatin results in increased expression of GMPS mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:63,871,054...63,928,975
Ensembl chr 3:63,883,527...63,930,000
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
EXP |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; Lovastatin inhibits the reaction [Dietary Fats results in increased expression of GPT protein] |
CTD |
PMID:29852127 PMID:30853469 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of GPX1 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Grin2b |
glutamate receptor, ionotropic, NMDA2B (epsilon 2) |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr 6:135,690,219...136,150,658
Ensembl chr 6:135,690,231...136,150,509
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation increases phosphorylation |
ISO |
Lovastatin results in decreased phosphorylation of GSK3B protein Lovastatin results in increased phosphorylation of GSK3B protein |
CTD |
PMID:17234346 PMID:19741129 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein] Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form] Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of H2AX protein] |
CTD |
PMID:21356574 PMID:22712078 PMID:26739623 PMID:28710503 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
Hdac1 |
histone deacetylase 1 |
increases expression |
EXP |
Lovastatin results in increased expression of HDAC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:129,409,897...129,436,516
Ensembl chr 4:129,409,897...129,436,506
|
|
G |
Hint1 |
histidine triad nucleotide binding protein 1 |
increases expression |
EXP |
Lovastatin results in increased expression of HINT1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:54,757,209...54,761,332
Ensembl chr11:54,757,209...54,761,327
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
multiple interactions affects expression decreases activity increases expression |
ISO EXP |
[Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of farnesyl pyrophosphate; [Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of geranylgeranyl pyrophosphate; Lovastatin inhibits the reaction [HMGCR protein results in increased abundance of geranyl diphosphate] [Dietary Fats co-treated with Lovastatin] affects the expression of HMGCR mRNA Lovastatin affects the expression of HMGCR mRNA Lovastatin results in increased expression of HMGCR mRNA |
CTD |
PMID:8517861 PMID:8593127 PMID:17208200 PMID:19260826 PMID:19699819 PMID:19856009 PMID:27208389 PMID:29852127 More...
|
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of HMGCS1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Lovastatin results in increased expression of HMOX1 protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:20594940 PMID:21910007 PMID:28710503 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hnrnpab |
heterogeneous nuclear ribonucleoprotein A/B |
increases expression |
EXP |
Lovastatin results in increased expression of HNRNPAB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:51,490,927...51,497,708
Ensembl chr11:51,490,927...51,497,674
|
|
G |
Hnrnpdl |
heterogeneous nuclear ribonucleoprotein D-like |
decreases expression |
EXP |
Lovastatin results in decreased expression of HNRNPDL mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:100,181,436...100,187,769
Ensembl chr 5:100,181,436...100,187,523
|
|
G |
Hnrnpf |
heterogeneous nuclear ribonucleoprotein F |
increases expression |
EXP |
Lovastatin results in increased expression of HNRNPF mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:117,877,301...117,902,583
Ensembl chr 6:117,877,285...117,902,583
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
decreases expression increases expression |
EXP |
Lovastatin results in decreased expression of HNRNPK mRNA Lovastatin results in increased expression of HNRNPK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr13:58,538,946...58,551,157
Ensembl chr13:58,538,956...58,551,157
|
|
G |
Hras |
Harvey rat sarcoma virus oncogene |
decreases prenylation multiple interactions |
ISO |
Lovastatin results in decreased prenylation of HRAS protein Lovastatin results in decreased prenylation of and results in decreased localization of HRAS protein |
CTD |
PMID:16156861 PMID:19360310 |
|
NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha (cytosolic), class B member 1 |
decreases expression |
EXP |
Lovastatin results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197
|
|
G |
Hspa8 |
heat shock protein 8 |
increases expression |
EXP |
Lovastatin results in increased expression of HSPA8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
increases expression |
EXP |
Lovastatin results in increased expression of HSPD1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases response to substance |
EXP |
IGF1 protein results in decreased susceptibility to Lovastatin |
CTD |
PMID:9525472 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Igf1r |
insulin-like growth factor I receptor |
multiple interactions |
ISO |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein] |
CTD |
PMID:19741129 |
|
NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein] |
CTD |
PMID:21430599 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein] |
CTD |
PMID:18809656 PMID:21430599 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of IL6 protein] |
CTD |
PMID:28710503 PMID:35734936 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins2 |
insulin II |
multiple interactions |
ISO |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein]; Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:19741129 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression multiple interactions |
ISO EXP |
Lovastatin results in increased expression of INSIG1 mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of INSIG1 mRNA |
CTD |
PMID:19260826 PMID:29852127 |
|
NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660
|
|
G |
Insig2 |
insulin induced gene 2 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of INSIG2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 1:121,232,082...121,260,391
Ensembl chr 1:121,232,082...121,260,318
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:19741129 |
|
NCBI chr 8:3,200,922...3,329,649
Ensembl chr 8:3,172,061...3,329,617
|
|
G |
Ipo5 |
importin 5 |
decreases expression |
EXP |
Lovastatin results in decreased expression of IPO5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:121,134,271...121,185,451
Ensembl chr14:121,148,636...121,185,411
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
EXP |
Lovastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr13:30,933,191...30,950,965
Ensembl chr13:30,933,209...30,950,959
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of IRS1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of IRS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458
|
|
G |
Isyna1 |
myo-inositol 1-phosphate synthase A1 |
increases expression |
EXP |
Lovastatin results in increased expression of ISYNA1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:71,047,131...71,049,940
Ensembl chr 8:71,047,023...71,049,940
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
decreases expression |
EXP |
Lovastatin results in decreased expression of ITGB1 protein |
CTD |
PMID:12405293 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Jun |
jun proto-oncogene |
affects expression multiple interactions decreases expression |
ISO EXP |
Lovastatin affects the expression of JUN protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of JUN mRNA] Lovastatin results in decreased expression of JUN |
CTD |
PMID:10412747 PMID:12392621 PMID:22712078 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
affects activity |
ISO |
Lovastatin affects the activity of KCNH2 protein |
CTD |
PMID:16278312 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kras |
Kirsten rat sarcoma viral oncogene homolog |
decreases prenylation increases expression affects localization increases activity |
ISO EXP |
Lovastatin results in decreased prenylation of KRAS protein Lovastatin results in increased expression of KRAS protein Lovastatin affects the localization of KRAS protein Lovastatin results in increased activity of KRAS protein |
CTD |
PMID:12106604 PMID:12907238 PMID:16156861 PMID:17005160 |
|
NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965
|
|
G |
Krt18 |
keratin 18 |
decreases expression |
EXP |
Lovastatin results in decreased expression of KRT18 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:101,936,651...101,940,461
Ensembl chr15:101,936,615...101,940,462
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
decreases expression |
EXP |
Lovastatin results in decreased expression of LASP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:97,689,748...97,729,591
Ensembl chr11:97,689,826...97,729,590
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases activity increases expression |
ISO EXP |
OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA] [Dietary Fats co-treated with Lovastatin] affects the expression of LDLR mRNA [Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA] Lovastatin results in increased activity of LDLR protein |
CTD |
PMID:8593127 PMID:11728391 PMID:12524230 PMID:20578043 PMID:29852127 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
affects localization |
ISO |
Lovastatin affects the localization of LEF1 protein |
CTD |
PMID:17234346 |
|
NCBI chr 3:130,903,972...131,018,006
Ensembl chr 3:130,904,120...131,018,005
|
|
G |
Lipc |
lipase, hepatic |
affects expression |
EXP |
Lovastatin affects the expression of LIPC mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508
|
|
G |
Lmnb1 |
lamin B1 |
decreases farnesylation increases degradation affects localization |
ISO |
Lovastatin results in decreased farnesylation of LMNB1 protein Lovastatin results in increased degradation of LMNB1 protein Lovastatin affects the localization of LMNB1 protein |
CTD |
PMID:10203554 PMID:11720884 |
|
NCBI chr18:56,840,885...56,886,496
Ensembl chr18:56,840,885...56,886,496
|
|
G |
Lpin2 |
lipin 2 |
decreases response to substance |
ISO |
LPIN2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr17:71,490,527...71,556,813
Ensembl chr17:71,489,555...71,556,812
|
|
G |
Lpl |
lipoprotein lipase |
affects expression multiple interactions |
EXP |
Lovastatin affects the expression of LPL mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of LPL mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Lrp5 |
low density lipoprotein receptor-related protein 5 |
increases expression |
EXP |
Lovastatin results in increased expression of LRP5 mRNA |
CTD |
PMID:24742230 |
|
NCBI chr19:3,634,825...3,736,574
Ensembl chr19:3,634,828...3,736,564
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation decreases activity decreases phosphorylation |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK1 protein] Lovastatin results in decreased activity of MAPK1 protein [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12213976 PMID:16952276 PMID:19360310 PMID:19760159 PMID:20578043 PMID:24718106 PMID:29341888 More...
|
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation decreases activity decreases phosphorylation |
ISO |
[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein] Lovastatin results in increased phosphorylation of MAPK3 protein Lovastatin results in decreased activity of MAPK3 protein Lovastatin results in decreased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased phosphorylation of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16952276 PMID:18434508 PMID:19360310 PMID:19760159 PMID:20578043 PMID:24718106 PMID:29341888 More...
|
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK8 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK9 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mbp |
myelin basic protein |
multiple interactions increases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA] |
CTD |
PMID:20578043 |
|
NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MFN2 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 4:147,958,043...147,989,527
Ensembl chr 4:147,958,056...147,989,161
|
|
G |
Mir133b |
microRNA 133b |
multiple interactions |
EXP |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 1:20,752,993...20,753,111
Ensembl chr 1:20,752,993...20,753,111
|
|
G |
Mir206 |
microRNA 206 |
multiple interactions |
EXP |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 1:20,749,234...20,749,306
Ensembl chr 1:20,749,234...20,749,306
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of MMP2 protein |
CTD |
PMID:19360310 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MMP3 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
ISO |
Lovastatin results in decreased expression of MMP9 protein |
CTD |
PMID:19360310 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MPO protein] |
CTD |
PMID:35734936 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mstn |
myostatin |
increases expression |
EXP |
Lovastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 1:53,100,799...53,107,238
Ensembl chr 1:53,100,799...53,107,238
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
EXP |
Doxorubicin inhibits the reaction [Lovastatin results in increased expression of NFE2L2 mRNA]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:22712078 PMID:28710503 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nmral1 |
NmrA-like family domain containing 1 |
increases expression |
EXP |
Lovastatin results in increased expression of NMRAL1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr16:4,529,181...4,537,220
Ensembl chr16:4,527,923...4,537,220
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP ISO |
Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein] |
CTD |
PMID:18809656 PMID:35734936 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nppa |
natriuretic peptide type A |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NPPA mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
increases expression |
EXP |
Lovastatin results in increased expression of NQO1 mRNA |
CTD |
PMID:1311272 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nras |
neuroblastoma ras oncogene |
decreases prenylation |
ISO |
Lovastatin results in decreased prenylation of NRAS protein |
CTD |
PMID:16156861 |
|
NCBI chr 3:102,965,643...102,975,230
Ensembl chr 3:102,965,601...102,975,230
|
|
G |
Nucb1 |
nucleobindin 1 |
increases expression |
EXP |
Lovastatin results in increased expression of NUCB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:45,142,300...45,159,813
Ensembl chr 7:45,139,882...45,159,830
|
|
G |
Oat |
ornithine aminotransferase |
decreases expression |
EXP |
Lovastatin results in decreased expression of OAT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:132,159,204...132,178,127
Ensembl chr 7:132,159,207...132,178,127
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA] |
CTD |
PMID:12524230 |
|
NCBI chr11:4,186,831...4,191,027
Ensembl chr11:4,186,420...4,191,026
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
increases expression |
EXP |
Lovastatin results in increased expression of PA2G4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:128,393,635...128,401,803
Ensembl chr10:128,393,635...128,401,856
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases cleavage |
ISO |
Lovastatin analog results in increased cleavage of PARP1 protein |
CTD |
PMID:26863638 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Parvb |
parvin, beta |
decreases response to substance |
ISO |
PARVB SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr15:84,116,244...84,199,890
Ensembl chr15:84,116,244...84,199,889
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1, cytosolic |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of PCK1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
|
|
G |
Pdgfra |
platelet derived growth factor receptor, alpha polypeptide |
decreases expression |
ISO |
Lovastatin results in decreased expression of PDGFRA mRNA |
CTD |
PMID:20578043 |
|
NCBI chr 5:75,311,988...75,358,867
Ensembl chr 5:75,312,953...75,358,876
|
|
G |
Pdia3 |
protein disulfide isomerase associated 3 |
decreases expression increases expression |
EXP |
Lovastatin results in decreased expression of PDIA3 mRNA Lovastatin results in increased expression of PDIA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:121,244,383...121,269,168
Ensembl chr 2:121,244,256...121,269,168
|
|
G |
Pdia4 |
protein disulfide isomerase associated 4 |
decreases expression |
EXP |
Lovastatin results in decreased expression of PDIA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:47,773,075...47,790,446
Ensembl chr 6:47,773,075...47,790,364
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
increases expression decreases expression |
EXP |
Lovastatin results in increased expression of PGAM1 mRNA Lovastatin results in decreased expression of PGAM1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:41,900,310...41,907,104
Ensembl chr19:41,900,362...41,907,099
|
|
G |
Pkm |
pyruvate kinase, muscle |
decreases expression |
EXP |
Lovastatin results in decreased expression of PKM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:59,563,859...59,586,655
Ensembl chr 9:59,563,651...59,586,658
|
|
G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
increases expression |
ISO |
Lovastatin results in increased expression of PLA2G4A mRNA |
CTD |
PMID:20578043 |
|
NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041
|
|
G |
Plat |
plasminogen activator, tissue |
multiple interactions increases secretion increases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PLAT protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PLAT protein] Lovastatin results in increased secretion of PLAT protein |
CTD |
PMID:10412747 PMID:12405293 |
|
NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases secretion |
EXP |
Lovastatin results in decreased secretion of PLAU protein |
CTD |
PMID:12405293 |
|
NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453
|
|
G |
Pon3 |
paraoxonase 3 |
increases hydrolysis increases metabolic processing multiple interactions |
ISO EXP |
PON3 protein results in increased hydrolysis of Lovastatin PON3 protein results in increased metabolism of Lovastatin 7-ketocholesterol inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]; Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin] |
CTD |
PMID:12615656 PMID:15772423 |
|
NCBI chr 6:5,216,253...5,256,236
Ensembl chr 6:5,220,852...5,256,286
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions affects localization increases expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein] geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; Lovastatin results in increased expression of and affects the localization of PPARG protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] [Dietary Fats co-treated with Lovastatin] affects the expression of PPARG mRNA; PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein] |
CTD |
PMID:16425225 PMID:20578043 PMID:26863638 PMID:29852127 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
decreases expression |
EXP |
Lovastatin results in decreased expression of PPP1CA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:4,242,173...4,245,418
Ensembl chr19:4,242,064...4,245,419
|
|
G |
Ppp2r1a |
protein phosphatase 2, regulatory subunit A, alpha |
increases expression |
EXP |
Lovastatin results in increased expression of PPP2R1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:21,165,716...21,186,167
Ensembl chr17:21,165,573...21,186,178
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions increases cleavage |
ISO |
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein] |
CTD |
PMID:16367743 |
|
NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167
|
|
G |
Psma3 |
proteasome subunit alpha 3 |
decreases expression |
EXP |
Lovastatin results in decreased expression of PSMA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:71,016,082...71,042,651
Ensembl chr12:71,021,395...71,043,121
|
|
G |
Psma6 |
proteasome subunit alpha 6 |
decreases expression |
EXP |
Lovastatin results in decreased expression of PSMA6 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:55,431,007...55,465,244
Ensembl chr12:55,431,007...55,465,239
|
|
G |
Psmc2 |
proteasome (prosome, macropain) 26S subunit, ATPase 2 |
decreases expression |
EXP |
Lovastatin results in decreased expression of PSMC2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:21,990,273...22,008,785
Ensembl chr 5:21,990,281...22,008,785
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; Lovastatin results in increased expression of and results in increased phosphorylation of PTEN protein; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein] |
CTD |
PMID:16425225 PMID:20578043 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression increases expression multiple interactions |
ISO |
Lovastatin results in decreased expression of PTGS2 protein Lovastatin analog results in increased expression of PTGS2 mRNA; Lovastatin analog results in increased expression of PTGS2 protein Mevalonic Acid affects the reaction [Lovastatin analog results in increased expression of PTGS2 protein] Lovastatin results in increased expression of PTGS2 mRNA; Lovastatin results in increased expression of PTGS2 protein |
CTD |
PMID:20578043 PMID:21910007 PMID:26863638 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rab1a |
RAB1A, member RAS oncogene family |
decreases expression |
EXP |
Lovastatin results in decreased expression of RAB1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:20,151,412...20,176,856
Ensembl chr11:20,151,432...20,176,856
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions affects localization decreases activity increases expression |
ISO |
geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RAC1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RAC1 protein] Lovastatin results in decreased activity of RAC1 protein Lovastatin results in increased expression of RAC1 protein |
CTD |
PMID:12933658 PMID:18766339 PMID:19360310 PMID:21356574 |
|
NCBI chr 5:143,491,236...143,513,786
Ensembl chr 5:143,489,389...143,513,791
|
|
G |
Raf1 |
v-raf-leukemia viral oncogene 1 |
multiple interactions decreases activity |
ISO |
Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein] Lovastatin results in decreased activity of RAF1 protein |
CTD |
PMID:19360310 PMID:19760159 |
|
NCBI chr 6:115,595,530...115,653,596
Ensembl chr 6:115,595,028...115,653,596
|
|
G |
Rap1a |
RAS-related protein 1a |
increases expression |
ISO |
Lovastatin results in increased expression of RAP1A protein |
CTD |
PMID:12467231 |
|
NCBI chr 3:105,634,576...105,708,740
Ensembl chr 3:105,634,583...105,708,652
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
Lovastatin results in decreased phosphorylation of RB1 protein |
CTD |
PMID:9848777 PMID:10502407 PMID:15118409 |
|
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions decreases expression decreases prenylation affects localization |
ISO EXP |
geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RHOA protein] Lovastatin results in decreased geranoylation of and affects the localization of RHOA protein Lovastatin results in decreased expression of RHOA mRNA Lovastatin results in decreased prenylation of RHOA protein Farnesol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein] |
CTD |
PMID:9398081 PMID:11178870 PMID:12405293 PMID:12933658 PMID:16156861 PMID:20493250 PMID:20578043 More...
|
|
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Rhob |
ras homolog family member B |
decreases prenylation multiple interactions increases expression |
ISO EXP |
Lovastatin results in decreased prenylation of RHOB protein Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein] Lovastatin results in increased expression of RHOB protein |
CTD |
PMID:12467231 PMID:16156861 PMID:16234849 |
|
NCBI chr12:8,547,661...8,550,009
Ensembl chr12:8,547,661...8,550,009
|
|
G |
Rpl27 |
ribosomal protein L27 |
increases expression |
EXP |
Lovastatin results in increased expression of RPL27 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:101,333,071...101,336,422
Ensembl chr11:101,333,124...101,336,355
|
|
G |
Rpl9 |
ribosomal protein L9 |
increases expression |
EXP |
Lovastatin results in increased expression of RPL9 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:65,545,707...65,548,774
Ensembl chr 5:65,545,707...65,548,787
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
increases expression |
EXP |
Lovastatin results in increased expression of RPLP0 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:115,697,526...115,701,788
Ensembl chr 5:115,697,526...115,701,786
|
|
G |
Rpsa |
ribosomal protein SA |
increases expression |
EXP |
Lovastatin results in increased expression of RPSA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:119,956,832...119,961,435
Ensembl chr 9:119,956,755...119,961,435
|
|
G |
Ruvbl2 |
RuvB-like AAA ATPase 2 |
decreases expression |
EXP |
Lovastatin results in decreased expression of RUVBL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:45,071,320...45,084,817
Ensembl chr 7:45,071,184...45,087,520
|
|
G |
S100a8 |
S100 calcium binding protein A8 (calgranulin A) |
multiple interactions |
EXP |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A8 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342
|
|
G |
S100a9 |
S100 calcium binding protein A9 (calgranulin B) |
multiple interactions |
EXP |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A9 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
decreases expression |
EXP |
Lovastatin results in decreased expression of SAE1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:16,054,161...16,121,821
Ensembl chr 7:16,054,159...16,121,731
|
|
G |
Scap |
SREBF chaperone |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of SCAP mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 9:110,162,356...110,214,017
Ensembl chr 9:110,162,356...110,214,018
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions affects expression |
EXP |
[Chloroquine co-treated with Lovastatin] inhibits the reaction [SCARB1 protein results in increased abundance of Progesterone] Lovastatin affects the expression of SCARB1 mRNA |
CTD |
PMID:20404351 PMID:27208389 |
|
NCBI chr 5:125,354,151...125,418,082
Ensembl chr 5:125,354,151...125,418,158
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of SCD1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Sephs1 |
selenophosphate synthetase 1 |
increases expression |
EXP |
Lovastatin results in increased expression of SEPHS1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:4,886,375...4,915,368
Ensembl chr 2:4,886,375...4,915,368
|
|
G |
Slc31a1 |
solute carrier family 31, member 1 |
increases expression |
ISO |
Lovastatin results in increased expression of SLC31A1 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 4:62,278,821...62,310,006
Ensembl chr 4:62,278,964...62,310,006
|
|
G |
Sox10 |
SRY (sex determining region Y)-box 10 |
multiple interactions increases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] |
CTD |
PMID:20578043 |
|
NCBI chr15:79,039,113...79,048,690
Ensembl chr15:79,039,108...79,049,440
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions increases expression |
EXP ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of SREBF1 mRNA Lovastatin results in increased expression of SREBF1 mRNA |
CTD |
PMID:29852127 PMID:32739440 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Srebf2 |
sterol regulatory element binding factor 2 |
increases localization multiple interactions |
ISO EXP |
Lovastatin results in increased localization of SREBF2 protein [Dietary Fats co-treated with Lovastatin] affects the expression of SREBF2 mRNA [Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein] |
CTD |
PMID:11728391 PMID:20578043 PMID:29852127 |
|
NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580
|
|
G |
Steap2 |
six transmembrane epithelial antigen of prostate 2 |
decreases response to substance |
ISO |
STEAP2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 5:5,714,829...5,744,649
Ensembl chr 5:5,714,829...5,744,578
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
EXP |
Lovastatin results in decreased expression of STIP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:6,998,064...7,017,394
Ensembl chr19:6,998,070...7,017,335
|
|
G |
Syngap1 |
synaptic Ras GTPase activating protein 1 homolog (rat) |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr17:27,160,186...27,191,408
Ensembl chr17:27,160,227...27,191,408
|
|
G |
Tcp1 |
t-complex protein 1 |
increases expression |
EXP |
Lovastatin results in increased expression of TCP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:13,135,216...13,143,954
Ensembl chr17:13,134,588...13,143,954
|
|
G |
Tg |
thyroglobulin |
increases secretion |
ISO |
Lovastatin results in increased secretion of TG protein |
CTD |
PMID:12843138 |
|
NCBI chr15:66,542,606...66,722,570
Ensembl chr15:66,542,602...66,722,570
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [TGFB1 protein results in increased abundance of Reactive Oxygen Species]; Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:22129737 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Th |
tyrosine hydroxylase |
increases expression multiple interactions |
ISO EXP |
Lovastatin results in increased expression of TH protein Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of TH protein] |
CTD |
PMID:20694854 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|
G |
Thop1 |
thimet oligopeptidase 1 |
increases expression |
EXP |
Lovastatin results in increased expression of THOP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:80,905,917...80,918,194
Ensembl chr10:80,905,869...80,918,393
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of TNF protein] |
CTD |
PMID:18809656 PMID:21430599 PMID:22712078 PMID:35734936 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
increases expression |
EXP |
Lovastatin results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:24742230 |
|
NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
increases response to substance |
ISO |
Lovastatin results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:17928957 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
decreases expression |
EXP |
Lovastatin results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:24742230 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Top2a |
topoisomerase (DNA) II alpha |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TOP2A mRNA] |
CTD |
PMID:22712078 |
|
NCBI chr11:98,883,773...98,915,037
Ensembl chr11:98,883,769...98,915,015
|
|
G |
Trim63 |
tripartite motif-containing 63 |
multiple interactions |
EXP |
Lovastatin promotes the reaction [Fenofibrate results in increased expression of TRIM63 protein] |
CTD |
PMID:33408297 |
|
NCBI chr 4:134,042,431...134,056,940
Ensembl chr 4:134,042,431...134,056,940
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions increases expression |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Lovastatin results in increased expression of and results in increased phosphorylation of TP53 protein Lovastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein modified form] Lovastatin results in increased expression of TP53 mRNA |
CTD |
PMID:17088865 PMID:21199873 PMID:26739623 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Ttc7 |
tetratricopeptide repeat domain 7 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of FSN mRNA |
CTD |
PMID:29852127 |
|
NCBI chr17:87,590,328...87,689,197
Ensembl chr17:87,590,314...87,689,197
|
|
G |
Tuba1a |
tubulin, alpha 1A |
increases expression |
EXP |
Lovastatin results in increased expression of TUBA1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:98,847,728...98,851,382
Ensembl chr15:98,847,718...98,851,584
|
|
G |
Tuba1b |
tubulin, alpha 1B |
decreases expression increases expression |
EXP |
Lovastatin results in decreased expression of TUBA1B mRNA Lovastatin results in increased expression of TUBA1B mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:98,829,310...98,832,271
Ensembl chr15:98,829,306...98,832,446
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
decreases expression |
EXP |
Lovastatin results in decreased expression of TUBB5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:36,144,812...36,149,193
Ensembl chr17:36,144,813...36,149,198
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
decreases expression |
EXP |
Lovastatin results in decreased expression of TUFM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:126,086,445...126,089,903
Ensembl chr 7:126,086,533...126,089,903
|
|
G |
U2af2 |
U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 2 |
increases expression |
EXP |
Lovastatin results in increased expression of U2AF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:5,063,884...5,082,937
Ensembl chr 7:5,065,142...5,082,937
|
|
G |
Ucp2 |
uncoupling protein 2 (mitochondrial, proton carrier) |
multiple interactions |
EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of UCP2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227
|
|
G |
Usp5 |
ubiquitin specific peptidase 5 (isopeptidase T) |
decreases expression |
EXP |
Lovastatin results in decreased expression of USP5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:124,791,982...124,806,404
Ensembl chr 6:124,791,982...124,806,447
|
|
G |
Vcp |
valosin containing protein |
decreases expression increases expression |
EXP |
Lovastatin results in decreased expression of VCP mRNA Lovastatin results in increased expression of VCP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:42,979,964...43,000,507
Ensembl chr 4:42,979,963...43,000,507
|
|
G |
Wee1 |
WEE 1 homolog 1 (S. pombe) |
multiple interactions increases expression |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of WEE1 mRNA] Lovastatin results in increased expression of WEE1 mRNA |
CTD |
PMID:22712078 |
|
NCBI chr 7:109,721,266...109,742,506
Ensembl chr 7:109,721,253...109,742,493
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases expression |
ISO |
Lovastatin results in increased expression of XIAP mRNA |
CTD |
PMID:26739623 |
|
NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533
|
|
G |
Xpa |
xeroderma pigmentosum, complementation group A |
increases expression |
ISO |
Lovastatin results in increased expression of XPA mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 4:46,175,222...46,196,317
Ensembl chr 4:46,155,347...46,196,311
|
|
G |
Ywhae |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide |
increases expression |
EXP |
Lovastatin results in increased expression of YWHAE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:75,620,121...75,656,667
Ensembl chr11:75,623,695...75,656,671
|
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
affects expression decreases expression multiple interactions |
ISO EXP |
mevastatin affects the expression of ABCA1 mRNA Mevastatin (compactin) decreases expression of abca1 mRNA in rat peripheral fibroblasts Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]] |
CTD RGD |
PMID:16415093 PMID:17526932 PMID:17526932 |
RGD:2308820 |
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions |
EXP |
mevastatin inhibits the reaction [BDNF protein results in decreased activity of HU 211] |
CTD |
PMID:20554863 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
mevastatin results in increased expression of BMP2 mRNA; mevastatin results in increased expression of BMP2 protein |
CTD |
PMID:10814523 |
|
NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805
|
|
G |
Cd40 |
CD40 antigen |
multiple interactions |
EXP |
mevastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions decreases expression |
EXP |
EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation |
EXP |
mevastatin results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:16330322 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
multiple interactions |
EXP |
EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Foxo1 |
forkhead box O1 |
decreases phosphorylation |
EXP |
mevastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase |
multiple interactions increases expression |
EXP |
EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr13:8,935,642...8,942,432
Ensembl chr13:8,935,537...8,942,487
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
mevastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein] |
CTD |
PMID:10946302 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
EXP |
mevastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr13:30,933,191...30,950,965
Ensembl chr13:30,933,209...30,950,959
|
|
G |
Msmo1 |
methylsterol monoxygenase 1 |
increases expression multiple interactions |
EXP |
mevastatin results in increased expression of MSMO1 mRNA EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr 8:65,171,157...65,186,822
Ensembl chr 8:65,171,173...65,186,826
|
|
G |
Mstn |
myostatin |
increases expression |
EXP |
mevastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 1:53,100,799...53,107,238
Ensembl chr 1:53,100,799...53,107,238
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
Mevastatin increases expression of NR1H3 mRNA in mononuclear cells |
RGD |
PMID:16252156 |
RGD:401827902 |
NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:12235278 PMID:17041008 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
EXP |
mevastatin results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein] |
CTD |
PMID:16734383 |
|
NCBI chr 5:143,491,236...143,513,786
Ensembl chr 5:143,489,389...143,513,791
|
|
G |
Rhoa |
ras homolog family member A |
decreases lipidation multiple interactions |
ISO |
mevastatin results in decreased lipidation of RHOA protein Mevalonic Acid inhibits the reaction [mevastatin results in decreased lipidation of RHOA protein] |
CTD |
PMID:17322126 |
|
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Sele |
selectin, endothelial cell |
multiple interactions |
ISO |
mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:10946302 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression increases cleavage multiple interactions |
ISO EXP |
mevastatin results in decreased expression of SREBF1 protein mevastatin results in increased cleavage of SREBF1 protein EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein] |
CTD |
PMID:16330322 PMID:17526932 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Srebf2 |
sterol regulatory element binding factor 2 |
increases expression increases cleavage |
ISO EXP |
mevastatin results in increased expression of SREBF2 protein mevastatin results in increased cleavage of SREBF2 protein |
CTD |
PMID:16330322 PMID:17526932 |
|
NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:10946302 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
EXP |
Tunicamycin inhibits the reaction [mevastatin results in increased cleavage of XBP1 protein] |
CTD |
PMID:16330322 |
|
NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
|
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
multiple interactions increases expression decreases expression |
ISO |
[[colestimide co-treated with Pravastatin] results in increased expression of ABCA1 protein] which results in decreased abundance of Cholesterol; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 mRNA; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 protein cotreatment with pravastatin and colestimide increases expression of abca1 mRNA and protein in rat liver; and decreases expression of abca1 mRNA and protein in rat small intestine Pravastatin results in decreased expression of ABCA1 |
CTD RGD |
PMID:17526932 PMID:19461118 PMID:17526932 |
RGD:2308820 |
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions affects import |
ISO |
Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid] ABCB11 protein affects the import of Pravastatin |
CTD |
PMID:15901796 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
increases transport |
ISO |
ABCB1 protein results in increased transport of Pravastatin; ABCB1 protein results in increased transport of Pravastatin analog |
CTD |
PMID:15616150 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
increases expression |
ISO |
Pravastatin results in increased expression of ABCB4 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
affects export increases expression multiple interactions affects transport |
ISO EXP |
ABCC2 protein affects the export of Pravastatin Pravastatin results in increased expression of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Pravastatin analog; Pravastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Pravastatin promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] ABCC2 protein affects the transport of Pravastatin |
CTD |
PMID:15901800 PMID:15955871 PMID:23562342 PMID:24909372 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
increases expression |
ISO |
Pravastatin results in increased expression of ABCC3 protein |
CTD |
PMID:24909372 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
increases transport |
ISO |
ABCC4 protein results in increased transport of Pravastatin |
CTD |
PMID:17939016 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Abcd3 |
ATP-binding cassette, sub-family D member 3 |
decreases expression |
EXP |
Pravastatin results in decreased expression of ABCD3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:121,552,553...121,609,851
Ensembl chr 3:121,552,423...121,608,951
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
affects export increases activity |
ISO |
ABCG2 protein affects the export of Pravastatin Pravastatin results in increased activity of ABCG2 protein |
CTD |
PMID:15901800 PMID:27475308 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
ISO |
Pravastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Pravastatin results in increased expression of ABCG8 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
decreases expression |
EXP |
Pravastatin results in decreased expression of ACAA1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:118,977,111...118,986,149
Ensembl chr 9:118,977,091...118,986,161
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ACAA2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:74,912,283...74,939,278
Ensembl chr18:74,912,268...74,939,279
|
|
G |
Acat1 |
acetyl-Coenzyme A acetyltransferase 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACAT1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:53,491,822...53,521,650
Ensembl chr 9:53,491,822...53,521,682
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in increased expression of ACE protein] |
CTD |
PMID:29682576 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO |
[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein] |
CTD |
PMID:29682576 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Acnat1 |
acyl-coenzyme A amino acid N-acyltransferase 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of ACNAT1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:49,443,532...49,481,315
Ensembl chr 4:49,447,105...49,473,912
|
|
G |
Acnat2 |
acyl-coenzyme A amino acid N-acyltransferase 2 |
decreases expression |
EXP |
Pravastatin results in decreased expression of ACNAT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:49,374,458...49,408,151
Ensembl chr 4:49,379,840...49,408,151
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of ACOT1 mRNA Pravastatin results in increased expression of ACOT1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:84,056,276...84,064,444
Ensembl chr12:84,056,264...84,065,145
|
|
G |
Acot12 |
acyl-CoA thioesterase 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACOT12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:91,889,635...91,934,271
Ensembl chr13:91,889,631...91,934,267
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
affects expression |
EXP |
Pravastatin affects the expression of ACOT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:84,034,635...84,040,651
Ensembl chr12:84,034,635...84,040,647
|
|
G |
Acot3 |
acyl-CoA thioesterase 3 |
decreases expression |
EXP |
Pravastatin results in decreased expression of ACOT3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:84,098,918...84,107,174
Ensembl chr12:84,098,918...84,107,176
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
decreases expression |
EXP |
Pravastatin results in decreased expression of ACOT4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:84,084,028...84,091,497
Ensembl chr12:84,085,153...84,095,375
|
|
G |
Acot5 |
acyl-CoA thioesterase 5 |
decreases expression |
EXP |
Pravastatin results in decreased expression of ACOT5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:84,115,908...84,122,798
Ensembl chr12:84,116,099...84,122,794
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACOX1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of ACSF2 mRNA Pravastatin results in increased expression of ACSF2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:94,447,928...94,492,822
Ensembl chr11:94,447,928...94,492,697
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of ACSL1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:46,924,214...46,989,088
Ensembl chr 8:46,924,074...46,989,088
|
|
G |
Acta1 |
actin alpha 1, skeletal muscle |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ACTA1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:124,618,497...124,621,514
Ensembl chr 8:124,618,508...124,621,490
|
|
G |
Adamdec1 |
ADAM-like, decysin 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of ADAMDEC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:68,800,829...68,819,535
Ensembl chr14:68,800,829...68,819,544
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ADH1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ADH7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:137,903,828...137,937,803
Ensembl chr 3:137,923,521...137,939,143
|
|
G |
Agt |
angiotensinogen |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AGT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AIF1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of AKR1C3 mRNA Pravastatin results in decreased expression of AKR1C18 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions increases phosphorylation |
EXP ISO |
Pravastatin inhibits the reaction [Carboplatin results in increased activity of and results in increased phosphorylation of AKT1 protein] [Pravastatin co-treated with olmesartan] results in increased phosphorylation of AKT1 protein; [resveratrol co-treated with Pravastatin] results in increased phosphorylation of AKT1 protein Pravastatin results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17170375 PMID:17188708 PMID:18483861 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase family 1, subfamily A1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:16763553 PMID:27225895 |
|
NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase family 1, subfamily A2 |
multiple interactions decreases expression |
EXP |
Cholesterol, Dietary inhibits the reaction [Pravastatin results in decreased expression of ALDH1A2 mRNA] |
CTD |
PMID:16763553 |
|
NCBI chr 9:71,123,071...71,203,525
Ensembl chr 9:71,123,071...71,203,525
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase family 1, subfamily A3 |
affects expression |
ISO EXP |
Pravastatin affects the expression of ALDH1A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:66,040,640...66,077,225
Ensembl chr 7:66,040,638...66,077,265
|
|
G |
Aldoart2 |
aldolase 1 A, retrogene 2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ALDOART2 mRNA Pravastatin results in decreased expression of ALDOART2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:55,611,990...55,613,681
Ensembl chr12:55,612,024...55,613,681
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of AMPD3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:110,367,291...110,411,612
Ensembl chr 7:110,367,413...110,411,612
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:98,919,191...98,926,429
Ensembl chr 4:98,919,191...98,934,348
|
|
G |
Ank2 |
ankyrin 2, brain |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of ANK2 mRNA Pravastatin results in decreased expression of ANK2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:126,715,256...127,293,996
Ensembl chr 3:126,715,261...127,292,999
|
|
G |
Anks6 |
ankyrin repeat and sterile alpha motif domain containing 6 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of ANKS6 mRNA Pravastatin results in decreased expression of ANKS6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:47,015,365...47,057,339
Ensembl chr 4:47,015,669...47,057,427
|
|
G |
Apoa1 |
apolipoprotein A-I |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of APOA1 mRNA Pravastatin results in decreased expression of APOA1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Apon |
apolipoprotein N |
decreases expression |
EXP |
Pravastatin results in decreased expression of APON mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:128,090,000...128,091,770
Ensembl chr10:128,089,965...128,091,765
|
|
G |
App |
amyloid beta precursor protein |
increases expression |
ISO |
Pravastatin results in increased expression of APP |
CTD |
PMID:19461118 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Arg2 |
arginase type II |
increases expression |
EXP |
Pravastatin results in increased expression of ARG2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:79,177,562...79,203,075
Ensembl chr12:79,177,551...79,203,075
|
|
G |
Arhgap11a |
Rho GTPase activating protein 11A |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of ARHGAP11A mRNA Pravastatin affects the expression of ARHGAP11A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:113,661,837...113,679,006
Ensembl chr 2:113,661,837...113,679,006
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ARRDC3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:81,031,508...81,044,161
Ensembl chr13:81,031,503...81,044,161
|
|
G |
Atp4a |
ATPase, H+/K+ exchanging, gastric, alpha polypeptide |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ATP4A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:30,411,634...30,424,959
Ensembl chr 7:30,411,634...30,424,959
|
|
G |
Atp6v0d2 |
ATPase, H+ transporting, lysosomal V0 subunit D2 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of ATP6V0D2 mRNA Pravastatin results in decreased expression of ATP6V0D2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:19,876,838...19,922,566
Ensembl chr 4:19,876,841...19,922,605
|
|
G |
Axin2 |
axin 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AXIN2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:108,808,687...108,841,609
Ensembl chr11:108,811,175...108,841,609
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of BARD1 mRNA Pravastatin results in decreased expression of BARD1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:71,066,694...71,142,300
Ensembl chr 1:71,066,657...71,142,305
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
EXP |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein |
CTD |
PMID:26875785 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
EXP |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein |
CTD |
PMID:26875785 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of BHLHA15 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:144,127,104...144,131,259
Ensembl chr 5:144,127,104...144,131,259
|
|
G |
Bmal2 |
basic helix-loop-helix ARNT like 2 |
affects expression increases expression |
ISO EXP |
Pravastatin affects the expression of BMAL2 mRNA Pravastatin results in increased expression of BMAL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:146,696,230...146,735,027
Ensembl chr 6:146,697,553...146,735,027
|
|
G |
Bmper |
BMP-binding endothelial regulator |
affects expression increases expression |
ISO EXP |
Pravastatin affects the expression of BMPER mRNA Pravastatin results in increased expression of BMPER mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:23,134,372...23,396,511
Ensembl chr 9:23,134,372...23,396,496
|
|
G |
Bub1b |
BUB1B, mitotic checkpoint serine/threonine kinase |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of BUB1B mRNA Pravastatin results in decreased expression of BUB1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:118,428,684...118,472,073
Ensembl chr 2:118,428,692...118,472,072
|
|
G |
C1qb |
complement component 1, q subcomponent, beta polypeptide |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of C1QB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:136,607,437...136,613,511
Ensembl chr 4:136,607,440...136,613,498
|
|
G |
C1qc |
complement component 1, q subcomponent, C chain |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of C1QC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376
|
|
G |
C5ar1 |
complement component 5a receptor 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of C5AR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:15,980,668...15,993,465
Ensembl chr 7:15,980,668...15,993,465
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
EXP ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein] Pravastatin results in increased cleavage of CASP3 protein Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:18483861 PMID:20368269 PMID:26875785 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP9 protein] |
CTD |
PMID:18483861 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
increases activity |
ISO |
Pravastatin results in increased activity of CAT protein |
CTD |
PMID:17479860 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CCL12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:81,992,671...81,994,225
Ensembl chr11:81,992,671...81,994,226
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of CCL2 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of CCL2 protein] |
CTD |
PMID:18323514 PMID:20884875 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CCL6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:83,478,712...83,483,913
Ensembl chr11:83,478,708...83,483,913
|
|
G |
Cd209d |
CD209d antigen |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of CD209 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:3,921,824...3,928,548
Ensembl chr 8:3,921,824...3,928,555
|
|
G |
Cd28 |
CD28 antigen |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of CD28 mRNA Pravastatin results in decreased expression of CD28 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518
|
|
G |
Cd40 |
CD40 antigen |
affects expression |
EXP ISO |
Pravastatin affects the expression of CD40 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868
|
|
G |
Cd7 |
CD7 antigen |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CD7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:120,927,573...120,930,304
Ensembl chr11:120,927,573...120,930,244
|
|
G |
Cdc27 |
cell division cycle 27 |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of CDC27 mRNA Pravastatin affects the expression of CDC27 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:104,393,350...104,441,371
Ensembl chr11:104,393,571...104,441,446
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CDC6 mRNA Pravastatin affects the expression of CDC6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:98,798,627...98,814,768
Ensembl chr11:98,798,627...98,814,766
|
|
G |
Cdca7l |
cell division cycle associated 7 like |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of CDCA7L mRNA Pravastatin results in decreased expression of CDCA7L mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:117,807,209...117,842,441
Ensembl chr12:117,768,024...117,842,441
|
|
G |
Cdhr5 |
cadherin-related family member 5 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of CDHR5 mRNA Pravastatin results in decreased expression of CDHR5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:140,848,993...140,856,708
Ensembl chr 7:140,848,996...140,856,699
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Benzo(a)pyrene results in decreased degradation of CDKN1A protein]; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein] |
CTD |
PMID:15625077 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cds1 |
CDP-diacylglycerol synthase 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of CDS1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:101,913,001...101,971,724
Ensembl chr 5:101,912,996...101,971,724
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
EXP |
Pravastatin results in increased expression of CEBPD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895
|
|
G |
Cers6 |
ceramide synthase 6 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CERS6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:68,691,489...68,944,628
Ensembl chr 2:68,691,785...68,944,626
|
|
G |
Ces1e |
carboxylesterase 1E |
decreases expression |
EXP |
Pravastatin results in decreased expression of CES1E mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:93,927,846...93,956,233
Ensembl chr 8:93,927,846...93,956,247
|
|
G |
Ces1f |
carboxylesterase 1F |
decreases expression |
EXP |
Pravastatin results in decreased expression of CES1F mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:93,982,864...94,006,394
Ensembl chr 8:93,982,864...94,006,375
|
|
G |
Ces2b |
carboxyesterase 2B |
increases expression |
EXP |
Pravastatin results in increased expression of CES2B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:105,555,130...105,566,725
Ensembl chr 8:105,558,204...105,566,725
|
|
G |
Cfap96 |
cilia and flagella associated protein 96 |
increases expression |
ISO |
Pravastatin results in increased expression of CFAP96 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:46,387,980...46,428,290
Ensembl chr 8:46,406,643...46,428,477
|
|
G |
Cip2a |
cell proliferation regulating inhibitor of protein phosphatase 2A |
decreases expression |
ISO |
Pravastatin results in decreased expression of CIP2A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:48,814,524...48,840,079
Ensembl chr16:48,814,548...48,840,072
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of CITED1 mRNA Pravastatin results in increased expression of CITED1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:101,290,984...101,295,787
Ensembl chr X:101,290,987...101,295,787
|
|
G |
Clcn6 |
chloride channel, voltage-sensitive 6 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of CLCN6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:148,088,716...148,123,270
Ensembl chr 4:148,088,716...148,123,278
|
|
G |
Clec4f |
C-type lectin domain family 4, member f |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CLEC4F mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:83,621,524...83,633,098
Ensembl chr 6:83,621,524...83,633,169
|
|
G |
Clstn3 |
calsyntenin 3 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of CLSTN3 mRNA Pravastatin affects the expression of CLSTN3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:124,407,715...124,441,743
Ensembl chr 6:124,407,540...124,441,753
|
|
G |
Cnn1 |
calponin 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CNN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:22,010,501...22,020,517
Ensembl chr 9:22,010,512...22,020,926
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1b, muscle |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of CPT1B mRNA Pravastatin affects the expression of CPT1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:89,300,608...89,310,065
Ensembl chr15:89,300,608...89,310,066
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CPT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:107,761,179...107,780,786
Ensembl chr 4:107,761,178...107,780,807
|
|
G |
Crat |
carnitine acetyltransferase |
increases expression affects expression |
ISO EXP |
Pravastatin results in increased expression of CRAT mRNA Pravastatin affects the expression of CRAT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:30,290,483...30,305,602
Ensembl chr 2:30,290,483...30,305,825
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of CREB3L3 mRNA Pravastatin results in decreased expression of CREB3L3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:80,920,163...80,934,706
Ensembl chr10:80,920,158...80,934,708
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of CRP mRNA Pravastatin results in decreased expression of CRP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSAD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:102,085,432...102,112,685
Ensembl chr15:102,085,434...102,113,159
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSF1R mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:61,238,644...61,264,211
Ensembl chr18:61,233,670...61,265,221
|
|
G |
Csmd1 |
CUB and Sushi multiple domains 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of CSMD1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:15,942,538...17,586,908
Ensembl chr 8:15,942,537...17,585,602
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects localization multiple interactions |
ISO |
Pravastatin affects the localization of CTNNB1 protein [resveratrol co-treated with Pravastatin] affects the localization of CTNNB1 protein |
CTD |
PMID:17188708 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of CXCL8 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of CXCL8 protein] |
CTD |
PMID:20884875 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
affects expression increases expression |
ISO EXP |
Pravastatin affects the expression of CXCL2 mRNA Pravastatin results in increased expression of CXCL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cyba |
cytochrome b-245, alpha polypeptide |
decreases expression |
ISO |
Pravastatin results in decreased expression of CYBA protein |
CTD |
PMID:17170375 |
|
NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Carboplatin results in increased expression of CYCS protein] |
CTD |
PMID:18483861 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
affects expression increases expression |
ISO EXP |
Pravastatin affects the expression of CYP1B1 mRNA Pravastatin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
affects expression |
EXP |
Pravastatin affects the expression of CYP2B10 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2b23 |
cytochrome P450, family 2, subfamily b, polypeptide 23 |
affects expression |
EXP |
Pravastatin affects the expression of CYP2B23 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:26,364,652...26,389,788
Ensembl chr 7:26,364,652...26,385,862
|
|
G |
Cyp2c23 |
cytochrome P450, family 2, subfamily c, polypeptide 23 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2C23 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:43,993,461...44,017,695
Ensembl chr19:43,993,461...44,017,647
|
|
G |
Cyp2d10 |
cytochrome P450, family 2, subfamily d, polypeptide 10 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2D10 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:82,287,046...82,291,449
Ensembl chr15:82,287,047...82,291,396
|
|
G |
Cyp2j6 |
cytochrome P450, family 2, subfamily j, polypeptide 6 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2J6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:96,404,375...96,449,835
Ensembl chr 4:96,404,375...96,441,898
|
|
G |
Cyp2j9 |
cytochrome P450, family 2, subfamily j, polypeptide 9 |
decreases expression |
ISO |
Pravastatin results in decreased expression of CYP2J4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815
|
|
G |
Cyp3a11 |
cytochrome P450, family 3, subfamily a, polypeptide 11 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP3A11 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774
|
|
G |
Cyp3a16 |
cytochrome P450, family 3, subfamily a, polypeptide 16 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP3A16 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:145,373,119...145,406,550
Ensembl chr 5:145,373,119...145,406,533
|
|
G |
Cyp4a10 |
cytochrome P450, family 4, subfamily a, polypeptide 10 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP4A10 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:115,375,484...115,390,846
Ensembl chr 4:115,375,461...115,390,846
|
|
G |
Cyp4a12b |
cytochrome P450, family 4, subfamily a, polypeptide 12B |
decreases expression |
ISO |
Pravastatin results in decreased expression of CYP4A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:115,268,821...115,296,231
Ensembl chr 4:115,268,821...115,296,231
|
|
G |
Cyp4a14 |
cytochrome P450, family 4, subfamily a, polypeptide 14 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP4A14 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:115,343,397...115,353,355
Ensembl chr 4:115,343,397...115,353,339
|
|
G |
Cyp4a31 |
cytochrome P450, family 4, subfamily a, polypeptide 31 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP4A31 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:115,420,824...115,436,212
Ensembl chr 4:115,420,846...115,436,212
|
|
G |
Cyp4a32 |
cytochrome P450, family 4, subfamily a, polypeptide 32 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP4A32 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:115,458,124...115,479,704
Ensembl chr 4:115,458,166...115,478,799
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of CYP51 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746
|
|
G |
Decr1 |
2,4-dienoyl CoA reductase 1, mitochondrial |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of DECR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:15,917,240...15,945,377
Ensembl chr 4:15,917,240...15,945,507
|
|
G |
Depdc1b |
DEP domain containing 1B |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of DEPDC1B mRNA Pravastatin affects the expression of DEPDC1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:108,452,592...108,526,100
Ensembl chr13:108,452,866...108,544,316
|
|
G |
Derl3 |
Der1-like domain family, member 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of DERL3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:75,729,232...75,731,775
Ensembl chr10:75,729,247...75,731,775
|
|
G |
Dio3 |
deiodinase, iodothyronine type III |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of DIO3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531
|
|
G |
Dlgap1 |
DLG associated protein 1 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of DLGAP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:70,276,068...71,128,408
Ensembl chr17:70,276,068...71,128,408
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
affects farnesylation |
ISO |
Pravastatin affects the farnesylation of DNAJA1 protein |
CTD |
PMID:20884875 |
|
NCBI chr 4:40,722,468...40,734,965
Ensembl chr 4:40,722,150...40,737,149
|
|
G |
Dnase2b |
deoxyribonuclease II beta |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of DNASE2B mRNA Pravastatin results in decreased expression of DNASE2B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:146,275,488...146,322,815
Ensembl chr 3:146,286,740...146,321,351
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of DPYSL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:67,040,313...67,148,490
Ensembl chr14:67,040,313...67,106,137
|
|
G |
Dtl |
denticleless E3 ubiquitin protein ligase |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of DTL mRNA Pravastatin results in decreased expression of DTL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:191,269,468...191,307,656
Ensembl chr 1:191,269,468...191,307,656
|
|
G |
Ech1 |
enoyl coenzyme A hydratase 1, peroxisomal |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ECH1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:28,524,763...28,531,664
Ensembl chr 7:28,524,642...28,531,672
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of EDN1 protein Pravastatin results in decreased expression of EDN1 mRNA; Pravastatin results in decreased expression of EDN1 protein |
CTD |
PMID:12105140 PMID:19812503 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Efhb |
EF hand domain family, member B |
increases expression |
ISO EXP |
Pravastatin results in increased expression of EFHB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:53,705,077...53,770,362
Ensembl chr17:53,705,917...53,770,349
|
|
G |
Ehhadh |
enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EHHADH mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:21,580,035...21,606,589
Ensembl chr16:21,580,037...21,606,557
|
|
G |
Enpp5 |
ectonucleotide pyrophosphatase/phosphodiesterase 5 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of ENPP5 mRNA Pravastatin affects the expression of ENPP5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:44,389,693...44,397,458
Ensembl chr17:44,389,704...44,397,458
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of ENTPD2 mRNA Pravastatin results in decreased expression of ENTPD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:25,285,886...25,291,335
Ensembl chr 2:25,285,886...25,291,333
|
|
G |
Ephx2 |
epoxide hydrolase 2, cytoplasmic |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EPHX2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:66,321,821...66,361,971
Ensembl chr14:66,321,823...66,361,949
|
|
G |
Ephx4 |
epoxide hydrolase 4 |
increases expression affects expression |
ISO EXP |
Pravastatin results in increased expression of EPHX4 mRNA Pravastatin affects the expression of EPHX4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:107,551,379...107,577,901
Ensembl chr 5:107,550,602...107,577,901
|
|
G |
Evi2a |
ecotropic viral integration site 2a |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EVI2A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:79,417,386...79,421,435
Ensembl chr11:79,417,386...79,421,435
|
|
G |
F13a1 |
coagulation factor XIII, A1 subunit |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of F13A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:37,051,150...37,234,220
Ensembl chr13:37,051,152...37,234,220
|
|
G |
Fabp1 |
fatty acid binding protein 1, liver |
decreases expression |
EXP |
Pravastatin results in decreased expression of FABP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:71,176,863...71,182,018
Ensembl chr 6:71,176,811...71,182,007
|
|
G |
Fabp2 |
fatty acid binding protein 2, intestinal |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of FABP2 mRNA Pravastatin results in decreased expression of FABP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:122,688,721...122,693,155
Ensembl chr 3:122,688,721...122,693,155
|
|
G |
Fabp5 |
fatty acid binding protein 5, epidermal |
increases expression |
ISO EXP |
Pravastatin results in increased expression of FABP5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:10,077,645...10,081,670
Ensembl chr 3:10,077,608...10,081,667
|
|
G |
Far1 |
fatty acyl CoA reductase 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of FAR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:113,113,008...113,170,713
Ensembl chr 7:113,113,041...113,170,718
|
|
G |
Fbn1 |
fibrillin 1 |
increases expression |
EXP |
Pravastatin results in increased expression of FBN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:125,142,514...125,348,417
Ensembl chr 2:125,142,514...125,349,913
|
|
G |
Fbp2 |
fructose bisphosphatase 2 |
affects expression |
ISO |
Pravastatin affects the expression of FBP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:62,984,698...63,006,214
Ensembl chr13:62,984,691...63,006,236
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
affects activity |
ISO |
Pravastatin affects the activity of FDFT1 protein |
CTD |
PMID:8517861 |
|
NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027
|
|
G |
Fgd2 |
FYVE, RhoGEF and PH domain containing 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of FGD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:29,579,878...29,598,509
Ensembl chr17:29,579,888...29,598,635
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
affects expression increases expression |
ISO EXP |
Pravastatin affects the expression of FGF13 mRNA Pravastatin results in increased expression of FGF13 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:58,107,499...58,630,932
Ensembl chr X:58,107,505...58,613,431
|
|
G |
Flacc1 |
flagellum associated containing coiled-coil domains 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of FLACC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:58,696,085...58,735,167
Ensembl chr 1:58,686,062...58,735,148
|
|
G |
Flot1 |
flotillin 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr17:36,134,243...36,143,674
Ensembl chr17:36,134,122...36,143,683
|
|
G |
Folr2 |
folate receptor beta |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of FOLR2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:101,489,195...101,506,397
Ensembl chr 7:101,489,195...101,506,401
|
|
G |
Foxo1 |
forkhead box O1 |
decreases phosphorylation |
EXP |
Pravastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Gck |
glucokinase |
decreases expression |
ISO |
Pravastatin results in decreased expression of GCK mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of GCLC mRNA Pravastatin results in decreased expression of GCLC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 (I blood group) |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of GCNT2 mRNA Pravastatin results in increased expression of GCNT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:41,013,417...41,114,368
Ensembl chr13:41,013,230...41,114,368
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased activity of GLB1 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein] |
CTD |
PMID:20884875 |
|
NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966
|
|
G |
Gldc |
glycine decarboxylase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of GLDC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:30,075,847...30,152,829
Ensembl chr19:30,075,847...30,152,829
|
|
G |
Gls2 |
glutaminase 2 (liver, mitochondrial) |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of GLS2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:128,030,504...128,045,873
Ensembl chr10:128,030,326...128,045,873
|
|
G |
Gpr85 |
G protein-coupled receptor 85 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of GPR85 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:13,834,405...13,839,951
Ensembl chr 6:13,834,457...13,839,941
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of GSTK1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:42,222,869...42,227,375
Ensembl chr 6:42,222,869...42,227,381
|
|
G |
Hadh |
hydroxyacyl-Coenzyme A dehydrogenase |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HADH mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:131,027,068...131,065,750
Ensembl chr 3:131,027,068...131,065,750
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HADHA mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:30,324,421...30,359,978
Ensembl chr 5:30,323,302...30,360,160
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of HADHB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:30,360,251...30,389,591
Ensembl chr 5:30,360,246...30,389,591
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression |
ISO EXP |
Pravastatin results in increased expression of HAMP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457
|
|
G |
Hax1 |
HCLS1 associated X-1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Carboplatin results in decreased expression of HAX1 protein] |
CTD |
PMID:18483861 |
|
NCBI chr 3:89,902,753...89,906,023
Ensembl chr 3:89,902,753...89,906,087
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
decreases response to substance increases expression decreases activity affects expression |
ISO EXP |
HMGCR gene SNP results in decreased susceptibility to Pravastatin Pravastatin results in increased expression of HMGCR mRNA Pravastatin results in decreased activity of HMGCR protein Pravastatin affects the expression of HMGCR mRNA |
CTD |
PMID:8517861 PMID:8593127 PMID:15199031 PMID:27225895 PMID:29969672 |
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 |
increases expression |
EXP |
Pravastatin results in increased expression of HMGCS1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with pirinixic acid] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin results in increased expression of HMOX1 protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter] |
CTD |
PMID:20368269 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hopx |
HOP homeobox |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of HOPX mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:77,234,831...77,262,970
Ensembl chr 5:77,234,835...77,262,968
|
|
G |
Hrg |
histidine-rich glycoprotein |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HRG mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:22,769,822...22,780,409
Ensembl chr16:22,769,822...22,780,406
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of HSD17B7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:169,777,109...169,796,757
Ensembl chr 1:169,777,104...169,796,810
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of HSDL2 mRNA Pravastatin results in decreased expression of HSDL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:59,581,515...59,618,694
Ensembl chr 4:59,581,563...59,618,689
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase |
increases expression |
ISO EXP |
Pravastatin results in increased expression of IDI1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:8,935,642...8,942,432
Ensembl chr13:8,935,537...8,942,487
|
|
G |
Ifnb1 |
interferon beta 1, fibroblast |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 4:88,440,253...88,441,083
Ensembl chr 4:88,440,262...88,441,011
|
|
G |
Il1b |
interleukin 1 beta |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of IL1B mRNA Pravastatin results in decreased expression of IL1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
EXP ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of IL6 protein] Pravastatin results in decreased expression of IL6 protein |
CTD |
PMID:17729120 PMID:18323514 PMID:19330073 PMID:20884875 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
multiple interactions increases response to substance |
EXP ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein [INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein]; [INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in increased expression of ACE protein] [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein |
CTD |
PMID:26875785 PMID:29682576 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Palmitic Acid results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:18323514 |
|
NCBI chr 7:44,647,072...44,652,272
Ensembl chr 7:44,647,072...44,652,272
|
|
G |
Itga2 |
integrin alpha 2 |
multiple interactions |
ISO |
geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein] |
CTD |
PMID:12500026 |
|
NCBI chr13:114,969,617...115,068,588
Ensembl chr13:114,969,617...115,068,636
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
multiple interactions |
ISO |
geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein] |
CTD |
PMID:12500026 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Itgb6 |
integrin beta 6 |
affects expression |
EXP |
Pravastatin affects the expression of ITGB6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:60,428,636...60,553,005
Ensembl chr 2:60,428,636...60,552,987
|
|
G |
Kcns3 |
potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of KCNS3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:11,140,738...11,201,186
Ensembl chr12:11,140,203...11,201,057
|
|
G |
Kctd12 |
potassium channel tetramerisation domain containing 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of KCTD12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:103,214,017...103,220,073
Ensembl chr14:103,214,017...103,220,073
|
|
G |
Kif20a |
kinesin family member 20A |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of KIF20A mRNA Pravastatin results in decreased expression of KIF20A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:34,757,677...34,766,330
Ensembl chr18:34,757,666...34,766,330
|
|
G |
Kif20b |
kinesin family member 20B |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of KIF20B mRNA Pravastatin results in decreased expression of KIF20B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:34,899,735...34,953,150
Ensembl chr19:34,899,761...34,953,145
|
|
G |
Kif23 |
kinesin family member 23 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of KIF23 mRNA Pravastatin affects the expression of KIF23 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:61,824,559...61,854,078
Ensembl chr 9:61,823,187...61,854,056
|
|
G |
Kitl |
kit ligand |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of KITL mRNA Pravastatin results in increased expression of KITLG mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278
|
|
G |
Klb |
klotho beta |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of KLB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:65,505,754...65,544,300
Ensembl chr 5:65,505,657...65,541,350
|
|
G |
Krt23 |
keratin 23 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of KRT23 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:99,368,799...99,383,946
Ensembl chr11:99,368,800...99,383,963
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases activity increases response to substance multiple interactions |
ISO EXP |
Pravastatin results in increased activity of LDLR protein [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein; LDLR gene mutant form results in increased susceptibility to Pravastatin [LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein |
CTD |
PMID:8593127 PMID:26875785 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lgals4 |
lectin, galactose binding, soluble 4 |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of LGALS4 mRNA Pravastatin results in increased expression of LGALS4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:28,533,559...28,541,128
Ensembl chr 7:28,533,279...28,541,133
|
|
G |
Lgi2 |
leucine-rich repeat LGI family, member 2 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of LGI2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:52,690,859...52,723,689
Ensembl chr 5:52,690,859...52,723,804
|
|
G |
Lmna |
lamin A |
increases expression |
ISO |
Pravastatin results in increased expression of LMNA protein |
CTD |
PMID:20884875 |
|
NCBI chr 3:88,388,455...88,413,842
Ensembl chr 3:88,387,454...88,417,263
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of LPL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Lrmda |
leucine rich melanocyte differentiation associated |
decreases expression |
EXP |
Pravastatin results in decreased expression of LRMDA mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:22,069,567...23,106,161
Ensembl chr14:22,069,780...23,106,153
|
|
G |
Lss |
lanosterol synthase |
increases expression |
ISO EXP |
Pravastatin results in increased expression of LSS mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:76,367,303...76,392,973
Ensembl chr10:76,367,422...76,392,972
|
|
G |
Ltbp2 |
latent transforming growth factor beta binding protein 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of LTBP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:84,829,986...84,923,581
Ensembl chr12:84,829,986...84,923,306
|
|
G |
Ly86 |
lymphocyte antigen 86 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of LY86 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:37,529,276...37,603,012
Ensembl chr13:37,529,184...37,603,012
|
|
G |
Mapt |
microtubule-associated protein tau |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of MAPT Pravastatin results in decreased expression of MAPT mRNA |
CTD |
PMID:19461118 PMID:27225895 |
|
NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916
|
|
G |
Mastl |
microtubule associated serine/threonine kinase-like |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of MASTL mRNA Pravastatin affects the expression of MASTL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:23,006,549...23,046,036
Ensembl chr 2:23,005,618...23,046,036
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
increases phosphorylation increases expression multiple interactions |
ISO |
Pravastatin results in increased phosphorylation of MDM2 protein Pravastatin results in increased expression of MDM2 protein [Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein; Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]; U 0126 inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein] |
CTD |
PMID:15625077 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Meiob |
meiosis specific with OB domains |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of MEIOB mRNA Pravastatin results in decreased expression of MEIOB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:25,023,275...25,058,762
Ensembl chr17:25,023,263...25,058,762
|
|
G |
Mgll |
monoglyceride lipase |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of MGLL mRNA Pravastatin results in decreased expression of MGLL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:88,701,397...88,805,342
Ensembl chr 6:88,701,394...88,805,342
|
|
G |
Miox |
myo-inositol oxygenase |
decreases expression |
EXP |
Pravastatin results in decreased expression of MIOX mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:89,218,676...89,221,210
Ensembl chr15:89,218,601...89,221,218
|
|
G |
Mis18a |
MIS18 kinetochore protein A |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of MIS18A mRNA Pravastatin results in increased expression of MIS18A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:90,516,200...90,524,259
Ensembl chr16:90,516,200...90,524,292
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of MLYCD mRNA Pravastatin affects the expression of MLYCD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:120,121,591...120,148,577
Ensembl chr 8:120,121,617...120,137,841
|
|
G |
Mme |
membrane metallo endopeptidase |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of MME mRNA Pravastatin results in decreased expression of MME mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:63,202,632...63,291,134
Ensembl chr 3:63,148,958...63,293,451
|
|
G |
Mmp14 |
matrix metallopeptidase 14 (membrane-inserted) |
decreases expression |
ISO |
Pravastatin results in decreased expression of MMP14 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr14:54,669,055...54,679,913
Ensembl chr14:54,669,069...54,682,821
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity decreases expression |
ISO |
Pravastatin results in decreased activity of MMP2 protein Pravastatin results in decreased expression of MMP2 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
affects response to substance |
ISO |
MMP3 promoter polymorphism affects the susceptibility to Pravastatin |
CTD |
PMID:8662692 |
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity decreases expression |
ISO |
Pravastatin results in decreased activity of MMP9 protein Pravastatin results in decreased expression of MMP9 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mss51 |
MSS51 mitochondrial translational activator |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of MSS51 mRNA Pravastatin results in increased expression of MSS51 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:20,532,925...20,546,969
Ensembl chr14:20,532,935...20,546,969
|
|
G |
Mstn |
myostatin |
increases expression |
EXP |
Pravastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 1:53,100,799...53,107,238
Ensembl chr 1:53,100,799...53,107,238
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
ISO |
Pravastatin results in increased phosphorylation of MTOR protein |
CTD |
PMID:15625077 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Mvd |
mevalonate (diphospho) decarboxylase |
increases expression |
ISO EXP |
Pravastatin results in increased expression of MVD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:123,160,335...123,170,161
Ensembl chr 8:123,160,340...123,170,161
|
|
G |
Nfe2 |
nuclear factor, erythroid derived 2 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of NFE2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:103,156,640...103,166,809
Ensembl chr15:103,156,639...103,166,830
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of NNMT mRNA Pravastatin results in increased expression of NNMT protein Pravastatin results in increased expression of NNMT mRNA |
CTD |
PMID:27225895 PMID:33073877 |
|
NCBI chr 9:48,448,905...48,518,958
Ensembl chr 9:48,503,177...48,516,453
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
multiple interactions increases phosphorylation |
ISO |
[resveratrol co-treated with Pravastatin] results in increased phosphorylation of NOS3 protein; Pravastatin promotes the reaction [NOS3 protein binds to NOS3 protein]; Pravastatin promotes the reaction [olmesartan results in increased activity of and results in increased phosphorylation of NOS3 protein]; Pravastatin results in increased activity of and results in increased phosphorylation of NOS3 protein Pravastatin results in increased phosphorylation of NOS3 protein |
CTD |
PMID:17170375 PMID:17188708 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of NR0B2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
ISO EXP |
Pravastatin results in increased expression of NSDHL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:71,962,127...72,002,134
Ensembl chr X:71,962,163...72,002,120
|
|
G |
Olr1 |
oxidized low density lipoprotein (lectin-like) receptor 1 |
increases expression |
EXP |
Pravastatin results in increased expression of OLR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128
|
|
G |
Orc1 |
origin recognition complex, subunit 1 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of ORC1 mRNA Pravastatin affects the expression of ORC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:108,436,651...108,472,030
Ensembl chr 4:108,436,620...108,472,030
|
|
G |
P2ry10b |
purinergic receptor P2Y, G-protein coupled 10B |
affects expression |
EXP ISO |
Pravastatin affects the expression of P2RY10B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:106,192,533...106,217,268
Ensembl chr X:106,192,533...106,217,267
|
|
G |
Pcdhb5 |
protocadherin beta 5 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of PCDHB4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:37,453,434...37,456,966
Ensembl chr18:37,453,434...37,456,968
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of PCSK9 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:106,299,531...106,321,522
Ensembl chr 4:106,299,526...106,321,526
|
|
G |
Pctp |
phosphatidylcholine transfer protein |
decreases expression |
EXP |
Pravastatin results in decreased expression of PCTP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:89,873,370...89,893,720
Ensembl chr11:89,873,491...89,893,720
|
|
G |
Pde4a |
phosphodiesterase 4A, cAMP specific |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of PDE4A mRNA Pravastatin results in increased expression of PDE4A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:21,076,998...21,124,544
Ensembl chr 9:21,077,010...21,124,544
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase, isoenzyme 4 |
affects expression increases expression |
ISO EXP |
Pravastatin affects the expression of PDK4 mRNA Pravastatin results in increased expression of PDK4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309
|
|
G |
Pemt |
phosphatidylethanolamine N-methyltransferase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PEMT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:59,861,440...59,937,394
Ensembl chr11:59,861,440...59,937,315
|
|
G |
Pex11a |
peroxisomal biogenesis factor 11 alpha |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PEX11A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:79,385,705...79,392,879
Ensembl chr 7:79,385,705...79,392,879
|
|
G |
Pf4 |
platelet factor 4 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of PF4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:90,920,362...90,921,242
Ensembl chr 5:90,920,294...90,921,242
|
|
G |
Pla2r1 |
phospholipase A2 receptor 1 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of PLA2R1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:60,247,887...60,383,669
Ensembl chr 2:60,247,887...60,383,652
|
|
G |
Plppr1 |
phospholipid phosphatase related 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PLPPR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:49,054,986...49,340,261
Ensembl chr 4:49,059,273...49,340,259
|
|
G |
Pmvk |
phosphomevalonate kinase |
increases expression |
ISO EXP |
Pravastatin results in increased expression of PMVK mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:89,361,848...89,376,321
Ensembl chr 3:89,361,848...89,376,320
|
|
G |
Pnpla7 |
patatin-like phospholipase domain containing 7 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PNPLA7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:24,865,235...24,944,084
Ensembl chr 2:24,866,045...24,944,069
|
|
G |
Pole2 |
polymerase (DNA directed), epsilon 2 (p59 subunit) |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of POLE2 mRNA Pravastatin affects the expression of POLE2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:69,248,547...69,274,979
Ensembl chr12:69,248,547...69,274,969
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions affects localization |
EXP ISO |
Pravastatin results in increased expression of PPARA protein Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] Pravastatin affects the localization of PPARA protein [[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin affects the localization of PPARA protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter] |
CTD |
PMID:18812576 PMID:20368269 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [[troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol] |
CTD |
PMID:12044893 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppm1j |
protein phosphatase 1J |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of PPM1J mRNA Pravastatin results in increased expression of PPM1J mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:104,688,322...104,693,334
Ensembl chr 3:104,688,372...104,693,334
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
increases activity |
ISO |
Pravastatin results in increased activity of PRKAA1 protein |
CTD |
PMID:33073877 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Prnd |
prion like protein doppel |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PRND mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:131,792,781...131,798,051
Ensembl chr 2:131,792,781...131,798,050
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Pravastatin results in increased expression of PTGS2 protein |
CTD |
PMID:20368269 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptprn |
protein tyrosine phosphatase receptor type N |
affects expression increases expression |
ISO EXP |
Pravastatin affects the expression of PTPRN mRNA Pravastatin results in increased expression of PTPRN mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:75,223,679...75,241,437
Ensembl chr 1:75,223,671...75,241,146
|
|
G |
Rdh11 |
retinol dehydrogenase 11 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of RDH11 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:79,221,007...79,238,629
Ensembl chr12:79,221,111...79,239,067
|
|
G |
Reep1 |
receptor accessory protein 1 |
affects expression increases expression |
ISO EXP |
Pravastatin affects the expression of REEP1 mRNA Pravastatin results in increased expression of REEP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:71,684,413...71,787,694
Ensembl chr 6:71,684,545...71,787,694
|
|
G |
Retsat |
retinol saturase (all trans retinol 13,14 reductase) |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of RETSAT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:72,575,585...72,584,471
Ensembl chr 6:72,575,458...72,585,408
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of RGS16 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:153,616,099...153,621,212
Ensembl chr 1:153,616,095...153,621,214
|
|
G |
Rnf186 |
ring finger protein 186 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of RNF186 mRNA Pravastatin affects the expression of RNF186 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:138,694,430...138,695,676
Ensembl chr 4:138,694,423...138,695,676
|
|
G |
Rragd |
Ras-related GTP binding D |
decreases expression |
EXP |
Pravastatin results in decreased expression of RRAGD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:32,982,998...33,022,180
Ensembl chr 4:32,983,037...33,022,180
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA |
CTD |
PMID:20368269 |
|
NCBI chr 2:27,566,457...27,653,331
Ensembl chr 2:27,566,452...27,652,969
|
|
G |
S100a4 |
S100 calcium binding protein A4 |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of S100A4 mRNA Pravastatin affects the expression of S100A4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:90,511,077...90,513,349
Ensembl chr 3:90,511,078...90,513,352
|
|
G |
S100g |
S100 calcium binding protein G |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of S100G mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:161,744,988...161,747,595
Ensembl chr X:161,744,988...161,747,595
|
|
G |
Sat2 |
spermidine/spermine N1-acetyl transferase 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SAT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:69,512,824...69,514,857
Ensembl chr11:69,512,850...69,514,696
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
increases expression |
ISO |
Pravastatin results in increased expression of SCD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression |
EXP |
Pravastatin results in increased expression of SCD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303
|
|
G |
Selp |
selectin, platelet |
decreases expression |
ISO |
Pravastatin results in decreased expression of SELP protein |
CTD |
PMID:11189483 |
|
NCBI chr 1:163,942,833...163,977,595
Ensembl chr 1:163,942,833...163,977,595
|
|
G |
Serpinb1a |
serine (or cysteine) peptidase inhibitor, clade B, member 1a |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SERPINB1A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:33,026,075...33,037,189
Ensembl chr13:33,026,075...33,035,168
|
|
G |
Sfrp1 |
secreted frizzled-related protein 1 |
increases expression |
EXP |
Pravastatin results in increased expression of SFRP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:23,901,401...23,939,648
Ensembl chr 8:23,901,518...23,939,648
|
|
G |
Shisa4 |
shisa family member 4 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of SHISA4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:135,298,578...135,302,812
Ensembl chr 1:135,298,795...135,302,975
|
|
G |
Sirt1 |
sirtuin 1 |
increases phosphorylation |
ISO |
Pravastatin results in increased phosphorylation of SIRT1 protein |
CTD |
PMID:33073877 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slc13a3 |
solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 |
decreases expression |
EXP |
Pravastatin results in decreased expression of SLC13A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:165,247,215...165,315,117
Ensembl chr 2:165,246,948...165,315,150
|
|
G |
Slc15a3 |
solute carrier family 15, member 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC15A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:10,819,908...10,835,279
Ensembl chr19:10,817,091...10,836,726
|
|
G |
Slc16a5 |
solute carrier family 16 (monocarboxylic acid transporters), member 5 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of SLC16A5 mRNA Pravastatin affects the expression of SLC16A5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:115,353,231...115,365,224
Ensembl chr11:115,353,300...115,365,224
|
|
G |
Slc17a1 |
solute carrier family 17 (sodium phosphate), member 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC17A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:24,051,607...24,079,713
Ensembl chr13:24,051,733...24,079,713
|
|
G |
Slc17a3 |
solute carrier family 17 (sodium phosphate), member 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC17A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:24,020,905...24,044,701
Ensembl chr13:24,023,417...24,044,699
|
|
G |
Slc22a5 |
solute carrier family 22 (organic cation transporter), member 5 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of SLC22A5 mRNA Pravastatin affects the expression of SLC22A5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486
|
|
G |
Slc23a1 |
solute carrier family 23 (nucleobase transporters), member 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC23A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:35,747,657...35,762,900
Ensembl chr18:35,747,657...35,760,297
|
|
G |
Slc25a20 |
solute carrier family 25 (mitochondrial carnitine/acylcarnitine translocase), member 20 |
decreases expression |
EXP |
Pravastatin results in decreased expression of SLC25A20 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:108,539,335...108,561,841
Ensembl chr 9:108,539,287...108,561,840
|
|
G |
Slc25a34 |
solute carrier family 25, member 34 |
affects expression |
ISO |
Pravastatin affects the expression of SLC25A34 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:141,346,130...141,351,202
Ensembl chr 4:141,346,135...141,351,132
|
|
G |
Slc25a42 |
solute carrier family 25, member 42 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC25A42 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:70,636,990...70,664,931
Ensembl chr 8:70,636,990...70,664,955
|
|
G |
Slc27a2 |
solute carrier family 27 (fatty acid transporter), member 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC27A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:126,394,944...126,430,163
Ensembl chr 2:126,394,327...126,430,163
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC2A4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc34a2 |
solute carrier family 34 (sodium phosphate), member 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC34A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:53,206,695...53,229,006
Ensembl chr 5:53,195,423...53,229,006
|
|
G |
Slc9b2 |
solute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2 |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of SLC9B2 mRNA Pravastatin affects the expression of SLC9B2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:135,013,083...135,048,606
Ensembl chr 3:135,013,461...135,051,148
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects transport decreases expression |
EXP ISO |
SLCO1A4 protein affects the transport of Pravastatin Pravastatin results in decreased expression of SLCO1A4 protein |
CTD |
PMID:19833843 PMID:24909372 |
|
NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
|
|
G |
Slco1a5 |
solute carrier organic anion transporter family, member 1a5 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of SLCO1A5 mRNA Pravastatin results in decreased expression of SLCO1A5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:142,179,953...142,268,707
Ensembl chr 6:142,179,953...142,268,707
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:21430235 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:21430235 |
|
NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547
|
|
G |
Slco4a1 |
solute carrier organic anion transporter family, member 4a1 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of SLCO4A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:180,098,019...180,116,646
Ensembl chr 2:180,098,038...180,116,660
|
|
G |
Smim3 |
small integral membrane protein 3 |
increases expression |
EXP |
Pravastatin results in increased expression of SMIM3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:60,607,263...60,635,055
Ensembl chr18:60,607,263...60,635,059
|
|
G |
Snap25 |
synaptosomal-associated protein 25 |
multiple interactions |
EXP |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein |
CTD |
PMID:26875785 |
|
NCBI chr 2:136,555,359...136,624,348
Ensembl chr 2:136,555,373...136,624,348
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
EXP |
Pravastatin results in increased expression of SOCS3 protein |
CTD |
PMID:19330073 |
|
NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873
|
|
G |
Spag5 |
sperm associated antigen 5 |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of SPAG5 mRNA Pravastatin results in decreased expression of SPAG5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:78,192,412...78,213,283
Ensembl chr11:78,192,355...78,213,283
|
|
G |
Spic |
Spi-C transcription factor (Spi-1/PU.1 related) |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of SPIC mRNA Pravastatin results in increased expression of SPIC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:88,511,131...88,518,885
Ensembl chr10:88,510,634...88,520,877
|
|
G |
Srd5a2 |
steroid 5 alpha-reductase 2 |
decreases expression |
EXP |
Pravastatin results in decreased expression of SRD5A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:74,321,886...74,354,855
Ensembl chr17:74,323,950...74,354,911
|
|
G |
St8sia3 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ST8SIA3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:64,387,430...64,409,217
Ensembl chr18:64,387,430...64,412,682
|
|
G |
Stard4 |
StAR related lipid transfer domain containing 4 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of STARD4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:33,332,191...33,346,937
Ensembl chr18:33,332,408...33,346,915
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:18323514 |
|
NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
EXP |
Pravastatin results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:19330073 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Stx1a |
syntaxin 1A (brain) |
multiple interactions |
EXP |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein |
CTD |
PMID:26875785 |
|
NCBI chr 5:135,051,473...135,079,954
Ensembl chr 5:135,052,336...135,079,954
|
|
G |
Sult1c2 |
sulfotransferase family, cytosolic, 1C, member 2 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of SULT1C2 mRNA Pravastatin affects the expression of SULT1C2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:54,136,665...54,152,986
Ensembl chr17:54,136,665...54,153,367
|
|
G |
Sult1e1 |
sulfotransferase family 1E, member 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of SULT1E1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:87,723,827...87,739,470
Ensembl chr 5:87,723,828...87,739,453
|
|
G |
Sult2a1 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:13,530,171...13,571,335
Ensembl chr 7:13,530,171...13,571,334
|
|
G |
Tex12 |
testis expressed 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of TEX12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:50,468,448...50,472,568
Ensembl chr 9:50,468,119...50,472,625
|
|
G |
Thbd |
thrombomodulin |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of THBD mRNA Pravastatin affects the expression of THBD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:148,246,391...148,250,108
Ensembl chr 2:148,246,386...148,250,108
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of TIMP1 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Timp2 |
tissue inhibitor of metalloproteinase 2 |
decreases expression |
ISO |
Pravastatin results in decreased expression of TIMP2 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566
|
|
G |
Tlcd4 |
TLC domain containing 4 |
decreases expression |
EXP |
Pravastatin results in decreased expression of TLCD4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:120,995,657...121,076,756
Ensembl chr 3:120,995,410...121,076,747
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of TM7SF2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:6,112,851...6,117,880
Ensembl chr19:6,112,851...6,118,403
|
|
G |
Tmem139 |
transmembrane protein 139 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of TMEM139 mRNA Pravastatin results in decreased expression of TMEM139 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:42,238,866...42,241,489
Ensembl chr 6:42,238,893...42,241,489
|
|
G |
Tmem164 |
transmembrane protein 164 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of TMEM164 mRNA Pravastatin results in decreased expression of TMEM164 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:141,463,343...141,626,490
Ensembl chr X:141,464,402...141,626,490
|
|
G |
Tmem205 |
transmembrane protein 205 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of TMEM205 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:21,832,305...21,838,831
Ensembl chr 9:21,832,304...21,838,852
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Pravastatin results in increased expression of TNF mRNA |
CTD |
PMID:17729120 PMID:18323514 PMID:27225895 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfsf18 |
tumor necrosis factor (ligand) superfamily, member 18 |
affects expression |
ISO EXP |
Pravastatin affects the expression of TNFSF18 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:161,322,221...161,333,903
Ensembl chr 1:161,322,224...161,332,859
|
|
G |
Tnnt2 |
troponin T2, cardiac |
increases expression |
EXP |
Pravastatin results in increased expression of TNNT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:135,763,933...135,780,006
Ensembl chr 1:135,764,092...135,779,998
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
[Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of TP53 protein]; Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein]; Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased expression of TP53 protein] Pravastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] |
CTD |
PMID:15625077 PMID:20650967 PMID:20884875 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Tspan13 |
tetraspanin 13 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of TSPAN13 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:36,064,554...36,092,477
Ensembl chr12:36,064,556...36,092,499
|
|
G |
Ttc41 |
tetratricopeptide repeat domain 41 |
decreases expression |
EXP |
Pravastatin results in decreased expression of TTC41 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:86,541,675...86,612,708
Ensembl chr10:86,541,675...86,612,708
|
|
G |
Tuba1a |
tubulin, alpha 1A |
increases expression |
EXP ISO |
Pravastatin results in increased expression of TUBA1A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:98,847,728...98,851,382
Ensembl chr15:98,847,718...98,851,584
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of UGT2B1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:87,064,498...87,074,362
Ensembl chr 5:87,064,497...87,074,389
|
|
G |
Uroc1 |
urocanase domain containing 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of UROC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:90,310,221...90,341,533
Ensembl chr 6:90,310,266...90,341,533
|
|
G |
Vamp2 |
vesicle-associated membrane protein 2 |
multiple interactions |
EXP |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein |
CTD |
PMID:26875785 |
|
NCBI chr11:68,979,354...68,983,207
Ensembl chr11:68,979,316...68,983,210
|
|
G |
Vnn1 |
vanin 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of VNN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:23,770,586...23,781,242
Ensembl chr10:23,770,586...23,781,241
|
|
G |
Zc3h12a |
zinc finger CCCH type containing 12A |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of ZC3H12A mRNA Pravastatin results in increased expression of ZC3H12A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:125,012,207...125,021,674
Ensembl chr 4:125,012,216...125,021,633
|
|
|
G |
A2m |
alpha-2-macroglobulin |
decreases expression |
ISO |
Simvastatin results in decreased expression of A2M mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 6:121,612,920...121,656,197
Ensembl chr 6:121,612,335...121,656,186
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
decreases expression increases expression |
ISO EXP |
Simvastatin results in decreased expression of ABCA1; Simvastatin results in decreased expression of ABCA1 mRNA Simvastatin results in increased expression of ABCA1 mRNA Simvastatin results in increased expression of ABCA1 mRNA; Simvastatin results in increased expression of ABCA1 protein |
CTD |
PMID:16282522 PMID:18270459 PMID:19383813 PMID:19461118 PMID:21241519 PMID:22120639 PMID:25055962 More...
|
|
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions decreases activity decreases expression |
ISO |
Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Simvastatin results in decreased activity of ABCB11 protein Simvastatin results in decreased expression of ABCB11 mRNA |
CTD |
PMID:20829430 PMID:23956101 PMID:24014644 PMID:27765674 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
increases transport multiple interactions decreases activity affects response to substance |
ISO |
ABCB1 protein results in increased transport of Simvastatin ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; Simvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] Simvastatin analog results in decreased activity of ABCB1 protein ABCB1 polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:15616150 PMID:16321621 PMID:19802823 PMID:19891551 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
increases expression decreases expression |
EXP ISO |
Simvastatin results in increased expression of ABCB4 mRNA Simvastatin results in decreased expression of ABCB4 mRNA |
CTD |
PMID:21241519 PMID:27765674 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
multiple interactions decreases activity affects response to substance decreases expression |
ISO |
ABCC2 protein binds to and results in increased uptake of Simvastatin analog; Simvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Simvastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Simvastatin analog results in decreased activity of ABCC2 protein ABCC2 polymorphism affects the susceptibility to Simvastatin Simvastatin results in decreased expression of ABCC2 mRNA |
CTD |
PMID:15616150 PMID:22186618 PMID:23562342 PMID:27765674 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
multiple interactions increases nitrosation |
ISO |
artemisinin inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; parthenolide inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased nitrosation of ABCC3 protein] |
CTD |
PMID:18463201 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
EXP ISO |
Simvastatin results in decreased expression of ABCG1 mRNA |
CTD |
PMID:19383813 PMID:22120639 |
|
NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
EXP |
Simvastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:21241519 |
|
NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ABCG8 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of ACAA2 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of ACAA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr18:74,912,283...74,939,278
Ensembl chr18:74,912,268...74,939,279
|
|
G |
Acacb |
acetyl-Coenzyme A carboxylase beta |
increases expression |
ISO |
Simvastatin results in increased expression of ACACB mRNA |
CTD |
PMID:12056585 |
|
NCBI chr 5:114,284,748...114,388,822
Ensembl chr 5:114,284,596...114,388,822
|
|
G |
Acan |
aggrecan |
multiple interactions increases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA] |
CTD |
PMID:18628692 PMID:19912653 |
|
NCBI chr 7:78,702,974...78,764,847
Ensembl chr 7:78,703,231...78,764,847
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA] Simvastatin results in decreased expression of ACTA2 protein |
CTD |
PMID:15677772 PMID:15855201 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Actb |
actin, beta |
increases expression |
ISO |
Simvastatin results in increased expression of ACTB mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509
|
|
G |
Actn4 |
actinin alpha 4 |
increases expression |
ISO |
Simvastatin results in increased expression of ACTN4 mRNA |
CTD |
PMID:16710349 |
|
NCBI chr 7:28,592,673...28,661,799
Ensembl chr 7:28,592,673...28,661,765
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP ISO |
Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of ADIPOQ mRNA]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of ADIPOQ protein] carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]]; Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein] |
CTD |
PMID:17641834 PMID:29071762 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Adora2b |
adenosine A2b receptor |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B protein] |
CTD |
PMID:33774062 |
|
NCBI chr11:62,139,810...62,157,278
Ensembl chr11:62,139,810...62,157,279
|
|
G |
Adrb1 |
adrenergic receptor, beta 1 |
increases expression |
EXP |
Simvastatin results in increased expression of ADRB1 mRNA; Simvastatin results in increased expression of ADRB1 protein |
CTD |
PMID:19262002 |
|
NCBI chr19:56,710,549...56,713,582
Ensembl chr19:56,710,631...56,721,545
|
|
G |
Afp |
alpha fetoprotein |
increases expression |
ISO |
Simvastatin results in increased expression of AFP mRNA |
CTD |
PMID:10365819 |
|
NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein] Simvastatin results in decreased expression of AGER protein |
CTD |
PMID:17038636 |
|
NCBI chr17:34,816,545...34,819,911
Ensembl chr17:34,816,836...34,819,910
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases expression |
ISO |
[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]] Simvastatin results in decreased expression of AGT mRNA Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA] |
CTD |
PMID:17513949 PMID:18400235 PMID:18475152 PMID:19100119 PMID:19225232 PMID:22306966 More...
|
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
decreases expression |
ISO |
Simvastatin results in decreased expression of AGTR1 mRNA |
CTD |
PMID:17513949 PMID:18475152 |
|
NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
decreases expression |
ISO |
Simvastatin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 6:37,506,913...37,551,856
Ensembl chr 6:37,507,108...37,545,750
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
decreases expression multiple interactions decreases activity increases phosphorylation decreases phosphorylation |
ISO EXP |
Simvastatin results in decreased expression of AKT1 mRNA; Simvastatin results in decreased expression of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein; [Simvastatin co-treated with Metformin] results in decreased phosphorylation of AKT1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of AKT1 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]] Simvastatin inhibits the reaction [Glucose results in decreased expression of AKT1 protein modified form]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein Simvastatin results in decreased activity of AKT1 protein Simvastatin results in increased phosphorylation of AKT1 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein] |
CTD |
PMID:12438947 PMID:17327694 PMID:17335931 PMID:18004065 PMID:18031796 PMID:18047562 PMID:19299917 PMID:20060890 PMID:20464445 PMID:20562903 PMID:20594940 PMID:21059805 PMID:22082490 PMID:22144680 PMID:25412314 PMID:27734117 PMID:33034787 More...
|
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase family 3, subfamily A1 |
increases expression |
ISO |
Simvastatin results in increased expression of ALDH3A1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:61,099,336...61,109,244
Ensembl chr11:61,098,363...61,109,247
|
|
G |
Alk |
anaplastic lymphoma kinase |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA |
CTD |
PMID:28263720 |
|
NCBI chr17:72,174,206...72,911,719
Ensembl chr17:72,175,967...72,911,622
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
increases expression |
ISO |
Simvastatin results in increased expression of ALOX5AP mRNA |
CTD |
PMID:17183729 |
|
NCBI chr 5:149,201,814...149,224,963
Ensembl chr 5:149,201,577...149,224,963
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
increases expression |
EXP |
Simvastatin results in increased expression of ALPI mRNA |
CTD |
PMID:14973129 |
|
NCBI chr 1:87,025,724...87,029,328
Ensembl chr 1:87,025,724...87,029,328
|
|
G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
increases expression multiple interactions affects expression |
EXP ISO |
Simvastatin results in increased expression of ALPL mRNA Hydroxychloroquine affects the reaction [Simvastatin affects the expression of ALPL mRNA] |
CTD |
PMID:20417880 PMID:28975700 |
|
NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695
|
|
G |
Angpt1 |
angiopoietin 1 |
increases expression |
ISO |
Simvastatin results in increased expression of ANGPT1; Simvastatin results in increased expression of ANGPT1 mRNA; Simvastatin results in increased expression of ANGPT1 protein |
CTD |
PMID:18544044 |
|
NCBI chr15:42,288,063...42,540,373
Ensembl chr15:42,288,119...42,540,373
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of ANGPT2 protein] |
CTD |
PMID:20821229 |
|
NCBI chr 8:18,740,279...18,791,578
Ensembl chr 8:18,740,279...18,791,578
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 4:98,919,191...98,926,429
Ensembl chr 4:98,919,191...98,934,348
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
EXP |
Simvastatin results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804
|
|
G |
Ankra2 |
ankyrin repeat family A member 2 |
increases expression |
ISO |
Simvastatin results in increased expression of ANKRA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr13:98,399,584...98,411,262
Ensembl chr13:98,399,582...98,411,262
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
increases expression |
EXP |
Simvastatin results in increased expression of ANPEP mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 7:79,471,551...79,497,958
Ensembl chr 7:79,471,551...79,510,807
|
|
G |
Anxa1 |
annexin A1 |
increases expression |
EXP |
Simvastatin results in increased expression of ANXA1 protein |
CTD |
PMID:14973129 |
|
NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308
|
|
G |
Anxa3 |
annexin A3 |
decreases expression |
ISO EXP |
Simvastatin results in decreased expression of ANXA3 mRNA Simvastatin results in decreased expression of ANXA3 protein |
CTD |
PMID:14973129 PMID:17428261 |
|
NCBI chr 5:96,941,257...96,993,825
Ensembl chr 5:96,941,198...96,993,825
|
|
G |
Aoc1 |
amine oxidase, copper-containing 1 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of AOC1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 6:48,872,189...48,886,122
Ensembl chr 6:48,849,830...48,886,122
|
|
G |
Apmap |
adipocyte plasma membrane associated protein |
decreases expression |
ISO |
Simvastatin results in decreased expression of APMAP protein |
CTD |
PMID:20217863 |
|
NCBI chr 2:150,425,000...150,450,487
Ensembl chr 2:150,425,000...150,450,487
|
|
G |
Apoa1 |
apolipoprotein A-I |
multiple interactions increases expression decreases expression |
EXP ISO |
MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein] Polystyrenes analog promotes the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Simvastatin promotes the reaction [Polystyrenes analog results in increased expression of APOA1 mRNA] Simvastatin results in increased expression of APOA1 mRNA; Simvastatin results in increased expression of APOA1 protein [Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]; Simvastatin results in increased expression of and results in increased secretion of APOA1 protein Simvastatin results in decreased expression of APOA1 mRNA; Simvastatin results in decreased expression of APOA1 protein |
CTD |
PMID:8289597 PMID:8461338 PMID:12048122 PMID:12633795 PMID:18270459 PMID:18420099 PMID:18540024 PMID:20152243 PMID:21241519 PMID:25055962 More...
|
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Apoa2 |
apolipoprotein A-II |
decreases expression |
ISO |
Simvastatin results in decreased expression of APOA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 1:171,049,133...171,053,948
Ensembl chr 1:171,052,623...171,053,948
|
|
G |
Apoa4 |
apolipoprotein A-IV |
multiple interactions increases expression decreases expression |
EXP ISO |
Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] Simvastatin results in increased expression of APOA4 protein Polystyrenes analog promotes the reaction [Simvastatin results in decreased expression of APOA4 protein]; Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOA4 protein] Simvastatin results in decreased expression of APOA4 mRNA; Simvastatin results in decreased expression of APOA4 protein |
CTD |
PMID:8289597 PMID:8461338 PMID:18224302 PMID:25055962 |
|
NCBI chr 9:46,152,142...46,154,756
Ensembl chr 9:46,151,994...46,154,757
|
|
G |
Apob |
apolipoprotein B |
multiple interactions affects response to substance decreases expression decreases secretion |
ISO |
[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB] APOB polymorphism affects the susceptibility to Simvastatin Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOB protein] Simvastatin results in decreased expression of APOB mRNA; Simvastatin results in decreased expression of APOB protein Simvastatin results in decreased secretion of APOB protein |
CTD |
PMID:1627634 PMID:8289597 PMID:8461338 PMID:9512650 PMID:10498134 PMID:11728391 PMID:12633795 PMID:12901521 PMID:15184351 PMID:18471454 PMID:18702965 PMID:20413733 More...
|
|
NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835
|
|
G |
Apoc1 |
apolipoprotein C-I |
decreases expression |
ISO |
Simvastatin results in decreased expression of APOC1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 7:19,423,405...19,426,584
Ensembl chr 7:19,423,406...19,426,585
|
|
G |
Apoc3 |
apolipoprotein C-III |
decreases expression |
ISO |
Simvastatin results in decreased expression of APOC3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 9:46,144,348...46,146,934
Ensembl chr 9:46,144,231...46,146,934
|
|
G |
Apoe |
apolipoprotein E |
decreases expression affects response to substance multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of APOE; Simvastatin results in decreased expression of APOE mRNA APOE affects the susceptibility to Simvastatin Polystyrenes analog inhibits the reaction [Simvastatin results in decreased expression of APOE protein] APOE polymorphism affects the susceptibility to Simvastatin Simvastatin results in decreased expression of APOE mRNA; Simvastatin results in decreased expression of APOE protein |
CTD |
PMID:8289597 PMID:8461338 PMID:11849659 PMID:11947894 PMID:12901521 PMID:18270459 PMID:19461118 PMID:25055962 More...
|
|
NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113
|
|
G |
Apof |
apolipoprotein F |
decreases expression |
ISO |
Simvastatin results in decreased expression of APOF mRNA |
CTD |
PMID:25055962 |
|
NCBI chr10:128,104,568...128,107,119
Ensembl chr10:128,103,866...128,106,022
|
|
G |
Apom |
apolipoprotein M |
decreases expression increases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of APOM mRNA Simvastatin results in increased expression of APOM mRNA; Simvastatin results in increased expression of APOM protein T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM protein]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM protein] |
CTD |
PMID:21729290 PMID:22160096 |
|
NCBI chr17:35,347,973...35,350,777
Ensembl chr17:35,347,973...35,351,026
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions decreases activity |
ISO |
oblimersen inhibits the reaction [Simvastatin results in decreased activity of APP protein alternative form]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein] Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein] |
CTD |
PMID:17241114 PMID:28734741 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Arhgap29 |
Rho GTPase activating protein 29 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ARHGAP29 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 3:121,746,752...121,810,326
Ensembl chr 3:121,746,190...121,810,402
|
|
G |
Arhgap4 |
Rho GTPase activating protein 4 |
increases expression |
ISO |
Simvastatin results in increased expression of ARHGAP4 mRNA |
CTD |
PMID:14630613 |
|
NCBI chr X:72,937,958...72,954,945
Ensembl chr X:72,935,048...72,965,476
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
increases expression |
ISO |
Simvastatin results in increased expression of ARHGEF2 mRNA |
CTD |
PMID:14630613 |
|
NCBI chr 3:88,500,427...88,556,839
Ensembl chr 3:88,513,273...88,555,359
|
|
G |
Ass1 |
argininosuccinate synthetase 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ASS1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 2:31,360,282...31,410,682
Ensembl chr 2:31,360,219...31,410,684
|
|
G |
Atf2 |
activating transcription factor 2 |
increases phosphorylation |
ISO |
Simvastatin results in increased phosphorylation of ATF2 protein |
CTD |
PMID:15488325 |
|
NCBI chr 2:73,646,853...73,723,094
Ensembl chr 2:73,646,853...73,722,983
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Simvastatin results in increased expression of ATF3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
ISO |
Simvastatin results in increased expression of ATF6 mRNA; Simvastatin results in increased expression of ATF6 protein |
CTD |
PMID:18807172 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Atm |
ataxia telangiectasia mutated |
multiple interactions |
ISO |
Simvastatin results in increased phosphorylation of and results in increased activity of ATM protein |
CTD |
PMID:20499237 |
|
NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040
|
|
G |
Atp2a2 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 |
increases expression |
ISO |
Simvastatin results in increased expression of ATP2A2 mRNA; Simvastatin results in increased expression of ATP2A2 protein |
CTD |
PMID:15916736 |
|
NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288
|
|
G |
Atp6v1e1 |
ATPase, H+ transporting, lysosomal V1 subunit E1 |
increases expression |
EXP |
Simvastatin results in increased expression of ATP6V1E1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 6:120,772,205...120,799,659
Ensembl chr 6:120,771,266...120,799,754
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
ISO |
Simvastatin results in decreased expression of AURKA mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 2:172,198,116...172,212,825
Ensembl chr 2:172,198,110...172,212,455
|
|
G |
Axin2 |
axin 2 |
affects expression |
ISO |
Simvastatin affects the expression of AXIN2 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr11:108,808,687...108,841,609
Ensembl chr11:108,811,175...108,841,609
|
|
G |
Axl |
AXL receptor tyrosine kinase |
decreases expression |
ISO |
Simvastatin results in decreased expression of AXL mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 7:25,455,925...25,488,502
Ensembl chr 7:25,456,698...25,488,130
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions decreases phosphorylation |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein] IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein] |
CTD |
PMID:12438947 PMID:27734117 |
|
NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267
|
|
G |
Bax |
BCL2-associated X protein |
affects localization increases expression |
ISO EXP |
Simvastatin affects the localization of BAX protein Simvastatin results in increased expression of BAX mRNA; Simvastatin results in increased expression of BAX protein |
CTD |
PMID:12557325 PMID:17901590 PMID:20045437 PMID:25300705 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbc3 |
BCL2 binding component 3 |
multiple interactions affects localization increases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BBC3 protein]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 mRNA]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 protein] Simvastatin affects the localization of BBC3 protein Simvastatin results in increased expression of BBC3 mRNA; Simvastatin results in increased expression of BBC3 protein |
CTD |
PMID:17428261 PMID:20045437 PMID:21199873 PMID:37956312 |
|
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions decreases expression increases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of BCL2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter] Simvastatin results in decreased expression of BCL2 mRNA; Simvastatin results in decreased expression of BCL2 protein Simvastatin results in increased expression of BCL2 protein Simvastatin results in increased expression of BCL2 mRNA; Simvastatin results in increased expression of BCL2 protein |
CTD |
PMID:17241114 PMID:17277159 PMID:17901590 PMID:18031796 PMID:18521906 PMID:20369390 PMID:21729534 PMID:25300705 More...
|
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein] Simvastatin results in decreased expression of BCL2L1 protein |
CTD |
PMID:17277159 PMID:18521906 PMID:20060890 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bdnf |
brain derived neurotrophic factor |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of BDNF Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of BDNF mRNA] |
CTD |
PMID:18047562 PMID:20851742 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
increases secretion increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased secretion of BGLAP protein Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA] Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA; Simvastatin results in increased expression of BGLAP protein [Simvastatin co-treated with Dexamethasone] results in increased expression of BGLAP |
CTD |
PMID:12914771 PMID:14601315 PMID:14973129 PMID:15953866 PMID:17252541 PMID:19216230 PMID:19249597 PMID:19292885 PMID:20381859 PMID:20417880 PMID:20564244 PMID:21431270 PMID:22058016 More...
|
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of BHLHA15 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 5:144,127,104...144,131,259
Ensembl chr 5:144,127,104...144,131,259
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] Simvastatin results in decreased expression of BIRC2 protein |
CTD |
PMID:17277159 PMID:18521906 PMID:19343037 |
|
NCBI chr 9:7,818,227...7,837,123
Ensembl chr 9:7,818,228...7,837,065
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein] |
CTD |
PMID:17277159 PMID:19343037 |
|
NCBI chr 9:7,848,698...7,873,199
Ensembl chr 9:7,848,700...7,873,187
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC5 protein] Simvastatin results in decreased expression of BIRC5 mRNA; Simvastatin results in decreased expression of BIRC5 protein |
CTD |
PMID:17277159 PMID:20464445 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
increases expression |
ISO |
Simvastatin results in increased expression of BMP1 mRNA |
CTD |
PMID:12963647 |
|
NCBI chr14:70,711,998...70,758,280
Ensembl chr14:70,711,998...70,757,674
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases secretion multiple interactions increases expression |
ISO EXP |
Simvastatin results in increased secretion of BMP2 protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BMP2 mRNA] Simvastatin results in increased expression of BMP2; Simvastatin results in increased expression of BMP2 mRNA farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]] Simvastatin results in increased expression of BMP2 mRNA; Simvastatin results in increased expression of BMP2 protein |
CTD |
PMID:10814523 PMID:11162604 PMID:12914771 PMID:16470222 PMID:17252541 PMID:18310456 PMID:18628692 PMID:19292885 PMID:19912653 PMID:20024970 PMID:20381859 PMID:20417880 PMID:20687301 More...
|
|
NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
affects expression increases expression increases stability |
ISO |
Simvastatin affects the expression of BMPR2 mRNA Simvastatin results in increased expression of BMPR2 protein Simvastatin results in increased stability of BMPR2 mRNA |
CTD |
PMID:16297860 |
|
NCBI chr 1:59,802,721...59,917,240
Ensembl chr 1:59,802,559...59,918,173
|
|
G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
increases expression |
ISO |
Simvastatin results in increased expression of BNIP3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
|
|
G |
C5ar1 |
complement component 5a receptor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of C5AR1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 7:15,980,668...15,993,465
Ensembl chr 7:15,980,668...15,993,465
|
|
G |
Cacna1c |
calcium channel, voltage-dependent, L type, alpha 1C subunit |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C protein] Simvastatin results in decreased expression of CACNA1C mRNA; Simvastatin results in decreased expression of CACNA1C protein |
CTD |
PMID:19791473 |
|
NCBI chr 6:118,564,201...119,174,345
Ensembl chr 6:118,564,201...119,173,851
|
|
G |
Cacna1h |
calcium channel, voltage-dependent, T type, alpha 1H subunit |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H protein] Simvastatin results in decreased expression of CACNA1H mRNA; Simvastatin results in decreased expression of CACNA1H protein |
CTD |
PMID:19791473 |
|
NCBI chr17:25,593,259...25,655,308
Ensembl chr17:25,593,259...25,652,759
|
|
G |
Calb1 |
calbindin 1 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Oxygen deficiency results in decreased expression of CALB1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 4:15,881,264...15,906,709
Ensembl chr 4:15,881,264...15,908,064
|
|
G |
Calb2 |
calbindin 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CALB2 protein |
CTD |
PMID:20217863 |
|
NCBI chr 8:110,869,158...110,894,844
Ensembl chr 8:110,864,134...110,894,842
|
|
G |
Cald1 |
caldesmon 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CALD1 mRNA; Simvastatin results in decreased expression of CALD1 protein |
CTD |
PMID:14630613 |
|
NCBI chr 6:34,575,433...34,752,404
Ensembl chr 6:34,575,435...34,752,408
|
|
G |
Calml3 |
calmodulin-like 3 |
increases expression |
ISO |
Simvastatin results in increased expression of CALML3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr13:3,852,893...3,854,318
Ensembl chr13:3,852,896...3,854,316
|
|
G |
Capn1 |
calpain 1 |
increases expression |
ISO |
Simvastatin results in increased expression of CAPN1 mRNA |
CTD |
PMID:18664198 PMID:19253821 |
|
NCBI chr19:6,038,573...6,065,855
Ensembl chr19:6,038,573...6,065,927
|
|
G |
Capza1 |
capping actin protein of muscle Z-line subunit alpha 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CAPZA1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 3:104,730,097...104,771,821
Ensembl chr 3:104,730,095...104,771,821
|
|
G |
Capza2 |
capping actin protein of muscle Z-line subunit alpha 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CAPZA2 protein |
CTD |
PMID:20217863 |
|
NCBI chr 6:17,637,009...17,666,971
Ensembl chr 6:17,636,233...17,666,971
|
|
G |
Casp1 |
caspase 1 |
decreases activity multiple interactions |
ISO |
Simvastatin results in decreased activity of CASP1 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of CASP1 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein] |
CTD |
PMID:16054375 PMID:30408459 PMID:35762198 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
Simvastatin results in increased cleavage of and results in increased activity of CASP12 protein |
CTD |
PMID:19253821 |
|
NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression decreases activity |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of CASP3 protein modified form]; Simvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein [Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein; [Lipopolysaccharides co-treated with Simvastatin] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein] carvacrol inhibits the reaction [Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]]; PD 150606 inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of CASP3 mRNA]; Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]; Simvastatin results in decreased expression of and results in decreased activity of CASP3 protein; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein; Verapamil inhibits the reaction [Simvastatin results in increased activity of CASP3 protein] Simvastatin results in increased expression of CASP3 mRNA; Simvastatin results in increased expression of CASP3 protein Simvastatin results in decreased activity of CASP3 protein |
CTD |
PMID:11868908 PMID:12557325 PMID:12962723 PMID:14527821 PMID:15200425 PMID:15949312 PMID:16054375 PMID:16325779 PMID:16470222 PMID:16698853 PMID:17241114 PMID:17428261 PMID:17928392 PMID:18004065 PMID:18031796 PMID:18521906 PMID:18826357 PMID:19253821 PMID:19343037 PMID:20045437 PMID:20403180 PMID:20427495 PMID:20464445 PMID:20883752 PMID:21651924 PMID:21729534 PMID:21968084 PMID:22022327 PMID:25300705 PMID:26773838 PMID:27734117 PMID:29071762 PMID:35762198 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
ISO |
Simvastatin results in increased cleavage of and results in increased activity of CASP6 protein |
CTD |
PMID:19253821 |
|
NCBI chr 3:129,695,064...129,707,761
Ensembl chr 3:129,695,074...129,707,752
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP7 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP7 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP7 protein |
CTD |
PMID:19253821 PMID:20045437 PMID:20427495 |
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions increases cleavage |
ISO EXP |
Simvastatin results in increased activity of CASP8 protein Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP8 protein] Simvastatin results in increased cleavage of CASP8 protein Simvastatin results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:12962723 PMID:15705602 PMID:20464445 PMID:20883752 PMID:21910007 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage decreases activity increases activity |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased activity of CASP9 protein]; DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP9 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:12438947 PMID:12962723 PMID:15705602 PMID:16470222 PMID:19253821 PMID:20045437 PMID:21910007 More...
|
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
decreases expression increases activity multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of CAT mRNA Simvastatin results in increased activity of CAT protein carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]]; Simvastatin inhibits the reaction [Diazepam results in decreased activity of CAT protein]; Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein] |
CTD |
PMID:17479860 PMID:20883752 PMID:27111380 PMID:29071762 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cav1 |
caveolin 1, caveolae protein |
multiple interactions decreases expression |
ISO EXP |
Simvastatin inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA] Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] Simvastatin results in decreased expression of CAV1 protein Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV1 protein] |
CTD |
PMID:16698853 PMID:18224302 PMID:19816600 |
|
NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451
|
|
G |
Cav2 |
caveolin 2 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV2 protein] |
CTD |
PMID:16698853 |
|
NCBI chr 6:17,281,184...17,289,129
Ensembl chr 6:17,281,184...17,289,114
|
|
G |
Cbs |
cystathionine beta-synthase |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] |
CTD |
PMID:18224302 |
|
NCBI chr17:31,831,602...31,856,170
Ensembl chr17:31,827,868...31,856,212
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression decreases response to substance affects expression |
ISO EXP |
[Simvastatin co-treated with Ramipril] results in decreased expression of CCL2 protein; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin results in decreased expression of and results in decreased secretion of CCL2 protein Simvastatin results in decreased expression of CCL2 mRNA; Simvastatin results in decreased expression of CCL2 protein Simvastatin results in decreased susceptibility to CCL2 protein Simvastatin affects the expression of CCL2 mRNA |
CTD |
PMID:12117737 PMID:12818400 PMID:15184351 PMID:15781755 PMID:15824212 PMID:15855201 PMID:16321392 PMID:16414398 PMID:16443229 PMID:16781696 PMID:17449418 PMID:18309148 PMID:19225232 PMID:19262002 PMID:21268089 PMID:22305382 More...
|
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CCL20 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr 1:83,094,487...83,096,888
Ensembl chr 1:83,094,487...83,096,888
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA] Simvastatin results in decreased expression of CCL3 mRNA |
CTD |
PMID:16321392 PMID:16414398 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA] |
CTD |
PMID:16321392 |
|
NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression decreases expression |
ISO |
Simvastatin results in increased expression of CCL5 mRNA Simvastatin results in decreased expression of CCL5 mRNA Simvastatin results in decreased expression of CCL5 protein |
CTD |
PMID:17112859 PMID:17183729 PMID:17449418 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA] Simvastatin results in decreased expression of CCN1 mRNA |
CTD |
PMID:17428261 PMID:20191585 |
|
NCBI chr 3:145,352,726...145,355,740
Ensembl chr 3:145,352,731...145,355,736
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions decreases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein] Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 protein] Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein] Simvastatin results in decreased expression of CCN2 mRNA; Simvastatin results in decreased expression of CCN2 protein |
CTD |
PMID:15200425 PMID:15298857 PMID:15677772 PMID:19080365 PMID:19099753 PMID:19659652 More...
|
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of CCNA2 mRNA geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein] |
CTD |
PMID:17428261 PMID:26577051 |
|
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein] Simvastatin results in decreased expression of CCND1 mRNA; Simvastatin results in decreased expression of CCND1 protein |
CTD |
PMID:17277159 PMID:17428261 PMID:20878096 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions decreases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein] |
CTD |
PMID:26577051 |
|
NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA] Simvastatin results in decreased expression of CCR1 mRNA |
CTD |
PMID:16321392 PMID:16414398 |
|
NCBI chr 9:123,762,163...123,768,729
Ensembl chr 9:123,762,161...123,768,729
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions decreases expression |
ISO |
[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA] Simvastatin results in decreased expression of CCR2 mRNA; Simvastatin results in decreased expression of CCR2 protein |
CTD |
PMID:15781755 PMID:16321392 PMID:16414398 PMID:16781696 PMID:17449418 |
|
NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA] |
CTD |
PMID:16321392 |
|
NCBI chr 9:114,319,384...114,334,544
Ensembl chr 9:114,319,384...114,333,984
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA] Simvastatin results in decreased expression of CCR5 mRNA Simvastatin results in decreased expression of CCR5 protein |
CTD |
PMID:16321392 PMID:17112859 PMID:17449418 |
|
NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736
|
|
G |
Cd14 |
CD14 antigen |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD14 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851
|
|
G |
Cd151 |
CD151 antigen |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD151 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 7:141,047,275...141,051,394
Ensembl chr 7:141,047,305...141,051,386
|
|
G |
Cd24a |
CD24a antigen |
increases expression |
ISO |
Simvastatin results in increased expression of CD24 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr10:43,454,433...43,460,261
Ensembl chr10:43,454,280...43,460,261
|
|
G |
Cd27 |
CD27 antigen |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD27 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr 6:125,209,583...125,214,014
Ensembl chr 6:125,209,585...125,213,973
|
|
G |
Cd2ap |
CD2-associated protein |
increases expression |
ISO |
Simvastatin results in increased expression of CD2AP mRNA |
CTD |
PMID:16710349 |
|
NCBI chr17:43,059,857...43,187,593
Ensembl chr17:43,103,842...43,187,556
|
|
G |
Cd40 |
CD40 antigen |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of CD40 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]] |
CTD |
PMID:16387846 PMID:17169357 PMID:17507688 |
|
NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression increases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of CD40LG protein; Simvastatin results in decreased expression of CD40LG protein modified form Simvastatin results in increased expression of CD40LG protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA] |
CTD |
PMID:17169357 PMID:18269829 PMID:21330348 |
|
NCBI chr X:56,257,448...56,269,402
Ensembl chr X:56,257,503...56,269,402
|
|
G |
Cd44 |
CD44 antigen |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CD44 protein]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter] Simvastatin results in decreased expression of CD44 mRNA; Simvastatin results in decreased expression of CD44 protein |
CTD |
PMID:21199873 |
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cd80 |
CD80 antigen |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD80 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr16:38,277,793...38,316,682
Ensembl chr16:38,275,923...38,316,697
|
|
G |
Cd83 |
CD83 antigen |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD83 protein |
CTD |
PMID:16387846 |
|
NCBI chr13:43,938,661...43,956,608
Ensembl chr13:43,938,251...43,956,608
|
|
G |
Cd86 |
CD86 antigen |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD86 protein |
CTD |
PMID:16387846 |
|
NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443
|
|
G |
Cdc25b |
cell division cycle 25B |
affects expression |
ISO |
Simvastatin affects the expression of CDC25B mRNA; Simvastatin affects the expression of CDC25B protein |
CTD |
PMID:19110722 |
|
NCBI chr 2:131,028,356...131,040,431
Ensembl chr 2:131,028,869...131,040,417
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases activity |
EXP |
Simvastatin results in decreased activity of CDC42 protein |
CTD |
PMID:17169357 |
|
NCBI chr 4:137,047,011...137,085,007
Ensembl chr 4:137,047,007...137,085,031
|
|
G |
Cdc45 |
cell division cycle 45 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CDC45 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr16:18,599,202...18,632,371
Ensembl chr16:18,599,197...18,630,737
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CDC6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:98,798,627...98,814,768
Ensembl chr11:98,798,627...98,814,766
|
|
G |
Cdh5 |
cadherin 5 |
increases expression |
ISO |
Simvastatin results in increased expression of CDH5 mRNA; Simvastatin results in increased expression of CDH5 protein |
CTD |
PMID:19109527 |
|
NCBI chr 8:104,828,247...104,871,136
Ensembl chr 8:104,828,257...104,871,143
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of CDK1 mRNA; Simvastatin results in decreased expression of CDK1 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein] |
CTD |
PMID:17428261 PMID:20878096 PMID:26577051 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases expression decreases activity |
ISO |
[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; [Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein Simvastatin results in decreased expression of CDK2 protein Simvastatin results in decreased activity of CDK2 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein] |
CTD |
PMID:10412745 PMID:17928568 PMID:18804536 PMID:20878096 PMID:26577051 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdk4 |
cyclin dependent kinase 4 |
decreases expression decreases activity |
ISO |
Simvastatin results in decreased expression of CDK4 protein Simvastatin results in decreased activity of CDK4 protein |
CTD |
PMID:18804536 PMID:20878096 |
|
NCBI chr10:126,899,404...126,903,157
Ensembl chr10:126,899,403...126,903,789
|
|
G |
Cdk5 |
cyclin dependent kinase 5 |
increases expression |
ISO |
Simvastatin results in increased expression of CDK5 |
CTD |
PMID:19461118 |
|
NCBI chr 5:24,612,595...24,628,737
Ensembl chr 5:24,623,239...24,628,528
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of CDKN1A protein]; Simvastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein] Simvastatin results in increased expression of CDKN1A mRNA; Simvastatin results in increased expression of CDKN1A protein |
CTD |
PMID:15625077 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18625202 PMID:18804536 More...
|
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO |
[Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein Simvastatin results in increased expression of CDKN1B mRNA; Simvastatin results in increased expression of CDKN1B protein |
CTD |
PMID:12963647 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18804536 PMID:20878096 More...
|
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn1c |
cyclin dependent kinase inhibitor 1C |
increases expression |
ISO |
Simvastatin results in increased expression of CDKN1C mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 7:143,012,076...143,014,735
Ensembl chr 7:143,012,076...143,014,787
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
increases expression |
ISO |
Simvastatin results in increased expression of CDKN2A protein |
CTD |
PMID:18804536 |
|
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
increases expression |
ISO |
Simvastatin results in increased expression of CDKN2D mRNA; Simvastatin results in increased expression of CDKN2D protein |
CTD |
PMID:20878096 |
|
NCBI chr 9:21,199,759...21,202,553
Ensembl chr 9:21,199,706...21,202,703
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CDT1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 8:123,294,754...123,299,869
Ensembl chr 8:123,294,754...123,300,293
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter] |
CTD |
PMID:16575855 |
|
NCBI chr17:79,226,432...79,244,499
Ensembl chr17:79,226,435...79,244,495
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO |
Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 protein] Simvastatin inhibits the reaction [CES1 protein results in increased hydrolysis of remdesivir] |
CTD |
PMID:33383043 PMID:34774545 |
|
NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions decreases expression increases expression |
ISO EXP |
Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein] Simvastatin results in decreased expression of CFLAR protein; Simvastatin results in decreased expression of CFLAR protein alternative form Simvastatin results in increased expression of CFLAR mRNA; Simvastatin results in increased expression of CFLAR protein |
CTD |
PMID:17277159 PMID:18521906 PMID:19262002 PMID:21910007 |
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR protein] |
CTD |
PMID:33774062 |
|
NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767
|
|
G |
Chat |
choline acetyltransferase |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA] |
CTD |
PMID:16828882 |
|
NCBI chr14:32,130,160...32,187,866
Ensembl chr14:32,130,160...32,187,946
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA] |
CTD |
PMID:16828882 |
|
NCBI chr 2:112,306,055...112,365,487
Ensembl chr 2:112,309,516...112,311,114
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
multiple interactions increases phosphorylation increases expression |
ISO EXP |
artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of CHUK protein] Simvastatin results in increased expression of CHUK mRNA |
CTD |
PMID:18463201 PMID:19262002 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Ciita |
class II transactivator |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein] |
CTD |
PMID:11219190 |
|
NCBI chr16:10,297,877...10,348,928
Ensembl chr16:10,297,923...10,346,282
|
|
G |
Ckm |
creatine kinase, muscle |
multiple interactions decreases expression increases secretion |
ISO |
[Clarithromycin co-treated with Simvastatin] results in increased expression of CKM protein Simvastatin results in decreased expression of CKM protein carvacrol inhibits the reaction [Simvastatin results in increased secretion of CKM protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein] |
CTD |
PMID:8611662 PMID:19252767 PMID:29071762 PMID:35762198 |
|
NCBI chr 7:19,145,019...19,155,508
Ensembl chr 7:19,138,701...19,156,766
|
|
G |
Clcn3 |
chloride channel, voltage-sensitive 3 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein] Simvastatin results in decreased expression of CLCN3 protein |
CTD |
PMID:20644009 |
|
NCBI chr 8:61,363,423...61,436,351
Ensembl chr 8:61,363,423...61,436,334
|
|
G |
Cldn18 |
claudin 18 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 protein] |
CTD |
PMID:33774062 |
|
NCBI chr 9:99,572,849...99,599,320
Ensembl chr 9:99,571,514...99,599,320
|
|
G |
Cldn4 |
claudin 4 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 protein] |
CTD |
PMID:33774062 |
|
NCBI chr 5:134,973,977...134,975,788
Ensembl chr 5:134,973,973...134,975,788
|
|
G |
Col11a1 |
collagen, type XI, alpha 1 |
increases expression |
EXP |
Simvastatin results in increased expression of COL11A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 3:113,823,933...114,014,405
Ensembl chr 3:113,824,189...114,014,367
|
|
G |
Col12a1 |
collagen, type XII, alpha 1 |
increases expression |
EXP |
Simvastatin results in increased expression of COL12A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 9:79,506,269...79,628,423
Ensembl chr 9:79,506,273...79,626,113
|
|
G |
Col13a1 |
collagen, type XIII, alpha 1 |
decreases response to substance |
ISO |
COL13A1 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr10:61,674,013...61,814,985
Ensembl chr10:61,674,015...61,814,887
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
multiple interactions decreases expression increases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter]; Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter] Simvastatin results in increased expression of COL1A1 mRNA |
CTD |
PMID:10412775 PMID:14973129 PMID:16274305 PMID:16575855 PMID:17252541 PMID:20417880 More...
|
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Col2a1 |
collagen, type II, alpha 1 |
multiple interactions increases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA] |
CTD |
PMID:18628692 PMID:19912653 |
|
NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576
|
|
G |
Col3a1 |
collagen, type III, alpha 1 |
increases expression decreases expression |
ISO EXP |
Simvastatin results in increased expression of COL3A1 mRNA Simvastatin results in decreased expression of COL3A1 mRNA |
CTD |
PMID:10412775 PMID:16274305 PMID:16414398 PMID:17183729 |
|
NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866
|
|
G |
Col4a1 |
collagen, type IV, alpha 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of COL4A1 mRNA |
CTD |
PMID:10412775 |
|
NCBI chr 8:11,248,423...11,362,889
Ensembl chr 8:11,248,423...11,362,826
|
|
G |
Col5a1 |
collagen, type V, alpha 1 |
increases expression |
EXP |
Simvastatin results in increased expression of COL5A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 2:27,776,393...27,929,522
Ensembl chr 2:27,776,437...27,929,526
|
|
G |
Col6a2 |
collagen, type VI, alpha 2 |
increases expression |
EXP |
Simvastatin results in increased expression of COL6A2 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr10:76,431,590...76,459,464
Ensembl chr10:76,431,596...76,459,464
|
|
G |
Col7a1 |
collagen, type VII, alpha 1 |
increases expression |
ISO |
Simvastatin results in increased expression of COL7A1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 9:108,782,654...108,813,943
Ensembl chr 9:108,782,654...108,813,943
|
|
G |
Coro1a |
coronin, actin binding protein 1A |
decreases expression |
ISO |
Simvastatin results in decreased expression of CORO1A protein |
CTD |
PMID:20217863 |
|
NCBI chr 7:126,298,946...126,303,925
Ensembl chr 7:126,298,945...126,306,959
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20191585 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of CRP protein [Ezetimibe co-treated with Simvastatin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in increased expression of CRP protein]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]; Simvastatin inhibits the reaction [ethinyl estradiol-desogestrel combination results in increased expression of CRP protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein] |
CTD |
PMID:15184351 PMID:15824212 PMID:17105841 PMID:18023360 PMID:18420099 PMID:20152243 More...
|
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Csn1s2a |
casein alpha s2-like A |
increases expression |
EXP |
Simvastatin results in increased expression of CSN1S2A mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 5:87,922,309...87,936,657
Ensembl chr 5:87,922,426...87,936,656
|
|
G |
Cspg4 |
chondroitin sulfate proteoglycan 4 |
increases expression |
EXP |
Simvastatin results in increased expression of CSPG4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 9:56,772,388...56,807,154
Ensembl chr 9:56,772,317...56,807,154
|
|
G |
Ctf1 |
cardiotrophin 1 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:16534557 PMID:18400235 PMID:19100119 |
|
NCBI chr 7:127,311,872...127,317,360
Ensembl chr 7:127,311,908...127,317,364
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte-associated protein 4 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CTLA4 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr 1:60,948,184...60,954,991
Ensembl chr 1:60,926,159...60,954,991
|
|
G |
Ctnnal1 |
catenin alpha like 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CTNNAL1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 4:56,810,935...56,865,370
Ensembl chr 4:56,810,935...56,865,188
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
EXP ISO |
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein] Simvastatin inhibits the reaction [Glucose results in decreased expression of CTNNB1 protein] Simvastatin results in increased expression of CTNNB1 protein |
CTD |
PMID:18004065 PMID:22058016 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Ctsl |
cathepsin L |
increases expression |
ISO |
Simvastatin results in increased expression of CTSL mRNA |
CTD |
PMID:19001041 |
|
NCBI chr13:64,509,704...64,518,586
Ensembl chr13:64,507,151...64,518,704
|
|
G |
Ctss |
cathepsin S |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS protein] |
CTD |
PMID:20835264 |
|
NCBI chr 3:95,434,097...95,463,716
Ensembl chr 3:95,434,097...95,463,714
|
|
G |
Cttn |
cortactin |
affects localization multiple interactions |
ISO |
Simvastatin affects the localization of CTTN protein Simvastatin affects the reaction [F2 affects the localization of CTTN protein] |
CTD |
PMID:14630613 |
|
NCBI chr 7:143,989,468...144,024,743
Ensembl chr 7:143,989,470...144,024,746
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CX3CR1 mRNA |
CTD |
PMID:18359719 |
|
NCBI chr 9:119,877,749...119,897,362
Ensembl chr 9:119,877,749...119,898,945
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions decreases expression |
EXP ISO |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL10 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL10 protein] Simvastatin results in decreased expression of CXCL10 mRNA; Simvastatin results in decreased expression of CXCL10 protein |
CTD |
PMID:15187114 PMID:16414398 PMID:17449418 PMID:22305382 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
Simvastatin results in increased expression of CXCL12 |
CTD |
PMID:19591934 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions decreases secretion decreases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CXCL8 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CXCL8 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]; Simvastatin results in decreased expression of and results in decreased secretion of CXCL8 protein Simvastatin results in decreased secretion of CXCL8 protein Simvastatin inhibits the reaction [TNF results in increased expression of CXCL15 mRNA] Simvastatin results in decreased expression of CXCL8 mRNA; Simvastatin results in decreased expression of CXCL8 protein |
CTD |
PMID:12117737 PMID:16387846 PMID:16511915 PMID:17178392 PMID:18203325 PMID:20065508 More...
|
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCL16 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr11:70,345,215...70,350,810
Ensembl chr11:70,344,809...70,350,810
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CXCL2 mRNA; Simvastatin results in decreased expression of CXCL2 protein |
CTD |
PMID:21330348 PMID:21441352 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CXCL1 mRNA; Simvastatin results in decreased expression of CXCL1 protein |
CTD |
PMID:21330348 PMID:21441352 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCR2 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 1:74,193,153...74,200,405
Ensembl chr 1:74,193,150...74,200,405
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression increases expression |
ISO |
Simvastatin results in decreased expression of CXCR4 mRNA Simvastatin results in increased expression of CXCR4 |
CTD |
PMID:16414398 PMID:19591934 |
|
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Cyba |
cytochrome b-245, alpha polypeptide |
affects response to substance |
ISO |
CYBA gene SNP affects the susceptibility to Simvastatin |
CTD |
PMID:15936011 |
|
NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
|
|
G |
Cybb |
cytochrome b-245, beta polypeptide |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein] |
CTD |
PMID:30513525 |
|
NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11A1 mRNA; [Simvastatin co-treated with resveratrol] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:24524197 PMID:25055962 |
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr15:74,722,467...74,728,080
Ensembl chr15:74,722,859...74,728,167
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of CYP17A1 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP17A1 mRNA; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; resveratrol promotes the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; Simvastatin promotes the reaction [resveratrol results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:21918126 PMID:24524197 PMID:25055962 |
|
NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Simvastatin results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Simvastatin results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:33383043 |
|
NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
increases expression |
ISO |
Simvastatin results in increased expression of CYP2B6 mRNA |
CTD |
PMID:15802384 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2c29 |
cytochrome P450, family 2, subfamily c, polypeptide 29 |
decreases activity |
ISO |
Simvastatin results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
multiple interactions |
ISO |
Simvastatin affects the reaction [CYP2C9 polymorphism affects the susceptibility to Warfarin] |
CTD |
PMID:22594507 |
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
affects response to substance |
ISO |
CYP2D6 polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:11753271 |
|
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CYP39A1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr17:43,978,263...44,062,322
Ensembl chr17:43,978,316...44,062,322
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
affects response to substance |
ISO |
CYP3A5 polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:17192506 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CYP46A1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr12:108,300,568...108,328,497
Ensembl chr12:108,300,640...108,328,493
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Simvastatin results in increased expression of CYP51 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746
|
|
G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]; Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 protein] |
CTD |
PMID:33383043 |
|
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
|
|
G |
Dbf4 |
DBF4 zinc finger |
decreases expression |
ISO |
Simvastatin results in decreased expression of DBF4 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 5:8,446,969...8,472,789
Ensembl chr 5:8,446,973...8,472,716
|
|
G |
Dbp |
D site albumin promoter binding protein |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of DBP mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 7:45,354,658...45,359,579
Ensembl chr 7:45,354,512...45,359,627
|
|
G |
Dcx |
doublecortin |
increases expression |
ISO |
Simvastatin results in increased expression of DCX |
CTD |
PMID:18544044 |
|
NCBI chr X:142,638,838...142,716,392
Ensembl chr X:142,638,838...142,716,307
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of DDAH1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 3:145,464,447...145,600,032
Ensembl chr 3:145,464,430...145,600,032
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
increases expression increases activity |
ISO |
Simvastatin results in increased expression of DGAT1 mRNA Simvastatin results in increased activity of DGAT1 protein |
CTD |
PMID:12056585 |
|
NCBI chr15:76,386,215...76,396,167
Ensembl chr15:76,386,215...76,396,153
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO EXP |
Simvastatin results in increased expression of DHCR24 Simvastatin results in increased expression of DHCR24 mRNA; Simvastatin results in increased expression of DHCR24 protein |
CTD |
PMID:21987590 PMID:25055962 |
|
NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
affects response to substance multiple interactions affects expression |
ISO EXP |
DHCR7 mutant form affects the susceptibility to Simvastatin Hydroxychloroquine affects the reaction [Simvastatin affects the expression of DHCR7 mRNA]; Simvastatin promotes the reaction [DHCR7 results in increased chemical synthesis of Cholesterol] Simvastatin inhibits the reaction [DHCR7 mutant form results in increased abundance of 7-dehydrocholesterol] [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of DHCR7 mRNA |
CTD |
PMID:15896653 PMID:16446309 PMID:19365639 PMID:25055962 PMID:28975700 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization multiple interactions |
ISO |
Simvastatin affects the localization of DIABLO protein DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein] |
CTD |
PMID:20045437 |
|
NCBI chr 5:123,649,393...123,664,825
Ensembl chr 5:123,647,828...123,662,239
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
EXP |
DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA] |
CTD |
PMID:22058016 |
|
NCBI chr19:30,523,276...30,526,896
Ensembl chr19:30,523,263...30,527,065
|
|
G |
Dll4 |
delta like canonical Notch ligand 4 |
increases expression |
ISO |
Simvastatin results in increased expression of DLL4 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 2:119,156,286...119,166,145
Ensembl chr 2:119,156,265...119,166,443
|
|
G |
Dnm1l |
dynamin 1-like |
affects localization increases expression |
ISO |
Simvastatin affects the localization of DNM1L protein Simvastatin results in increased expression of DNM1L protein |
CTD |
PMID:20045437 |
|
NCBI chr16:16,130,092...16,176,863
Ensembl chr16:16,130,094...16,176,823
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions increases expression |
ISO |
SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein] Simvastatin results in increased expression of DRD1 mRNA; Simvastatin results in increased expression of DRD1 protein |
CTD |
PMID:15711596 |
|
NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724
|
|
G |
Drd2 |
dopamine receptor D2 |
increases expression |
ISO |
Simvastatin results in increased expression of DRD2 mRNA; Simvastatin results in increased expression of DRD2 protein |
CTD |
PMID:15711596 |
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Dspp |
dentin sialophosphoprotein |
increases expression |
ISO |
Simvastatin results in increased expression of DSPP mRNA |
CTD |
PMID:19249597 |
|
NCBI chr 5:104,318,569...104,327,993
Ensembl chr 5:104,318,578...104,327,993
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of DUSP1 mRNA; Simvastatin results in decreased expression of DUSP1 protein |
CTD |
PMID:21080865 |
|
NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of E2F1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
|
|
G |
Eaf2 |
ELL associated factor 2 |
decreases response to substance |
ISO |
EAF2 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr16:36,613,246...36,695,275
Ensembl chr16:36,613,246...36,695,365
|
|
G |
Edn1 |
endothelin 1 |
decreases expression multiple interactions decreases secretion |
ISO |
Simvastatin results in decreased expression of EDN1 mRNA; Simvastatin results in decreased expression of EDN1 protein Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 protein]; Simvastatin results in increased expression of and results in increased secretion of EDN1 protein Simvastatin results in decreased secretion of EDN1 protein Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDN1 mRNA] |
CTD |
PMID:16375908 PMID:18390205 PMID:19099753 PMID:20369390 PMID:20644009 PMID:21844074 PMID:22022327 More...
|
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDNRA mRNA] |
CTD |
PMID:19505368 PMID:22022327 |
|
NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:20359552 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of EGR1 protein |
CTD |
PMID:12818400 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation multiple interactions |
EXP |
Simvastatin results in decreased phosphorylation of EIF4EBP1 protein IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22144680 PMID:27734117 |
|
NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702
|
|
G |
Eno1 |
enolase 1, alpha non-neuron |
decreases expression |
ISO |
Simvastatin results in decreased expression of ENO1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
|
|
G |
Entpd1 |
ectonucleoside triphosphate diphosphohydrolase 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein] |
CTD |
PMID:12067895 |
|
NCBI chr19:40,600,810...40,730,046
Ensembl chr19:40,600,810...40,730,046
|
|
G |
Epha3 |
Eph receptor A3 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA3 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr16:63,363,895...63,684,538
Ensembl chr16:63,363,897...63,684,538
|
|
G |
Epha8 |
Eph receptor A8 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA8 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 4:136,656,729...136,684,170
Ensembl chr 4:136,656,730...136,684,127
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPO protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPO mRNA] |
CTD |
PMID:20821229 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPOR protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPOR mRNA] |
CTD |
PMID:20821229 |
|
NCBI chr 9:21,870,193...21,874,915
Ensembl chr 9:21,870,193...21,874,802
|
|
G |
F2 |
coagulation factor II |
multiple interactions decreases activity |
ISO |
Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein]; Simvastatin affects the reaction [F2 affects the localization of CTTN protein]; Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein] |
CTD |
PMID:12067895 PMID:14630613 |
|
NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759
|
|
G |
F3 |
coagulation factor III |
multiple interactions decreases expression increases expression affects response to substance decreases activity |
ISO EXP |
geranylgeraniol inhibits the reaction [Simvastatin results in decreased expression of F3]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of F3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of F3]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein] Simvastatin results in decreased expression of F3; Simvastatin results in decreased expression of F3 mRNA; Simvastatin results in decreased expression of F3 protein Simvastatin results in increased expression of F3 mRNA; Simvastatin results in increased expression of F3 protein F3 polymorphism affects the susceptibility to Simvastatin Simvastatin results in decreased activity of F3 protein |
CTD |
PMID:9081680 PMID:10830219 PMID:12753293 PMID:12818400 PMID:15824212 PMID:17513194 PMID:18031796 PMID:18841289 PMID:19027114 More...
|
|
NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Simvastatin results in increased expression of FASN mRNA |
CTD |
PMID:11728391 PMID:12056585 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fbxo32 |
F-box protein 32 |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of FBXO32 mRNA; Simvastatin results in increased expression of FBXO32 protein FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA] |
CTD |
PMID:19001041 PMID:25300705 PMID:27734117 PMID:33034787 |
|
NCBI chr15:58,039,275...58,078,288
Ensembl chr15:58,039,275...58,078,328
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression increases activity multiple interactions |
ISO |
Simvastatin results in increased expression of FDFT1 protein Simvastatin results in increased activity of FDFT1 protein resveratrol inhibits the reaction [Simvastatin results in increased expression of FDFT1 mRNA] |
CTD |
PMID:8517861 PMID:12518039 PMID:23386644 |
|
NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027
|
|
G |
Fdps |
farnesyl diphosphate synthetase |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of FDPS mRNA resveratrol inhibits the reaction [Simvastatin results in increased expression of FDPS mRNA] |
CTD |
PMID:23386644 |
|
NCBI chr 3:89,000,895...89,009,274
Ensembl chr 3:89,000,895...89,009,266
|
|
G |
Fgf15 |
fibroblast growth factor 15 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Dietary Fats results in increased expression of FGF19 mRNA] |
CTD |
PMID:33383043 |
|
NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Simvastatin results in increased expression of FGF2 |
CTD |
PMID:20381859 |
|
NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
|
|
G |
Fkbp1a |
FK506 binding protein 1a |
decreases expression |
ISO |
Simvastatin results in decreased expression of FKBP1A mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 2:151,384,403...151,403,611
Ensembl chr 2:151,384,403...151,403,612
|
|
G |
Fkbp4 |
FK506 binding protein 4 |
increases expression |
EXP |
Simvastatin results in increased expression of FKBP4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 6:128,407,066...128,415,619
Ensembl chr 6:128,406,698...128,415,640
|
|
G |
Flot1 |
flotillin 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr17:36,134,243...36,143,674
Ensembl chr17:36,134,122...36,143,683
|
|
G |
Flt1 |
FMS-like tyrosine kinase 1 |
multiple interactions increases expression |
ISO |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of FLT1 mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of FLT1 protein] Simvastatin results in increased expression of FLT1 mRNA |
CTD |
PMID:19109527 PMID:20821229 |
|
NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression increases expression |
EXP ISO |
Simvastatin results in decreased expression of FN1 mRNA Simvastatin results in increased expression of FN1 mRNA |
CTD |
PMID:10412775 PMID:15855201 PMID:16274305 PMID:16414398 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions decreases localization decreases expression |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of FOS mRNA] Simvastatin results in decreased localization of FOS protein FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FOS protein] Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA] |
CTD |
PMID:12753293 PMID:12963647 PMID:15187114 PMID:16005304 PMID:19100119 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Fosb |
FBJ osteosarcoma oncogene B |
multiple interactions |
EXP |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr 7:19,036,621...19,043,970
Ensembl chr 7:19,036,621...19,043,976
|
|
G |
Fosl1 |
fos-like antigen 1 |
increases expression |
EXP |
Simvastatin results in increased expression of FOSL1 protein |
CTD |
PMID:20025956 |
|
NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974
|
|
G |
Fosl2 |
fos-like antigen 2 |
multiple interactions |
EXP |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr 5:32,292,599...32,315,184
Ensembl chr 5:32,293,145...32,315,186
|
|
G |
Foxo1 |
forkhead box O1 |
affects localization decreases phosphorylation increases phosphorylation multiple interactions decreases localization |
ISO EXP |
Simvastatin affects the localization of FOXO1 protein Simvastatin results in decreased phosphorylation of FOXO1 protein Simvastatin results in increased phosphorylation of FOXO1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased localization of FOXO1 protein] farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of FOXO1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of and affects the localization of FOXO1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of and affects the localization of FOXO1 protein] |
CTD |
PMID:12438947 PMID:18826357 PMID:19001041 PMID:33034787 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions increases phosphorylation decreases expression decreases phosphorylation affects localization |
EXP ISO |
Acetylcysteine inhibits the reaction [Simvastatin results in increased phosphorylation of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein] Simvastatin results in decreased expression of FOXO3 protein Simvastatin results in decreased phosphorylation of FOXO3 protein |
CTD |
PMID:19001041 PMID:20883752 PMID:27734117 |
|
NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
|
|
G |
Foxp3 |
forkhead box P3 |
increases expression multiple interactions affects methylation decreases expression |
ISO EXP |
Simvastatin results in increased expression of FOXP3 IL2 affects the reaction [Simvastatin results in increased expression of FOXP3]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of FOXP3] Simvastatin affects the methylation of FOXP3 promoter Simvastatin results in decreased expression of FOXP3 mRNA |
CTD |
PMID:20408897 PMID:20491794 PMID:22305382 |
|
NCBI chr X:7,445,915...7,461,482
Ensembl chr X:7,439,883...7,461,484
|
|
G |
Fst |
follistatin |
multiple interactions |
EXP |
FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of MTOR protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 protein]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 protein]; FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD2 protein]; FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:33034787 |
|
NCBI chr13:114,588,798...114,595,522
Ensembl chr13:114,588,826...114,595,487
|
|
G |
Fzd2 |
frizzled class receptor 2 |
increases expression |
ISO |
Simvastatin results in increased expression of FZD2 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr11:102,495,257...102,498,884
Ensembl chr11:102,495,222...102,498,884
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression |
ISO |
Simvastatin results in decreased expression of GAPDH mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430
|
|
G |
Gata6 |
GATA binding protein 6 |
increases expression |
ISO |
Simvastatin results in increased expression of GATA6 mRNA; Simvastatin results in increased expression of GATA6 protein |
CTD |
PMID:19842842 |
|
NCBI chr18:11,052,510...11,085,636
Ensembl chr18:11,052,064...11,085,635
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of GDI2 protein |
CTD |
PMID:20217863 |
|
NCBI chr13:3,588,075...3,616,261
Ensembl chr13:3,588,063...3,617,871
|
|
G |
Gdnf |
glial cell line derived neurotrophic factor |
increases expression |
ISO |
Simvastatin results in increased expression of GDNF |
CTD |
PMID:20851742 |
|
NCBI chr15:7,839,529...7,867,061
Ensembl chr15:7,840,327...7,867,056
|
|
G |
Gfra1 |
glial cell line derived neurotrophic factor family receptor alpha 1 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of GFRA1 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr19:58,224,013...58,444,387
Ensembl chr19:58,224,036...58,444,341
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP |
GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Simvastatin affects the localization of and results in decreased phosphorylation of GJA1 protein |
CTD |
PMID:23978459 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
increases expression |
ISO |
Simvastatin results in increased expression of GJB2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr14:57,336,059...57,342,159
Ensembl chr14:57,336,057...57,342,159
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Coal Ash results in increased expression of GLB1 protein] |
CTD |
PMID:26773838 |
|
NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966
|
|
G |
Gm7030 |
predicted gene 7030 |
affects expression |
ISO |
Simvastatin affects the expression of HLA-F mRNA |
CTD |
PMID:25811541 |
|
NCBI chr17:36,438,501...36,440,317
Ensembl chr17:36,420,611...36,440,317
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of GPX1 mRNA Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of GPX1 mRNA] |
CTD |
PMID:20883752 PMID:28734741 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Simvastatin results in increased expression of GPX2 mRNA |
CTD |
PMID:18787804 |
|
NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of GSK3B Simvastatin inhibits the reaction [Glucose results in decreased phosphorylation of and results in increased activity of GSK3B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of GSK3B protein] Simvastatin results in increased expression of GSK3B protein modified form |
CTD |
PMID:18004065 PMID:18047562 PMID:19461118 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
|
|
G |
H2-Ab1 |
histocompatibility 2, class II antigen A, beta 1 |
affects expression |
ISO |
Simvastatin affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr17:34,482,201...34,488,392
Ensembl chr17:34,476,663...34,488,393
|
|
G |
H2-DMa |
histocompatibility 2, class II, locus DMa |
decreases expression |
ISO |
Simvastatin results in decreased expression of RT1-DMA mRNA |
CTD |
PMID:16414398 |
|
NCBI chr17:34,338,667...34,358,075
Ensembl chr17:34,338,515...34,358,075
|
|
G |
H2-Ea |
histocompatibility 2, class II antigen E alpha |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein] |
CTD |
PMID:11219190 |
|
NCBI chr17:34,560,926...34,563,619
Ensembl chr17:34,560,926...34,563,618
|
|
G |
H2-T23 |
histocompatibility 2, T region locus 23 |
affects expression |
ISO |
Simvastatin affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr17:36,340,869...36,343,593
Ensembl chr17:36,340,665...36,343,747
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Simvastatin results in increased phosphorylation of H2AX protein |
CTD |
PMID:20499237 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
Hes5 |
hes family bHLH transcription factor 5 |
increases expression |
ISO |
Simvastatin results in increased expression of HES5 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 4:155,042,358...155,046,829
Ensembl chr 4:155,045,380...155,046,828
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
increases expression multiple interactions decreases expression |
ISO |
Simvastatin results in increased expression of HIF1A protein HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA] Simvastatin results in decreased expression of HIF1A mRNA |
CTD |
PMID:18356691 PMID:21844074 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholecalciferol] results in increased expression of HMGB1 mRNA] [Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein] |
CTD |
PMID:20519084 PMID:25412314 |
|
NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
decreases response to substance affects response to substance increases activity multiple interactions increases expression decreases activity |
ISO EXP |
HMGCR exon alternative form results in decreased susceptibility to Simvastatin HMGCR intron polymorphism affects the susceptibility to Simvastatin; HMGCR polymorphism affects the susceptibility to Simvastatin Simvastatin results in increased activity of HMGCR protein [HMGCR intron polymorphism affects the expression of HMGCR exon alternative form] which results in decreased susceptibility to Simvastatin; [MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; [Simvastatin co-treated with Ezetimibe] results in increased expression of HMGCR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; Resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin affects the reaction [Hydroxychloroquine affects the expression of HMGCR mRNA]; Simvastatin results in increased expression of and results in increased activity of HMGCR protein Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of HMGCR protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin results in increased expression of and results in decreased activity of HMGCR protein; Simvastatin results in increased expression of and results in increased activity of HMGCR protein Simvastatin results in increased expression of HMGCR mRNA; Simvastatin results in increased expression of HMGCR protein |
CTD |
PMID:1627634 PMID:8517861 PMID:8593127 PMID:9512650 PMID:10357840 PMID:12056585 PMID:12477733 PMID:12518039 PMID:16282522 PMID:17870053 PMID:17980884 PMID:18332269 PMID:18559695 PMID:19383813 PMID:20413733 PMID:21257924 PMID:21907337 PMID:22120639 PMID:23386644 PMID:24524197 PMID:24613879 PMID:25055962 PMID:28975700 PMID:29969672 More...
|
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases stability decreases expression increases activity increases expression increases response to substance |
EXP ISO |
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; tin protoporphyrin IX inhibits the reaction [Simvastatin results in increased expression of HMOX1 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased stability of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA] Simvastatin results in decreased expression of HMOX1 mRNA Simvastatin results in increased activity of HMOX1 protein Simvastatin results in increased expression of HMOX1 mRNA; Simvastatin results in increased expression of HMOX1 protein HMOX1 gene mutant form results in increased susceptibility to Simvastatin |
CTD |
PMID:16375908 PMID:16414398 PMID:16628357 PMID:17928392 PMID:18073186 PMID:18787804 PMID:20368269 PMID:20594940 PMID:21844074 PMID:21910007 PMID:21925249 PMID:21968084 PMID:30513525 More...
|
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hnf1a |
HNF1 homeobox A |
increases expression |
EXP |
Simvastatin results in increased expression of HNF1A mRNA |
CTD |
PMID:22160096 |
|
NCBI chr 5:115,087,039...115,109,121
Ensembl chr 5:115,087,039...115,109,153
|
|
G |
Hras |
Harvey rat sarcoma virus oncogene |
multiple interactions decreases activity |
ISO EXP |
Farnesol inhibits the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of HRAS protein]; Simvastatin results in decreased prenylation of and results in decreased localization of HRAS protein Simvastatin results in decreased activity of HRAS |
CTD |
PMID:11914545 PMID:12477733 PMID:18625914 PMID:19360310 |
|
NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with resveratrol] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:24524197 |
|
NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110
|
|
G |
Hsf1 |
heat shock factor 1 |
affects localization |
ISO |
Simvastatin affects the localization of HSF1 protein |
CTD |
PMID:16375908 |
|
NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
increases expression |
ISO |
Simvastatin results in increased expression of HSP90AA1 protein |
CTD |
PMID:16375908 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hspa4 |
heat shock protein 4 |
increases expression |
ISO |
Simvastatin results in increased expression of HSPA4 protein |
CTD |
PMID:16375908 |
|
NCBI chr11:53,150,641...53,191,306
Ensembl chr11:53,150,641...53,191,284
|
|
G |
Hspa5 |
heat shock protein 5 |
increases expression |
ISO |
Simvastatin results in increased expression of HSPA5 mRNA; Simvastatin results in increased expression of HSPA5 protein |
CTD |
PMID:18664198 PMID:19253821 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Hspa8 |
heat shock protein 8 |
decreases expression |
ISO |
Simvastatin results in decreased expression of HSPA8 protein |
CTD |
PMID:20217863 |
|
NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
affects localization |
ISO |
Simvastatin affects the localization of HTRA2 protein |
CTD |
PMID:20045437 |
|
NCBI chr 6:83,028,247...83,031,552
Ensembl chr 6:83,028,247...83,032,254
|
|
G |
Ibsp |
integrin binding sialoprotein |
increases expression |
EXP |
Simvastatin results in increased expression of IBSP mRNA |
CTD |
PMID:20417880 |
|
NCBI chr 5:104,447,153...104,459,338
Ensembl chr 5:104,447,037...104,459,335
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Simvastatin affects the expression of and affects the secretion of ICAM1 protein; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of ICAM1 protein modified form] Simvastatin results in decreased expression of ICAM1 mRNA; Simvastatin results in decreased expression of ICAM1 protein; Simvastatin results in decreased expression of ICAM1 protein modified form |
CTD |
PMID:10946302 PMID:12615677 PMID:14602771 PMID:15234187 PMID:16054375 PMID:16193989 PMID:17277159 PMID:19166837 PMID:20863785 PMID:21764683 PMID:21874229 PMID:21994025 More...
|
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression |
EXP |
Simvastatin results in increased expression of ID1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase |
increases expression |
ISO |
Simvastatin results in increased expression of IDI1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr13:8,935,642...8,942,432
Ensembl chr13:8,935,537...8,942,487
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression |
ISO |
Simvastatin results in increased expression of IDO1 |
CTD |
PMID:20491794 |
|
NCBI chr 8:25,074,148...25,086,987
Ensembl chr 8:25,074,152...25,087,025
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression increases secretion |
ISO EXP |
IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA] Simvastatin results in increased expression of IFNG mRNA Simvastatin results in increased secretion of IFNG protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2] |
CTD |
PMID:11219190 PMID:16321392 PMID:17507688 PMID:18453621 PMID:19589242 PMID:19886038 PMID:21268089 More...
|
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
EXP |
[Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein] |
CTD |
PMID:17327694 PMID:27734117 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Igf1r |
insulin-like growth factor I receptor |
decreases expression increases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of IGF1R; Simvastatin results in decreased expression of IGF1R mRNA; Simvastatin results in decreased expression of IGF1R protein Simvastatin results in increased expression of IGF1R protein alternative form [Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein] |
CTD |
PMID:17158816 PMID:17327694 PMID:18489904 PMID:27734117 |
|
NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416
|
|
G |
Igfbp6 |
insulin-like growth factor binding protein 6 |
increases expression |
ISO |
Simvastatin results in increased expression of IGFBP6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr15:102,052,621...102,057,947
Ensembl chr15:102,052,797...102,057,946
|
|
G |
Ikbkb |
inhibitor of kappaB kinase beta |
multiple interactions decreases expression increases phosphorylation |
ISO |
artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of IKBKB protein] Simvastatin results in decreased expression of IKBKB mRNA |
CTD |
PMID:17277159 PMID:18463201 |
|
NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of IL10 Simvastatin results in increased expression of IL10 mRNA; Simvastatin results in increased expression of IL10 protein Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] 1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of IL10 protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of IL10 protein] |
CTD |
PMID:15883752 PMID:20491794 PMID:21925249 PMID:33774062 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il12b |
interleukin 12b |
multiple interactions increases expression |
EXP |
FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B protein]; Simvastatin promotes the reaction [Pam(3)CSK(4) peptide results in increased expression of IL12B protein]; Simvastatin promotes the reaction [resiquimod results in increased expression of IL12B protein] |
CTD |
PMID:15187114 |
|
NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860
|
|
G |
Il13 |
interleukin 13 |
decreases expression |
EXP |
Simvastatin results in decreased expression of IL13 mRNA; Simvastatin results in decreased expression of IL13 protein |
CTD |
PMID:17169357 |
|
NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529
|
|
G |
Il16 |
interleukin 16 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of IL16 mRNA |
CTD |
PMID:15665042 |
|
NCBI chr 7:83,292,027...83,395,479
Ensembl chr 7:83,292,033...83,394,934
|
|
G |
Il17a |
interleukin 17A |
multiple interactions decreases expression decreases secretion |
ISO |
IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL17A mRNA] |
CTD |
PMID:18453621 PMID:21856936 |
|
NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720
|
|
G |
Il17f |
interleukin 17F |
decreases secretion |
ISO |
Simvastatin results in decreased secretion of IL17F protein |
CTD |
PMID:21856936 |
|
NCBI chr 1:20,847,370...20,855,498
Ensembl chr 1:20,847,370...20,860,841
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]]; Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA] Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL18 protein] |
CTD |
PMID:18660453 PMID:27377765 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]] |
CTD |
PMID:15705589 PMID:15728660 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression decreases secretion |
ISO |
1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B mRNA]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA] farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] Simvastatin results in decreased expression of IL1B mRNA; Simvastatin results in decreased expression of IL1B protein Simvastatin results in decreased secretion of IL1B protein |
CTD |
PMID:10946302 PMID:12829860 PMID:15883752 PMID:16054375 PMID:17075836 PMID:18047562 PMID:18309148 PMID:18791746 PMID:19166837 PMID:19574840 PMID:20126887 PMID:20191585 PMID:21910007 PMID:22305382 PMID:27377765 PMID:30408459 PMID:31260663 PMID:33774062 PMID:35762198 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il1r2 |
interleukin 1 receptor, type II |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL1R2 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 1:40,123,872...40,164,390
Ensembl chr 1:40,113,239...40,164,391
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 1:40,444,105...40,504,575
Ensembl chr 1:40,468,730...40,504,575
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
EXP |
IL2 affects the reaction [Simvastatin results in increased expression of FOXP3] |
CTD |
PMID:20408897 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il20rb |
interleukin 20 receptor beta |
increases expression |
ISO |
Simvastatin results in increased expression of IL20RB mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 9:100,339,772...100,368,526
Ensembl chr 9:100,339,772...100,368,841
|
|
G |
Il21 |
interleukin 21 |
decreases expression decreases secretion |
ISO |
Simvastatin results in decreased expression of IL21 mRNA Simvastatin results in decreased secretion of IL21 protein |
CTD |
PMID:18453621 PMID:21856936 |
|
NCBI chr 3:37,276,908...37,286,785
Ensembl chr 3:37,276,908...37,286,785
|
|
G |
Il22b |
interleukin 22B |
decreases secretion |
ISO |
Simvastatin results in decreased secretion of IL22 protein |
CTD |
PMID:21856936 |
|
NCBI chr10:118,125,534...118,130,943
Ensembl chr10:118,125,534...118,130,943
|
|
G |
Il23a |
interleukin 23, alpha subunit p19 |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL23A mRNA |
CTD |
PMID:18453621 PMID:22305382 |
|
NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621
|
|
G |
Il25 |
interleukin 25 |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL25 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr14:55,170,152...55,173,294
Ensembl chr14:55,170,152...55,173,294
|
|
G |
Il27 |
interleukin 27 |
increases expression multiple interactions increases secretion |
ISO |
Simvastatin results in increased expression of IL27 mRNA IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein] Simvastatin results in increased secretion of IL27 protein |
CTD |
PMID:18453621 |
|
NCBI chr 7:126,188,181...126,194,197
Ensembl chr 7:126,188,182...126,194,113
|
|
G |
Il2ra |
interleukin 2 receptor, alpha chain |
affects expression decreases expression |
ISO |
Simvastatin affects the expression of IL2RA protein Simvastatin results in decreased expression of IL2RA mRNA |
CTD |
PMID:16387846 PMID:18453621 |
|
NCBI chr 2:11,647,603...11,698,005
Ensembl chr 2:11,647,618...11,698,004
|
|
G |
Il4 |
interleukin 4 |
multiple interactions increases expression increases secretion decreases expression |
ISO EXP |
IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein] Simvastatin results in increased expression of IL4 mRNA Simvastatin results in increased secretion of IL4 protein Simvastatin results in decreased expression of IL4 mRNA; Simvastatin results in decreased expression of IL4 protein |
CTD |
PMID:17169357 PMID:18453621 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il4ra |
interleukin 4 receptor, alpha |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL4R mRNA Simvastatin results in decreased expression of IL4RA mRNA |
CTD |
PMID:16414398 PMID:18453621 |
|
NCBI chr 7:125,151,443...125,178,646
Ensembl chr 7:125,151,292...125,178,646
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression decreases expression decreases secretion affects secretion |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL6 mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Simvastatin results in decreased expression of and results in decreased secretion of IL6 protein Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein] Simvastatin results in increased expression of IL6 mRNA geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Simvastatin results in decreased expression of IL6 mRNA; Simvastatin results in decreased expression of IL6 protein Simvastatin results in decreased secretion of IL6 protein Simvastatin affects the secretion of IL6 protein |
CTD |
PMID:12117737 PMID:15665042 PMID:15883752 PMID:16387846 PMID:16424782 PMID:16511915 PMID:17075836 PMID:17641834 PMID:17729120 PMID:18203325 PMID:18453621 PMID:18504409 PMID:19001041 PMID:19166837 PMID:20065508 PMID:20126887 PMID:21994025 PMID:22305382 More...
|
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Inha |
inhibin alpha |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INHA mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 1:75,483,872...75,487,010
Ensembl chr 1:75,483,721...75,487,010
|
|
G |
Insig2 |
insulin induced gene 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of INSIG2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 1:121,232,082...121,260,391
Ensembl chr 1:121,232,082...121,260,318
|
|
G |
Insl3 |
insulin-like 3 |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INSL3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 8:72,141,896...72,143,221
Ensembl chr 8:72,141,858...72,143,219
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr11:53,660,841...53,669,200
Ensembl chr11:53,660,841...53,669,200
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of IRF4 protein Simvastatin results in decreased expression of IRF4 mRNA; Simvastatin results in decreased expression of IRF4 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of IRF4 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of IRF4 protein]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IRF4 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IRF4 protein] |
CTD |
PMID:21856936 PMID:33034787 |
|
NCBI chr13:30,933,191...30,950,965
Ensembl chr13:30,933,209...30,950,959
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein] |
CTD |
PMID:27734117 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Itgal |
integrin alpha L |
affects binding multiple interactions decreases expression |
ISO |
Simvastatin binds to [ITGAL protein binds to ITGB2 protein] Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL] Simvastatin results in decreased expression of ITGAL mRNA |
CTD |
PMID:12615677 PMID:15041742 PMID:16828882 |
|
NCBI chr 7:126,895,404...126,934,309
Ensembl chr 7:126,895,432...126,934,310
|
|
G |
Itgam |
integrin alpha M |
multiple interactions decreases expression |
EXP ISO |
Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein] Simvastatin results in decreased expression of ITGAM mRNA; Simvastatin results in decreased expression of ITGAM protein |
CTD |
PMID:16414398 PMID:21330348 PMID:21441352 |
|
NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
decreases expression |
ISO |
Simvastatin results in decreased expression of ITGB1 mRNA; Simvastatin results in decreased expression of ITGB1 protein |
CTD |
PMID:17428261 PMID:21874229 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Itgb2 |
integrin beta 2 |
affects binding multiple interactions decreases expression |
ISO EXP |
Simvastatin binds to [ITGAL protein binds to ITGB2 protein] Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein] Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2] Simvastatin results in decreased expression of ITGB2 mRNA |
CTD |
PMID:12615677 PMID:15041742 PMID:21330348 |
|
NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542
|
|
G |
Itgb3bp |
integrin beta 3 binding protein (beta3-endonexin) |
decreases expression |
ISO |
Simvastatin results in decreased expression of ITGB3BP mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 4:99,655,643...99,717,403
Ensembl chr 4:99,653,639...99,787,010
|
|
G |
Itgb4 |
integrin beta 4 |
affects expression increases expression |
ISO |
Simvastatin affects the expression of ITGB4 mRNA; Simvastatin affects the expression of ITGB4 protein Simvastatin results in increased expression of ITGB4 mRNA; Simvastatin results in increased expression of ITGB4 protein |
CTD |
PMID:14630613 PMID:19110722 |
|
NCBI chr11:115,865,556...115,899,238
Ensembl chr11:115,865,535...115,899,238
|
|
G |
Itgbl1 |
integrin, beta-like 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ITGBL1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr14:123,897,331...124,215,173
Ensembl chr14:123,897,383...124,213,030
|
|
G |
Jak1 |
Janus kinase 1 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein] |
CTD |
PMID:16534557 |
|
NCBI chr 4:101,009,171...101,122,493
Ensembl chr 4:101,009,564...101,122,479
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions decreases expression decreases phosphorylation |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein] Simvastatin results in decreased expression of JAK2 mRNA Simvastatin results in decreased phosphorylation of JAK2 protein |
CTD |
PMID:16414398 PMID:16534557 PMID:18400235 PMID:19100119 |
|
NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions increases phosphorylation decreases localization decreases expression |
ISO EXP |
pyrazolanthrone inhibits the reaction [Simvastatin results in increased phosphorylation of JUN protein] JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of JUN protein] Simvastatin results in decreased localization of JUN protein Simvastatin results in decreased expression of JUN mRNA |
CTD |
PMID:12753293 PMID:12963647 PMID:15187114 PMID:15488325 PMID:17125918 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Junb |
jun B proto-oncogene |
multiple interactions |
EXP |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases localization multiple interactions decreases activity |
ISO |
Simvastatin results in decreased localization of KCNH2 protein Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:21525004 PMID:30086269 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kdr |
kinase insert domain protein receptor |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of KDR mRNA; Simvastatin results in increased expression of KDR protein Simvastatin inhibits the reaction [Streptozocin results in increased expression of KDR mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of KDR protein] |
CTD |
PMID:15572054 PMID:19109527 PMID:20821229 |
|
NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of KIT mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382
|
|
G |
Klf10 |
Kruppel-like transcription factor 10 |
multiple interactions |
ISO |
[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA] |
CTD |
PMID:19225232 |
|
NCBI chr15:38,291,702...38,300,950
Ensembl chr15:38,291,707...38,300,950
|
|
G |
Klf16 |
Kruppel-like transcription factor 16 |
increases expression |
EXP |
Simvastatin results in increased expression of KLF16 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr10:80,402,955...80,413,130
Ensembl chr10:80,402,958...80,413,155
|
|
G |
Klf2 |
Kruppel-like transcription factor 2 (lung) |
increases expression multiple interactions decreases expression |
ISO |
Simvastatin results in increased expression of KLF2 mRNA Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of KLF2 mRNA] Simvastatin results in decreased expression of KLF2 mRNA |
CTD |
PMID:17428261 PMID:20493886 PMID:20737288 PMID:22305382 |
|
NCBI chr 8:73,072,906...73,075,498
Ensembl chr 8:73,072,877...73,075,500
|
|
G |
Klf6 |
Kruppel-like transcription factor 6 |
increases expression |
ISO |
Simvastatin results in increased expression of KLF6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393
|
|
G |
Kras |
Kirsten rat sarcoma viral oncogene homolog |
decreases prenylation |
ISO |
Simvastatin results in decreased prenylation of KRAS protein |
CTD |
PMID:8063617 |
|
NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965
|
|
G |
Krt13 |
keratin 13 |
increases expression |
ISO |
Simvastatin results in increased expression of KRT13 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:100,008,153...100,012,392
Ensembl chr11:100,008,153...100,012,392
|
|
G |
Krt15 |
keratin 15 |
increases expression |
ISO |
Simvastatin results in increased expression of KRT15 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:100,022,585...100,026,775
Ensembl chr11:100,022,584...100,026,754
|
|
G |
Krt17 |
keratin 17 |
increases expression |
ISO |
Simvastatin results in increased expression of KRT17 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:100,147,041...100,151,855
Ensembl chr11:100,147,043...100,151,855
|
|
G |
Lbh |
limb-bud and heart |
increases expression |
EXP |
Simvastatin results in increased expression of LBH mRNA |
CTD |
PMID:19262002 |
|
NCBI chr17:73,225,300...73,248,941
Ensembl chr17:73,225,300...73,248,942
|
|
G |
Lbp |
lipopolysaccharide binding protein |
decreases expression |
ISO |
Simvastatin results in decreased expression of LBP mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 2:158,148,413...158,174,772
Ensembl chr 2:158,148,413...158,174,772
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
increases activity decreases expression |
EXP ISO |
Simvastatin results in increased activity of LCAT protein Simvastatin results in decreased expression of LCAT mRNA |
CTD |
PMID:21241519 PMID:25055962 |
|
NCBI chr 8:106,666,183...106,670,034
Ensembl chr 8:106,666,183...106,670,014
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions affects response to substance increases expression increases activity |
ISO EXP |
[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Simvastatin co-treated with Ezetimibe] results in increased expression of LDLR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB] LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin; LDLR mutant form affects the susceptibility to Simvastatin Simvastatin results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA] Simvastatin results in increased activity of LDLR protein Simvastatin results in increased expression of LDLR mRNA; Simvastatin results in increased expression of LDLR protein |
CTD |
PMID:1627634 PMID:8457250 PMID:8593127 PMID:9633944 PMID:10208479 PMID:10357840 PMID:11181283 PMID:11600564 PMID:11728391 PMID:11849659 PMID:17980884 PMID:18640378 PMID:19383813 PMID:20018177 PMID:20413733 PMID:22120639 More...
|
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
increases expression |
ISO |
Simvastatin results in increased expression of LEF1 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr 3:130,903,972...131,018,006
Ensembl chr 3:130,904,120...131,018,005
|
|
G |
Lep |
leptin |
multiple interactions decreases expression decreases secretion |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; GGTI 298 inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; GGTI 298 inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA] Simvastatin results in decreased expression of LEP mRNA; Simvastatin results in decreased expression of LEP mRNA alternative form Simvastatin inhibits the reaction [Poloxamer results in increased secretion of LEP protein] |
CTD |
PMID:19254925 PMID:29071762 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lepr |
leptin receptor |
affects response to substance |
ISO |
LEPR polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:14625131 PMID:18854995 |
|
NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549
|
|
G |
Lhb |
luteinizing hormone beta |
multiple interactions |
ISO |
Simvastatin promotes the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in decreased expression of LHB protein]; Simvastatin promotes the reaction [ethinyl estradiol-desogestrel combination results in decreased expression of LHB protein] |
CTD |
PMID:17105841 |
|
NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
|
|
G |
Lif |
leukemia inhibitory factor |
multiple interactions |
ISO |
[Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]] |
CTD |
PMID:19225232 |
|
NCBI chr11:4,207,587...4,222,514
Ensembl chr11:4,207,557...4,222,514
|
|
G |
Litaf |
LPS-induced TN factor |
decreases expression |
ISO |
Simvastatin results in decreased expression of LITAF mRNA |
CTD |
PMID:16414398 |
|
NCBI chr16:10,777,137...10,810,985
Ensembl chr16:10,777,139...10,884,021
|
|
G |
Lox |
lysyl oxidase |
decreases expression |
ISO |
Simvastatin results in decreased expression of LOX mRNA |
CTD |
PMID:16414398 |
|
NCBI chr18:52,649,132...52,662,939
Ensembl chr18:52,649,139...52,662,939
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression increases expression |
ISO |
Simvastatin results in decreased expression of LPL Simvastatin results in increased expression of LPL protein |
CTD |
PMID:2009092 PMID:19216230 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Lrp6 |
low density lipoprotein receptor-related protein 6 |
decreases expression |
ISO |
Simvastatin results in decreased expression of LRP6 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 6:134,423,439...134,543,876
Ensembl chr 6:134,423,439...134,543,928
|
|
G |
Lrrc2 |
leucine rich repeat containing 2 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of LRRC2 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 9:110,780,613...110,813,134
Ensembl chr 9:110,780,613...110,813,134
|
|
G |
Ltb |
lymphotoxin B |
decreases expression |
ISO |
Simvastatin results in decreased expression of LTB mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:35,413,483...35,415,281
Ensembl chr17:35,413,415...35,415,296
|
|
G |
Mad2l1 |
MAD2 mitotic arrest deficient-like 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 6:66,512,205...66,518,091
Ensembl chr 6:66,512,374...66,524,204
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of MAP1LC3B protein [Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form; Chloroquine promotes the reaction [[Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:23817226 PMID:25412314 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Map3k14 |
mitogen-activated protein kinase kinase kinase 14 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MAP3K14 mRNA |
CTD |
PMID:17277159 |
|
NCBI chr11:103,110,590...103,158,227
Ensembl chr11:103,110,588...103,158,298
|
|
G |
Map3k7 |
mitogen-activated protein kinase kinase kinase 7 |
multiple interactions |
ISO |
Simvastatin results in decreased activity of [MAP3K7 protein co-treated with TAB1 protein] |
CTD |
PMID:17277159 |
|
NCBI chr 4:31,963,659...32,023,470
Ensembl chr 4:31,964,097...32,023,467
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases activity increases phosphorylation decreases phosphorylation |
ISO EXP |
[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of NFE2L2 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of NQO1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein Simvastatin results in decreased activity of MAPK1 protein Simvastatin results in increased phosphorylation of MAPK1 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of MAPK1 protein Simvastatin results in decreased phosphorylation of MAPK1 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK1 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein |
CTD |
PMID:17169357 PMID:17327694 PMID:17428261 PMID:17928392 PMID:18047562 PMID:18310456 PMID:18625914 PMID:19299917 PMID:19360310 PMID:19383813 PMID:20359552 PMID:20417880 PMID:20464445 PMID:20594940 PMID:21080865 PMID:21910007 PMID:30513525 More...
|
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk14 |
mitogen-activated protein kinase 14 |
multiple interactions decreases expression |
EXP ISO |
Simvastatin results in increased phosphorylation of and results in increased activity of MAPK14 protein Simvastatin results in decreased expression of MAPK14 mRNA |
CTD |
PMID:16414398 PMID:17928392 |
|
NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases activity increases phosphorylation decreases phosphorylation |
ISO EXP |
[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK3 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein Simvastatin results in decreased activity of MAPK3 protein Simvastatin results in increased phosphorylation of MAPK3 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of MAPK3 protein Simvastatin results in decreased phosphorylation of MAPK3 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK3 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein |
CTD |
PMID:17169357 PMID:17327694 PMID:17428261 PMID:17928392 PMID:18047562 PMID:18310456 PMID:18625914 PMID:19299917 PMID:19360310 PMID:19383813 PMID:20359552 PMID:20417880 PMID:20464445 PMID:20594940 PMID:21080865 PMID:21910007 PMID:30513525 More...
|
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases activity |
EXP ISO |
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein] Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein] Simvastatin results in increased activity of MAPK8 protein |
CTD |
PMID:15187114 PMID:18047562 PMID:18310456 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases activity |
EXP |
Simvastatin results in increased activity of MAPK9 protein |
CTD |
PMID:15187114 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mapt |
microtubule-associated protein tau |
affects expression |
ISO |
Simvastatin affects the expression of MAPT |
CTD |
PMID:19461118 |
|
NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916
|
|
G |
Mb |
myoglobin |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Poloxamer results in increased secretion of MB protein] |
CTD |
PMID:29071762 |
|
NCBI chr15:76,899,687...76,934,868
Ensembl chr15:76,899,687...76,934,870
|
|
G |
Mcm4 |
minichromosome maintenance complex component 4 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MCM4 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr16:15,441,761...15,455,264
Ensembl chr16:15,441,761...15,455,264
|
|
G |
Mdh1 |
malate dehydrogenase 1, NAD (soluble) |
decreases expression |
ISO |
Simvastatin results in decreased expression of MDH1 protein |
CTD |
PMID:20217863 |
|
NCBI chr11:21,506,692...21,521,934
Ensembl chr11:21,506,692...21,522,367
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
increases phosphorylation multiple interactions |
ISO |
Simvastatin results in increased phosphorylation of MDM2 protein Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]] |
CTD |
PMID:15625077 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Mertk |
MER proto-oncogene tyrosine kinase |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of MERTK mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 2:128,540,836...128,645,082
Ensembl chr 2:128,540,876...128,644,814
|
|
G |
Mir221 |
microRNA 221 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MIR221 |
CTD |
PMID:25517390 |
|
NCBI chr X:19,012,533...19,012,627
Ensembl chr X:19,012,533...19,012,627
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MKI67 protein |
CTD |
PMID:26577051 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression |
ISO |
Simvastatin results in increased expression of MMP10 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 9:7,502,343...7,510,243
Ensembl chr 9:7,502,353...7,510,241
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
increases expression |
ISO |
Simvastatin results in increased expression of MMP12 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 9:7,344,397...7,360,461
Ensembl chr 9:7,344,381...7,369,499
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of MMP13 mRNA Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA] |
CTD |
PMID:16274305 PMID:17428261 PMID:31260663 |
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp1b |
matrix metallopeptidase 1b (interstitial collagenase) |
decreases secretion increases expression decreases expression multiple interactions |
ISO |
Simvastatin results in decreased secretion of MMP1 mRNA; Simvastatin results in decreased secretion of MMP1 protein Simvastatin results in increased expression of MMP1 mRNA Simvastatin results in decreased expression of MMP1 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP1]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of MMP1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of MMP1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased secretion of MMP1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of MMP1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of MMP1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased secretion of MMP1 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein] |
CTD |
PMID:17303772 PMID:17428261 PMID:18625914 PMID:31260663 |
|
NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity increases activity multiple interactions decreases expression |
ISO EXP |
Simvastatin results in decreased activity of MMP2 protein Simvastatin results in increased activity of MMP2 protein Simvastatin inhibits the reaction [Monocrotaline results in increased expression of MMP2 mRNA]; Simvastatin results in decreased expression of and results in decreased activity of MMP2 protein Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP2 protein] Simvastatin results in decreased expression of MMP2 mRNA Simvastatin results in decreased expression of MMP2 protein |
CTD |
PMID:15210533 PMID:17038636 PMID:17158816 PMID:17169357 PMID:18309148 PMID:19360310 PMID:22022327 PMID:23831763 PMID:31260663 More...
|
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp28 |
matrix metallopeptidase 28 (epilysin) |
increases expression |
ISO |
Simvastatin results in increased expression of MMP28 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:83,331,594...83,353,890
Ensembl chr11:83,331,594...83,353,897
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of MMP3 mRNA Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA] |
CTD |
PMID:16414398 PMID:31260663 |
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp8 |
matrix metallopeptidase 8 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP8 mRNA] |
CTD |
PMID:18625914 |
|
NCBI chr 9:7,558,430...7,568,487
Ensembl chr 9:7,558,457...7,568,486
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases activity decreases activity decreases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of MMP9 protein]; Simvastatin promotes the reaction [TNF results in increased expression of MMP9 mRNA] Simvastatin results in increased activity of MMP9 protein Simvastatin results in decreased activity of MMP9 protein Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of MMP9 protein] farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of MMP9 mRNA]; Simvastatin results in decreased expression of and results in decreased activity of MMP9 protein Simvastatin results in decreased expression of MMP9 protein Simvastatin results in decreased expression of MMP9 mRNA; Simvastatin results in decreased expression of MMP9 protein |
CTD |
PMID:15107580 PMID:15210533 PMID:15537504 PMID:15728660 PMID:16002570 PMID:16414398 PMID:17038636 PMID:17169357 PMID:17277159 PMID:17560598 PMID:18309148 PMID:18569431 PMID:18625914 PMID:19299917 PMID:19360310 PMID:19505368 PMID:19589242 PMID:19820293 PMID:20835264 PMID:23831763 PMID:31260663 More...
|
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases expression decreases activity |
ISO EXP |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein] Simvastatin results in decreased expression of MPO protein Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein] Simvastatin results in decreased activity of MPO protein 1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein] |
CTD |
PMID:15665042 PMID:17038636 PMID:21764683 PMID:33774062 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mras |
muscle and microspikes RAS |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Glucose results in increased activity of MRAS protein]; Simvastatin inhibits the reaction [Smoke analog results in increased activity of MRAS protein] |
CTD |
PMID:18569938 PMID:19299917 |
|
NCBI chr 9:99,267,473...99,319,505
Ensembl chr 9:99,267,473...99,319,434
|
|
G |
Mrps31 |
mitochondrial ribosomal protein S31 |
decreases response to substance |
ISO |
MRPS31 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr 8:22,901,356...22,919,685
Ensembl chr 8:22,901,377...22,919,681
|
|
G |
Mstn |
myostatin |
multiple interactions increases expression |
EXP |
5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Simvastatin results in increased expression of and results in increased secretion of MSTN protein Simvastatin results in increased expression of MSTN mRNA; Simvastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 1:53,100,799...53,107,238
Ensembl chr 1:53,100,799...53,107,238
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
multiple interactions increases expression affects response to substance |
ISO EXP |
Homocysteine inhibits the reaction [Simvastatin results in increased expression of MTHFR protein modified form]; Simvastatin promotes the reaction [Homocysteine results in increased expression of MTHFR protein] MTHFR affects the susceptibility to Simvastatin MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 mRNA]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 protein] |
CTD |
PMID:18540024 |
|
NCBI chr 4:148,123,534...148,144,019
Ensembl chr 4:148,123,534...148,144,008
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation multiple interactions |
EXP |
Simvastatin results in decreased phosphorylation of MTOR protein FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:22144680 PMID:33034787 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Muc5ac |
mucin 5, subtypes A and C, tracheobronchial/gastric |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA]; Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MUC5AC mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MUC5AC protein] Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]]; Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein] |
CTD |
PMID:19024099 PMID:20359552 |
|
NCBI chr 7:141,342,695...141,372,964
Ensembl chr 7:141,342,709...141,372,968
|
|
G |
Mvd |
mevalonate (diphospho) decarboxylase |
increases expression |
ISO |
Simvastatin results in increased expression of MVD mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 8:123,160,335...123,170,161
Ensembl chr 8:123,160,340...123,170,161
|
|
G |
Mvk |
mevalonate kinase |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of MVK mRNA [MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein] |
CTD |
PMID:12477733 PMID:25055962 |
|
NCBI chr 5:114,582,324...114,598,652
Ensembl chr 5:114,582,330...114,598,652
|
|
G |
Mybph |
myosin binding protein H |
increases expression |
ISO |
Simvastatin results in increased expression of MYBPH mRNA |
CTD |
PMID:17183729 |
|
NCBI chr 1:134,121,159...134,128,975
Ensembl chr 1:134,121,186...134,128,970
|
|
G |
Myh10 |
myosin, heavy polypeptide 10, non-muscle |
decreases expression |
ISO |
Simvastatin results in decreased expression of MYH10 protein |
CTD |
PMID:16005304 |
|
NCBI chr11:68,581,228...68,707,451
Ensembl chr11:68,582,385...68,707,458
|
|
G |
Myh6 |
myosin, heavy polypeptide 6, cardiac muscle, alpha |
increases expression |
EXP |
Simvastatin results in increased expression of MYH6 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr14:55,179,378...55,205,553
Ensembl chr14:55,179,378...55,204,384
|
|
G |
Ndrg1 |
N-myc downstream regulated gene 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of NDRG1 protein |
CTD |
PMID:20217863 |
|
NCBI chr15:66,801,167...66,841,490
Ensembl chr15:66,801,167...66,841,489
|
|
G |
Neat1 |
nuclear paraspeckle assembly transcript 1 (non-protein coding) |
increases expression |
ISO |
Simvastatin results in increased expression of NEAT1 mRNA; Simvastatin results in increased expression of NEAT1 mRNA alternative form |
CTD |
PMID:31311324 |
|
NCBI chr19:5,874,736...5,895,508
Ensembl chr19:5,874,736...5,895,898
|
|
G |
Nfatc3 |
nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 3 |
multiple interactions decreases localization increases localization |
ISO |
Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter] Simvastatin results in decreased localization of NFATC3 protein alternative form Simvastatin results in increased localization of NFATC3 protein |
CTD |
PMID:20369390 |
|
NCBI chr 8:106,785,450...106,857,169
Ensembl chr 8:106,785,472...106,857,169
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
increases localization multiple interactions increases expression |
EXP ISO |
Simvastatin results in increased localization of NFE2L2 protein NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]] Mevalonic Acid affects the reaction [Simvastatin results in increased localization of NFE2L2 protein] Simvastatin results in increased expression of NFE2L2 mRNA MAPK1 promotes the reaction [Simvastatin results in increased expression of NFE2L2 mRNA]; Simvastatin results in increased expression of and affects the localization of NFE2L2 protein |
CTD |
PMID:17928392 PMID:18787804 PMID:30513525 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions increases localization decreases localization decreases activity decreases expression |
ISO EXP |
artemisinin inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; artemisinin inhibits the reaction [Simvastatin results in increased localization of NFKB1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; parthenolide inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; parthenolide inhibits the reaction [Simvastatin results in increased localization of NFKB1 protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of and results in increased activity of NFKB1 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of NFKB1 protein]; Simvastatin results in increased localization of and results in increased activity of NFKB1 protein Simvastatin results in decreased localization of NFKB1 protein Simvastatin results in decreased activity of NFKB1 protein Simvastatin results in decreased expression of NFKB1 mRNA Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]] |
CTD |
PMID:12753293 PMID:17038636 PMID:17277159 PMID:18463201 PMID:21465237 PMID:21925249 More...
|
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions increases phosphorylation |
ISO EXP |
artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of NFKBIA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of NFKBIA protein] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:15705589 PMID:17075836 PMID:17178392 PMID:17277159 PMID:18073186 PMID:18463201 PMID:18826357 PMID:19299917 PMID:21925249 More...
|
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nlgn3 |
neuroligin 3 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NLGN3 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr X:100,342,785...100,364,956
Ensembl chr X:100,342,774...100,369,569
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of NLRP3 mRNA]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein] |
CTD |
PMID:30408459 PMID:35762198 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nog |
noggin |
multiple interactions |
ISO |
NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA] |
CTD |
PMID:18628692 |
|
NCBI chr11:89,191,464...89,193,385
Ensembl chr11:89,191,464...89,193,158
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions increases expression decreases expression |
ISO EXP |
Simvastatin promotes the reaction [Doxorubicin results in increased expression of NOS2 protein] Simvastatin results in increased expression of NOS2 mRNA; Simvastatin results in increased expression of NOS2 protein Homocysteine affects the reaction [Simvastatin results in increased expression of NOS2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 mRNA]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]; Simvastatin promotes the reaction [Homocysteine results in increased expression of NOS2 mRNA]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]] Simvastatin results in decreased expression of NOS2 mRNA; Simvastatin results in decreased expression of NOS2 protein |
CTD |
PMID:10188333 PMID:11470468 PMID:15705589 PMID:16414398 PMID:17729120 PMID:18047562 PMID:18309148 PMID:18463201 PMID:18540024 PMID:19505368 PMID:19729986 PMID:20452610 PMID:21844074 PMID:21925249 PMID:22022327 More...
|
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
increases expression multiple interactions increases phosphorylation decreases expression |
ISO EXP |
Simvastatin results in increased expression of NOS3; Simvastatin results in increased expression of NOS3 mRNA; Simvastatin results in increased expression of NOS3 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of NOS3 mRNA]; Simvastatin inhibits the reaction [Smoke analog affects the expression of NOS3 mRNA]; Simvastatin results in increased expression of and results in increased phosphorylation of and results in increased activity of NOS3 protein Simvastatin results in increased phosphorylation of NOS3 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of NOS3 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Nifedipine promotes the reaction [Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]; Simvastatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]; Simvastatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]]; wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]] Simvastatin results in decreased expression of NOS3 mRNA Simvastatin results in decreased expression of NOS3 mRNA; Simvastatin results in decreased expression of NOS3 protein |
CTD |
PMID:10188333 PMID:11470468 PMID:11947894 PMID:12379581 PMID:12406854 PMID:12963647 PMID:15572054 PMID:15711596 PMID:16002570 PMID:16375908 PMID:16414398 PMID:17335931 PMID:18221806 PMID:18309148 PMID:18826357 PMID:18981156 PMID:20493886 PMID:20562903 PMID:20659230 PMID:20737288 PMID:21968084 PMID:22022327 PMID:25517390 PMID:35762198 More...
|
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Notch1 |
notch 1 |
increases cleavage increases expression |
ISO |
Simvastatin results in increased cleavage of NOTCH1 protein Simvastatin results in increased expression of NOTCH1 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 2:26,347,914...26,393,834
Ensembl chr 2:26,347,915...26,406,675
|
|
G |
Notch4 |
notch 4 |
increases expression |
ISO |
Simvastatin results in increased expression of NOTCH4 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr17:34,783,257...34,807,517
Ensembl chr17:34,783,242...34,807,477
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:17980884 |
|
NCBI chr11:6,161,011...6,180,245
Ensembl chr11:6,161,013...6,180,143
|
|
G |
Nphs2 |
nephrosis 2, podocin |
increases expression |
ISO |
Simvastatin results in increased expression of NPHS2 mRNA |
CTD |
PMID:16710349 |
|
NCBI chr 1:156,138,105...156,155,605
Ensembl chr 1:156,138,297...156,155,605
|
|
G |
Nppa |
natriuretic peptide type A |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA] Simvastatin results in decreased expression of NPPA mRNA |
CTD |
PMID:16029635 PMID:16534557 |
|
NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536
|
|
G |
Nppb |
natriuretic peptide type B |
decreases expression |
ISO |
Simvastatin results in decreased expression of NPPB; Simvastatin results in decreased expression of NPPB protein |
CTD |
PMID:16628357 PMID:21124329 |
|
NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of NQO1 mRNA; Simvastatin results in increased expression of NQO1 protein MAPK1 promotes the reaction [Simvastatin results in increased expression of NQO1 mRNA] |
CTD |
PMID:30513525 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of NR0B1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr X:85,235,381...85,239,553
Ensembl chr X:85,235,370...85,239,553
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NR1D1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr11:98,658,758...98,666,233
Ensembl chr11:98,658,758...98,666,159
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
decreases expression |
EXP |
Simvastatin results in decreased expression of NR1H3 mRNA |
CTD |
PMID:22160096 |
|
NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Simvastatin affects the reaction [Dietary Fats affects the expression of NR1H4 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of NR1H4 protein] |
CTD |
PMID:33383043 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Simvastatin results in increased activity of NR1I2 protein [Simvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose; [Simvastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose]; Simvastatin promotes the reaction [NR1I2 protein binds to SGK2 promoter] |
CTD |
PMID:15802384 PMID:17041008 PMID:24204015 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO EXP |
Simvastatin results in increased activity of NR1I3 protein |
CTD |
PMID:15802384 |
|
NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of NR4A3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of NR4A3 mRNA] |
CTD |
PMID:16005304 |
|
NCBI chr 4:48,045,098...48,086,446
Ensembl chr 4:48,045,153...48,086,447
|
|
G |
Nrp1 |
neuropilin 1 |
decreases response to substance |
ISO |
NRP1 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr 8:129,085,553...129,231,957
Ensembl chr 8:129,085,085...129,229,844
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
ISO |
Simvastatin results in decreased expression of NSDHL mRNA |
CTD |
PMID:25055962 |
|
NCBI chr X:71,962,127...72,002,134
Ensembl chr X:71,962,163...72,002,120
|
|
G |
Ntrk1 |
neurotrophic tyrosine kinase, receptor, type 1 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of NTRK1 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 3:87,685,551...87,702,549
Ensembl chr 3:87,685,551...87,702,469
|
|
G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of NTRK2 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr13:58,954,363...59,281,782
Ensembl chr13:58,954,383...59,281,784
|
|
G |
Ocln |
occludin |
increases expression |
ISO |
Simvastatin results in increased expression of OCLN |
CTD |
PMID:18544044 |
|
NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226
|
|
G |
Olr1 |
oxidized low density lipoprotein (lectin-like) receptor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of OLR1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128
|
|
G |
Osbpl1a |
oxysterol binding protein-like 1A |
decreases expression |
ISO |
Simvastatin results in decreased expression of OSBPL1A mRNA |
CTD |
PMID:25055962 |
|
NCBI chr18:12,886,955...13,074,933
Ensembl chr18:12,888,371...13,074,898
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA]; Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20191585 |
|
NCBI chr11:4,186,831...4,191,027
Ensembl chr11:4,186,420...4,191,026
|
|
G |
P4hb |
prolyl 4-hydroxylase, beta polypeptide |
decreases expression |
ISO |
Simvastatin results in decreased expression of P4HB mRNA |
CTD |
PMID:16414398 |
|
NCBI chr11:120,451,124...120,464,079
Ensembl chr11:120,451,124...120,464,079
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions decreases cleavage increases cleavage |
ISO EXP |
[Simvastatin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; Mevalonic Acid inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; pifithrin inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of PARP1 protein modified form]; Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein] Simvastatin results in decreased cleavage of PARP1 mRNA Simvastatin inhibits the reaction [Glucose results in increased activity of PARP1 protein] IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:16054375 PMID:18004065 PMID:20045437 PMID:20464445 PMID:21910007 PMID:26773838 PMID:27734117 More...
|
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
Simvastatin results in decreased expression of PCNA mRNA; Simvastatin results in decreased expression of PCNA protein |
CTD |
PMID:17428261 PMID:18824851 |
|
NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions |
ISO |
[Simvastatin co-treated with Ezetimibe] results in increased expression of PCSK9 mRNA |
CTD |
PMID:17980884 |
|
NCBI chr 4:106,299,531...106,321,522
Ensembl chr 4:106,299,526...106,321,526
|
|
G |
Pde4b |
phosphodiesterase 4B, cAMP specific |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of PDE4B mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 4:101,944,529...102,464,459
Ensembl chr 4:101,944,740...102,464,456
|
|
G |
Pdgfa |
platelet derived growth factor, alpha |
decreases expression |
ISO |
Simvastatin results in decreased expression of PDGFA mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 5:138,961,761...138,986,336
Ensembl chr 5:138,961,769...138,983,125
|
|
G |
Pdgfb |
platelet derived growth factor, B polypeptide |
decreases expression multiple interactions decreases activity |
ISO EXP |
Simvastatin results in decreased expression of PDGFB protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased activity of PDGFB protein]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein] Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of PDGFB mRNA] Simvastatin results in decreased expression of PDGFB mRNA |
CTD |
PMID:8231022 PMID:10412745 PMID:10412775 PMID:15728660 PMID:16373842 |
|
NCBI chr15:79,880,066...79,899,178
Ensembl chr15:79,880,075...79,899,178
|
|
G |
Pdgfra |
platelet derived growth factor receptor, alpha polypeptide |
decreases expression |
ISO |
Simvastatin results in decreased expression of PDGFRA mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 5:75,311,988...75,358,867
Ensembl chr 5:75,312,953...75,358,876
|
|
G |
Pdgfrb |
platelet derived growth factor receptor, beta polypeptide |
decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of PDGFRB mRNA [Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of PDGFRB mRNA |
CTD |
PMID:10412775 PMID:28263720 |
|
NCBI chr18:61,178,194...61,218,139
Ensembl chr18:61,178,222...61,218,133
|
|
G |
Pdk2 |
pyruvate dehydrogenase kinase, isoenzyme 2 |
increases expression |
ISO |
Simvastatin results in increased expression of PDK2 mRNA |
CTD |
PMID:19001041 |
|
NCBI chr11:94,917,084...94,932,197
Ensembl chr11:94,917,084...94,932,180
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase, isoenzyme 4 |
increases expression |
ISO EXP |
Simvastatin results in increased expression of PDK4 mRNA |
CTD |
PMID:19001041 PMID:19262002 |
|
NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309
|
|
G |
Pecam1 |
platelet/endothelial cell adhesion molecule 1 |
increases expression |
ISO |
Simvastatin results in increased expression of PECAM1 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr11:106,545,039...106,606,107
Ensembl chr11:106,545,043...106,641,454
|
|
G |
Phb2 |
prohibitin 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PHB2 protein |
CTD |
PMID:20217863 |
|
NCBI chr 6:124,689,252...124,693,908
Ensembl chr 6:124,689,299...124,693,913
|
|
G |
Pigc |
phosphatidylinositol glycan anchor biosynthesis, class C |
decreases expression |
EXP |
Simvastatin results in decreased expression of PIGC mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 1:161,796,757...161,801,029
Ensembl chr 1:161,796,755...161,801,004
|
|
G |
Pitx2 |
paired-like homeodomain transcription factor 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of PITX2 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 3:128,993,527...129,013,243
Ensembl chr 3:128,993,527...129,013,240
|
|
G |
Pkmyt1 |
protein kinase, membrane associated tyrosine/threonine 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PKMYT1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:23,945,385...23,955,709
Ensembl chr17:23,945,310...23,955,709
|
|
G |
Pla2g2a |
phospholipase A2, group IIA (platelets, synovial fluid) |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of PLA2G2A protein] |
CTD |
PMID:19237014 |
|
NCBI chr 4:138,559,168...138,562,500
Ensembl chr 4:138,559,171...138,562,497
|
|
G |
Pla2g7 |
phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PLA2G7 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G7 mRNA] |
CTD |
PMID:21176638 |
|
NCBI chr17:43,879,009...43,923,093
Ensembl chr17:43,878,989...43,923,092
|
|
G |
Plat |
plasminogen activator, tissue |
multiple interactions increases expression increases activity decreases expression |
ISO |
geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PLAT]; Simvastatin inhibits the reaction [TNF results in decreased expression of PLAT] Simvastatin results in increased expression of PLAT; Simvastatin results in increased expression of PLAT mRNA; Simvastatin results in increased expression of PLAT protein Simvastatin results in increased activity of PLAT protein Simvastatin results in decreased expression of PLAT mRNA |
CTD |
PMID:12371961 PMID:12753293 PMID:16414398 |
|
NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases expression |
EXP |
Simvastatin results in decreased expression of PLAU mRNA |
CTD |
PMID:10412775 |
|
NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453
|
|
G |
Plcg2 |
phospholipase C, gamma 2 |
increases expression |
ISO |
Simvastatin results in increased expression of PLCG2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 8:118,225,014...118,361,881
Ensembl chr 8:118,225,030...118,361,881
|
|
G |
Plk2 |
polo like kinase 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of PLK2 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr13:110,531,578...110,537,378
Ensembl chr13:110,531,580...110,537,378
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PLOD3 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 5:137,015,873...137,025,500
Ensembl chr 5:137,015,873...137,025,502
|
|
G |
Plxnd1 |
plexin D1 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of PLXND1 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 6:115,931,772...115,972,300
Ensembl chr 6:115,931,772...115,971,966
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
affects localization multiple interactions increases expression |
ISO |
Simvastatin affects the localization of PMAIP1 protein pifithrin inhibits the reaction [Simvastatin results in increased expression of PMAIP1 mRNA] Simvastatin results in increased expression of PMAIP1 mRNA; Simvastatin results in increased expression of PMAIP1 protein |
CTD |
PMID:20045437 |
|
NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636
|
|
G |
Pmvk |
phosphomevalonate kinase |
increases expression |
ISO |
Simvastatin results in increased expression of PMVK mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 3:89,361,848...89,376,321
Ensembl chr 3:89,361,848...89,376,320
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
increases expression |
EXP |
Simvastatin results in increased expression of POMT1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 2:32,126,321...32,145,017
Ensembl chr 2:32,126,602...32,145,017
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions increases expression |
ISO |
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; PON1 gene polymorphism affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene SNP affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 protein affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]; Simvastatin results in increased expression of and results in increased activity of PON1 protein; Squalene inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA] |
CTD |
PMID:14500290 PMID:15690306 PMID:16238680 |
|
NCBI chr 6:5,168,101...5,193,824
Ensembl chr 6:5,168,090...5,193,946
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of PPARA mRNA PPARA mutant form inhibits the reaction [Simvastatin results in increased expression of SCARB1]; Simvastatin promotes the reaction [TNF results in increased expression of PPARA] Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARA mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARA protein]; Simvastatin promotes the reaction [Zymosan results in increased expression of PPARA] |
CTD |
PMID:15234187 PMID:18981156 PMID:19001041 PMID:20835264 PMID:21323892 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions decreases expression |
ISO EXP |
[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein] Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARG mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARG protein] Simvastatin results in decreased expression of PPARG |
CTD |
PMID:15781755 PMID:19216230 PMID:20835264 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
ISO |
geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:24449418 |
|
NCBI chr10:107,997,913...108,115,846
Ensembl chr10:107,998,054...108,120,336
|
|
G |
Ppp1r14a |
protein phosphatase 1, regulatory inhibitor subunit 14A |
multiple interactions |
ISO |
geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R14A protein] |
CTD |
PMID:24449418 |
|
NCBI chr 7:28,988,732...28,992,817
Ensembl chr 7:28,988,733...28,993,226
|
|
G |
Prim1 |
DNA primase, p49 subunit |
decreases expression |
ISO |
Simvastatin results in decreased expression of PRIM1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:127,851,084...127,865,899
Ensembl chr10:127,851,041...127,865,906
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
increases expression |
ISO |
Simvastatin results in increased expression of PRKAA1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Psen1 |
presenilin 1 |
increases expression |
ISO |
Simvastatin results in increased expression of PSEN1 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973
|
|
G |
Ptafr |
platelet-activating factor receptor |
decreases expression |
ISO |
Simvastatin results in decreased expression of PTAFR mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 4:132,291,378...132,309,994
Ensembl chr 4:132,291,378...132,309,994
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
EXP |
Simvastatin results in increased expression of PTEN mRNA; Simvastatin results in increased expression of PTEN protein |
CTD |
PMID:20060890 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGES protein] Simvastatin results in decreased expression of PTGES protein |
CTD |
PMID:17038636 |
|
NCBI chr 2:30,779,483...30,793,309
Ensembl chr 2:30,779,483...30,819,875
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
JTE 013 inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]; Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; Suramin inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]] Simvastatin results in increased expression of PTGS2 mRNA Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2] Simvastatin results in decreased expression of PTGS2 protein Simvastatin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein] |
CTD |
PMID:17038636 PMID:17277159 PMID:17901590 PMID:18612546 PMID:19225232 PMID:19886038 PMID:20659230 PMID:21910007 PMID:30408459 More...
|
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptk2 |
PTK2 protein tyrosine kinase 2 |
decreases activity |
ISO |
Simvastatin results in decreased activity of PTK2 protein |
CTD |
PMID:17428261 |
|
NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129
|
|
G |
Pxn |
paxillin |
multiple interactions affects localization decreases phosphorylation |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein] Simvastatin affects the localization of PXN protein Simvastatin results in decreased phosphorylation of PXN protein |
CTD |
PMID:22306966 |
|
NCBI chr 5:115,630,035...115,694,046
Ensembl chr 5:115,644,735...115,694,046
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions affects localization increases expression decreases activity decreases expression increases activity |
ISO EXP |
Cholesterol inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RAC1 protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]]; Simvastatin affects the localization of and results in decreased activity of RAC1 protein; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of RAC1 protein] Simvastatin affects the localization of RAC1 protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of RAC1 protein] Simvastatin results in decreased activity of RAC1 protein Simvastatin results in decreased expression of RAC1 Simvastatin results in increased activity of RAC1 protein |
CTD |
PMID:16698853 PMID:17169357 PMID:17303772 PMID:17513949 PMID:18625914 PMID:19332549 PMID:19360310 PMID:20045437 PMID:21334995 More...
|
|
NCBI chr 5:143,491,236...143,513,786
Ensembl chr 5:143,489,389...143,513,791
|
|
G |
Rac2 |
Rac family small GTPase 2 |
affects localization decreases activity |
ISO EXP |
Simvastatin affects the localization of RAC2 protein Simvastatin results in decreased activity of RAC2 protein |
CTD |
PMID:17169357 PMID:20045437 |
|
NCBI chr15:78,443,369...78,456,983
Ensembl chr15:78,443,367...78,456,983
|
|
G |
Rac3 |
Rac family small GTPase 3 |
affects localization |
ISO |
Simvastatin affects the localization of RAC3 protein |
CTD |
PMID:20045437 |
|
NCBI chr11:120,612,294...120,614,795
Ensembl chr11:120,612,296...120,614,795
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr15:99,518,377...99,549,504
Ensembl chr15:99,518,377...99,549,537
|
|
G |
Raf1 |
v-raf-leukemia viral oncogene 1 |
decreases activity multiple interactions |
ISO |
Simvastatin results in decreased activity of RAF1 protein Simvastatin inhibits the reaction [Streptozocin results in increased expression of RAF1 protein] |
CTD |
PMID:18569938 PMID:19360310 |
|
NCBI chr 6:115,595,530...115,653,596
Ensembl chr 6:115,595,028...115,653,596
|
|
G |
Rap1a |
RAS-related protein 1a |
decreases prenylation multiple interactions decreases geranoylation decreases expression |
ISO EXP |
Simvastatin results in decreased prenylation of RAP1A protein Mevalonic Acid inhibits the reaction [Simvastatin results in decreased geranoylation of RAP1A protein]; Simvastatin results in decreased geranoylation of and results in decreased prenylation of RAP1A protein Simvastatin results in decreased expression of RAP1A protein alternative form |
CTD |
PMID:20018177 PMID:22120639 PMID:25578243 PMID:37956312 |
|
NCBI chr 3:105,634,576...105,708,740
Ensembl chr 3:105,634,583...105,708,652
|
|
G |
Rasgrf1 |
RAS protein-specific guanine nucleotide-releasing factor 1 |
affects localization affects phosphorylation |
EXP |
Simvastatin affects the localization of RASGRF1 protein Simvastatin affects the phosphorylation of RASGRF1 protein |
CTD |
PMID:20417880 |
|
NCBI chr 9:89,791,565...89,909,032
Ensembl chr 9:89,791,961...89,909,030
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
Simvastatin results in decreased phosphorylation of RB1 protein |
CTD |
PMID:17928568 PMID:18804536 |
|
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions increases localization decreases localization decreases expression |
ISO EXP |
artemisinin inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; artemisinin inhibits the reaction [Simvastatin results in increased localization of RELA protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; parthenolide inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; parthenolide inhibits the reaction [Simvastatin results in increased localization of RELA protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Simvastatin inhibits the reaction [TNF results in increased localization of RELA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of and results in increased activity of RELA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of RELA protein]; Simvastatin results in increased localization of and results in increased activity of RELA protein [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of RELA protein] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; Homocysteine inhibits the reaction [Simvastatin results in decreased expression of RELA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]] Simvastatin results in decreased localization of RELA protein Simvastatin results in decreased expression of RELA mRNA; Simvastatin results in decreased expression of RELA protein |
CTD |
PMID:12753293 PMID:15705589 PMID:16414398 PMID:17038636 PMID:17075836 PMID:17277159 PMID:17507688 PMID:18073186 PMID:18463201 PMID:18540024 PMID:18791746 PMID:19299917 PMID:21465237 PMID:21764683 PMID:21910007 PMID:21925249 More...
|
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Ret |
ret proto-oncogene |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of RET mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 6:118,128,709...118,174,705
Ensembl chr 6:118,128,706...118,174,679
|
|
G |
Retn |
resistin |
multiple interactions |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein] |
CTD |
PMID:18023360 |
|
NCBI chr 8:3,705,770...3,709,818
Ensembl chr 8:3,705,770...3,710,110
|
|
G |
Rfc5 |
replication factor C (activator 1) 5 |
decreases expression |
ISO |
Simvastatin results in decreased expression of RFC5 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 5:117,517,210...117,527,088
Ensembl chr 5:117,516,168...117,527,112
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
ISO |
Simvastatin results in increased expression of RGS2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:143,875,076...143,879,887
Ensembl chr 1:143,875,076...143,879,899
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions decreases activity decreases expression increases expression increases localization affects localization decreases prenylation |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]]; geranylgeraniol inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased activity of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased localization of RHOA protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; RHOA inhibits the reaction [Simvastatin results in increased expression of SCARB1]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; Simvastatin affects the localization of and results in decreased activity of RHOA protein; Simvastatin inhibits the reaction [geranylgeranyl pyrophosphate affects the localization of RHOA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]; Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]; Simvastatin results in decreased localization of and results in decreased activity of RHOA protein; Simvastatin results in increased localization of and results in decreased prenylation of RHOA protein geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of RHOA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of RHOA]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]; Simvastatin results in decreased geranoylation of and results in decreased prenylation of RHOA protein Simvastatin results in decreased expression of RHOA; Simvastatin results in decreased expression of RHOA protein Simvastatin results in increased expression of RHOA mRNA farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein] Simvastatin results in increased expression of RHOA protein Simvastatin affects the localization of RHOA protein Simvastatin results in decreased prenylation of RHOA protein |
CTD |
PMID:12477733 PMID:14630613 PMID:15200425 PMID:16005304 PMID:16470222 PMID:16698853 PMID:16740276 PMID:17075836 PMID:17560598 PMID:18031796 PMID:18310456 PMID:18463201 PMID:18625202 PMID:18625914 PMID:18981156 PMID:19024099 PMID:19659652 PMID:20045437 PMID:21124329 PMID:21257924 PMID:24449418 More...
|
|
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Rhoc |
ras homolog family member C |
increases expression |
ISO |
Simvastatin results in increased expression of RHOC mRNA |
CTD |
PMID:14630613 |
|
NCBI chr 3:104,696,350...104,701,775
Ensembl chr 3:104,695,691...104,701,775
|
|
G |
Ripk1 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]; [Simvastatin co-treated with Metformin] results in increased expression of RIPK1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]; RIPK3 protein affects the reaction [necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]] |
CTD |
PMID:25412314 |
|
NCBI chr13:34,181,072...34,219,153
Ensembl chr13:34,186,346...34,221,130
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
multiple interactions |
ISO |
[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]; RIPK3 protein affects the reaction [necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]] |
CTD |
PMID:25412314 |
|
NCBI chr14:56,022,452...56,026,314
Ensembl chr14:56,022,452...56,026,322
|
|
G |
Rorc |
RAR-related orphan receptor gamma |
multiple interactions decreases expression |
ISO |
IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of RORC mRNA] |
CTD |
PMID:18453621 |
|
NCBI chr 3:94,280,106...94,305,583
Ensembl chr 3:94,280,101...94,305,583
|
|
G |
Rpl39 |
ribosomal protein L39 |
increases expression |
EXP |
Simvastatin results in increased expression of RPL39 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr X:36,346,169...36,348,852
Ensembl chr X:36,346,173...36,349,055
|
|
G |
Rps10 |
ribosomal protein S10 |
increases expression |
EXP |
Simvastatin results in increased expression of RPS10 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr17:27,849,389...27,854,218
Ensembl chr17:27,849,392...27,855,643
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation multiple interactions |
EXP |
Simvastatin results in decreased phosphorylation of RPS6 protein IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:27734117 |
|
NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
decreases phosphorylation multiple interactions |
EXP |
Simvastatin results in decreased phosphorylation of RPS6KB1 protein FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:27734117 PMID:33034787 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Runx2 |
runt related transcription factor 2 |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of RUNX2 DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]] |
CTD |
PMID:18310456 PMID:20381859 PMID:20417880 PMID:22058016 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Ryr2 |
ryanodine receptor 2, cardiac |
increases expression |
ISO |
Simvastatin results in increased expression of RYR2 mRNA; Simvastatin results in increased expression of RYR2 protein |
CTD |
PMID:15916736 |
|
NCBI chr13:11,567,985...12,121,831
Ensembl chr13:11,567,988...12,121,831
|
|
G |
S100a6 |
S100 calcium binding protein A6 (calcyclin) |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of S100A6 mRNA Simvastatin results in increased expression of and results in increased localization of S100A6 protein Simvastatin results in increased expression of S100A6 mRNA; Simvastatin results in increased expression of S100A6 protein |
CTD |
PMID:14973129 PMID:17428261 |
|
NCBI chr 3:90,520,491...90,531,797
Ensembl chr 3:90,520,189...90,531,488
|
|
G |
S100a8 |
S100 calcium binding protein A8 (calgranulin A) |
increases expression |
ISO |
Simvastatin results in increased expression of S100A8 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342
|
|
G |
S100a9 |
S100 calcium binding protein A9 (calgranulin B) |
increases expression |
ISO |
Simvastatin results in increased expression of S100A9 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
increases expression |
ISO |
Simvastatin results in increased expression of S1PR1 mRNA |
CTD |
PMID:18612546 |
|
NCBI chr 3:115,504,082...115,508,704
Ensembl chr 3:115,504,082...115,508,721
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
increases expression decreases expression |
ISO |
Simvastatin results in increased expression of S1PR3 mRNA Simvastatin results in decreased expression of S1PR3 mRNA |
CTD |
PMID:18612546 PMID:18981156 |
|
NCBI chr13:51,562,654...51,576,833
Ensembl chr13:51,562,675...51,576,833
|
|
G |
Scap |
SREBF chaperone |
affects response to substance |
ISO |
SCAP polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:16158080 |
|
NCBI chr 9:110,162,356...110,214,017
Ensembl chr 9:110,162,356...110,214,018
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions increases expression |
ISO EXP |
PPARA mutant form inhibits the reaction [Simvastatin results in increased expression of SCARB1]; RHOA inhibits the reaction [Simvastatin results in increased expression of SCARB1] Simvastatin results in increased expression of SCARB1; Simvastatin results in increased expression of SCARB1 mRNA; Simvastatin results in increased expression of SCARB1 protein [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of SCARB1 mRNA; Simvastatin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 mRNA]; Simvastatin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 protein] |
CTD |
PMID:18981156 PMID:20025956 PMID:21241519 PMID:25055962 PMID:33383043 |
|
NCBI chr 5:125,354,151...125,418,082
Ensembl chr 5:125,354,151...125,418,158
|
|
G |
Sdc1 |
syndecan 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of SDC1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr12:8,821,396...8,843,716
Ensembl chr12:8,821,323...8,843,715
|
|
G |
Sdc4 |
syndecan 4 |
decreases expression |
ISO |
Simvastatin results in decreased expression of SDC4 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 2:164,266,167...164,285,512
Ensembl chr 2:164,266,167...164,285,807
|
|
G |
Sele |
selectin, endothelial cell |
multiple interactions decreases expression affects expression |
ISO |
farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of SELE protein modified form] Simvastatin affects the expression of SELE protein |
CTD |
PMID:10946302 PMID:14602771 PMID:16740276 PMID:21994025 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Selp |
selectin, platelet |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [staphylococcal alpha-toxin results in increased expression of SELP protein] Simvastatin results in decreased expression of SELP mRNA |
CTD |
PMID:12379581 PMID:16414398 |
|
NCBI chr 1:163,942,833...163,977,595
Ensembl chr 1:163,942,833...163,977,595
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
decreases expression multiple interactions decreases activity decreases secretion |
ISO |
Simvastatin results in decreased expression of SERPINE1 mRNA; Simvastatin results in decreased expression of SERPINE1 protein [Simvastatin co-treated with Dexamethasone] results in increased secretion of SERPINE1 protein Simvastatin results in decreased activity of SERPINE1 protein Simvastatin results in decreased secretion of SERPINE1 protein |
CTD |
PMID:16375908 PMID:16414398 PMID:17513194 PMID:21524281 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
EXP |
Simvastatin results in increased expression of SESN2 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812
|
|
G |
Sesn3 |
sestrin 3 |
decreases expression |
EXP |
Simvastatin results in decreased expression of SESN3 mRNA |
CTD |
PMID:20883752 |
|
NCBI chr 9:14,187,597...14,237,430
Ensembl chr 9:14,186,363...14,244,397
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions |
ISO |
[Simvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose]; Simvastatin promotes the reaction [NR1I2 protein binds to SGK2 promoter] |
CTD |
PMID:24204015 |
|
NCBI chr 2:162,829,249...162,856,059
Ensembl chr 2:162,829,250...162,856,047
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slc38a4 |
solute carrier family 38, member 4 |
increases expression |
EXP |
Simvastatin results in increased expression of SLC38A4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr15:96,892,701...96,953,837
Ensembl chr15:96,892,701...96,953,837
|
|
G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
increases activity |
ISO |
Simvastatin results in increased activity of SLC6A4 protein |
CTD |
PMID:15740995 |
|
NCBI chr11:76,889,423...76,923,169
Ensembl chr11:76,889,429...76,923,166
|
|
G |
Smad1 |
SMAD family member 1 |
multiple interactions increases expression increases phosphorylation |
EXP |
Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]] Simvastatin results in increased expression of SMAD1 mRNA Simvastatin results in increased phosphorylation of SMAD1 protein |
CTD |
PMID:18310456 PMID:20417880 |
|
NCBI chr 8:80,065,024...80,126,057
Ensembl chr 8:80,065,024...80,126,147
|
|
G |
Smad2 |
SMAD family member 2 |
decreases phosphorylation increases expression increases phosphorylation multiple interactions |
ISO EXP |
Simvastatin results in decreased phosphorylation of SMAD2 protein Simvastatin results in increased expression of SMAD2 mRNA Simvastatin results in increased phosphorylation of SMAD2 protein FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:18310456 PMID:19659652 PMID:33034787 |
|
NCBI chr18:76,369,898...76,444,819
Ensembl chr18:76,374,651...76,444,034
|
|
G |
Smad3 |
SMAD family member 3 |
increases expression decreases phosphorylation multiple interactions increases phosphorylation |
EXP ISO |
Simvastatin results in increased expression of SMAD3 mRNA Simvastatin results in decreased phosphorylation of SMAD3 protein FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:18310456 PMID:19659652 PMID:33034787 |
|
NCBI chr 9:63,554,048...63,665,276
Ensembl chr 9:63,554,049...63,665,276
|
|
G |
Smad5 |
SMAD family member 5 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]] |
CTD |
PMID:18310456 |
|
NCBI chr13:56,850,804...56,890,191
Ensembl chr13:56,850,823...56,890,190
|
|
G |
Smad9 |
SMAD family member 9 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]] |
CTD |
PMID:18310456 |
|
NCBI chr 3:54,662,873...54,709,162
Ensembl chr 3:54,663,003...54,708,678
|
|
G |
Snx17 |
sorting nexin 17 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of SNX17 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of SNX17 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 5:31,350,634...31,356,244
Ensembl chr 5:31,350,571...31,356,487
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
increases expression |
ISO |
Simvastatin results in increased expression of SOAT1 mRNA |
CTD |
PMID:12056585 |
|
NCBI chr 1:156,255,678...156,301,898
Ensembl chr 1:156,252,095...156,301,901
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
ISO |
Simvastatin results in increased expression of SOCS3 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873
|
|
G |
Socs4 |
suppressor of cytokine signaling 4 |
increases expression |
EXP |
Simvastatin results in increased expression of SOCS4 mRNA; Simvastatin results in increased expression of SOCS4 protein |
CTD |
PMID:19262002 |
|
NCBI chr14:47,514,377...47,533,559
Ensembl chr14:47,514,388...47,533,559
|
|
G |
Socs7 |
suppressor of cytokine signaling 7 |
increases expression |
ISO |
Simvastatin results in increased expression of SOCS7 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr11:97,253,044...97,289,368
Ensembl chr11:97,253,261...97,289,368
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
decreases expression |
EXP ISO |
Simvastatin results in decreased expression of SOD2 mRNA |
CTD |
PMID:16414398 PMID:20883752 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sod3 |
superoxide dismutase 3, extracellular |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD3 mRNA] |
CTD |
PMID:28734741 |
|
NCBI chr 5:52,521,146...52,527,080
Ensembl chr 5:52,521,133...52,528,760
|
|
G |
Sp1 |
trans-acting transcription factor 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter] |
CTD |
PMID:16575855 |
|
NCBI chr15:102,314,751...102,344,839
Ensembl chr15:102,314,578...102,344,839
|
|
G |
Sp7 |
Sp7 transcription factor 7 |
multiple interactions increases expression |
EXP |
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA] Simvastatin results in increased expression of SP7; Simvastatin results in increased expression of SP7 mRNA; Simvastatin results in increased expression of SP7 protein |
CTD |
PMID:20564244 PMID:22058016 |
|
NCBI chr15:102,265,038...102,275,498
Ensembl chr15:102,265,041...102,275,617
|
|
G |
Spon2 |
spondin 2, extracellular matrix protein |
increases expression |
ISO |
Simvastatin results in increased expression of SPON2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 5:33,370,862...33,375,596
Ensembl chr 5:33,355,528...33,375,799
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression increases expression |
ISO EXP |
Simvastatin results in decreased expression of SPP1 mRNA Simvastatin results in increased expression of SPP1 protein |
CTD |
PMID:12914771 PMID:14601315 PMID:21076490 PMID:21109955 PMID:22058016 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein; Chloroquine inhibits the reaction [[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein] |
CTD |
PMID:25412314 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases localization decreases expression |
ISO |
Simvastatin results in increased localization of SREBF1 protein Simvastatin results in decreased expression of SREBF1 mRNA |
CTD |
PMID:17655842 PMID:25055962 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Srebf2 |
sterol regulatory element binding factor 2 |
multiple interactions increases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]]; Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter] Simvastatin results in increased expression of SREBF2 protein modified form Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of SREBF2 mRNA]; Simvastatin results in increased activity of and results in increased localization of SREBF2 protein |
CTD |
PMID:12056585 PMID:14500290 PMID:20018177 |
|
NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of STAR mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of STAR mRNA |
CTD |
PMID:24524197 PMID:25055962 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions decreases expression decreases activity decreases phosphorylation |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of STAT1 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA] Simvastatin results in decreased expression of STAT1 mRNA Simvastatin results in decreased activity of STAT1 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of STAT1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of STAT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of STAT1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of STAT1 protein]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein] Simvastatin results in decreased expression of STAT1 mRNA; Simvastatin results in decreased expression of STAT1 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein] |
CTD |
PMID:16534557 PMID:17507688 PMID:18453621 PMID:19886038 PMID:21268089 |
|
NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases activity multiple interactions affects expression decreases phosphorylation |
ISO EXP |
Simvastatin results in decreased activity of STAT3 protein Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of STAT3 protein] Simvastatin affects the expression of STAT3 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:16534557 PMID:17507688 PMID:18400235 PMID:18453621 PMID:19100119 PMID:19886038 PMID:20821229 PMID:21910007 More...
|
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
affects expression |
EXP |
Simvastatin affects the expression of STAT5A protein |
CTD |
PMID:17507688 |
|
NCBI chr11:100,750,177...100,775,995
Ensembl chr11:100,750,177...100,775,995
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
affects expression |
EXP |
Simvastatin affects the expression of STAT6 protein |
CTD |
PMID:17507688 |
|
NCBI chr10:127,478,855...127,496,856
Ensembl chr10:127,478,855...127,496,826
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases phosphorylation |
EXP |
Simvastatin results in increased phosphorylation of STK11 protein |
CTD |
PMID:19332549 |
|
NCBI chr10:79,951,602...79,966,513
Ensembl chr10:79,951,637...79,966,516
|
|
G |
Tab1 |
TGF-beta activated kinase 1/MAP3K7 binding protein 1 |
multiple interactions |
ISO |
Simvastatin results in decreased activity of [MAP3K7 protein co-treated with TAB1 protein] |
CTD |
PMID:17277159 |
|
NCBI chr15:80,017,333...80,045,908
Ensembl chr15:80,017,328...80,045,908
|
|
G |
Tank |
TRAF family member-associated Nf-kappa B activator |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of TANK mRNA |
CTD |
PMID:15665042 |
|
NCBI chr 2:61,408,901...61,484,515
Ensembl chr 2:61,408,929...61,484,515
|
|
G |
Tbxas1 |
thromboxane A synthase 1, platelet |
decreases expression increases expression |
ISO |
Simvastatin results in decreased expression of TBXAS1 mRNA Simvastatin results in increased expression of TBXAS1 mRNA |
CTD |
PMID:16414398 PMID:20659230 |
|
NCBI chr 6:38,817,897...39,061,524
Ensembl chr 6:38,852,338...39,061,519
|
|
G |
Tek |
TEK receptor tyrosine kinase |
multiple interactions increases expression |
ISO |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of TEK mRNA]; Simvastatin results in increased expression of and results in increased activity of TEK protein Simvastatin results in increased expression of TEK; Simvastatin results in increased expression of TEK mRNA |
CTD |
PMID:18544044 PMID:20821229 |
|
NCBI chr 4:94,627,322...94,763,213
Ensembl chr 4:94,627,526...94,763,213
|
|
G |
Tfrc |
transferrin receptor |
affects expression |
ISO |
Simvastatin affects the expression of TFRC protein |
CTD |
PMID:16387846 |
|
NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression increases activity decreases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein] Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein] Simvastatin results in increased expression of TGFB1 mRNA Simvastatin results in increased activity of TGFB1 protein Simvastatin results in decreased expression of TGFB1 mRNA; Simvastatin results in decreased expression of TGFB1 protein |
CTD |
PMID:15298857 PMID:15677772 PMID:15855201 PMID:16320597 PMID:19080365 PMID:19262002 PMID:19659652 PMID:20024970 PMID:20687301 PMID:21844074 More...
|
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor II |
multiple interactions decreases expression |
EXP ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of TGFBR2 mRNA] Simvastatin results in decreased expression of TGFBR2 mRNA |
CTD |
PMID:16320597 PMID:16373842 |
|
NCBI chr 9:115,916,763...116,004,431
Ensembl chr 9:115,913,361...116,004,428
|
|
G |
Thbd |
thrombomodulin |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of THBD mRNA; Simvastatin results in increased expression of THBD protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of THBD mRNA] |
CTD |
PMID:14630613 PMID:16375908 PMID:20493886 PMID:20737288 |
|
NCBI chr 2:148,246,391...148,250,108
Ensembl chr 2:148,246,386...148,250,108
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of THBS1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
multiple interactions decreases expression |
ISO |
Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16414398 PMID:20137537 PMID:22022327 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Timp2 |
tissue inhibitor of metalloproteinase 2 |
multiple interactions decreases expression |
ISO |
Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP2 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP2 mRNA] |
CTD |
PMID:20137537 |
|
NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of TLR2 protein Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 protein] |
CTD |
PMID:16387846 PMID:16443229 |
|
NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression decreases expression multiple interactions |
ISO |
Simvastatin results in increased expression of TLR4 protein Simvastatin results in decreased expression of TLR4 mRNA; Simvastatin results in decreased expression of TLR4 protein Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein] |
CTD |
PMID:16387846 PMID:16443229 PMID:19166837 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
increases expression |
ISO |
Simvastatin results in increased expression of TM7SF2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr19:6,112,851...6,117,880
Ensembl chr19:6,112,851...6,118,403
|
|
G |
Tnc |
tenascin C |
decreases expression |
ISO |
Simvastatin results in decreased expression of TNC mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 4:63,878,022...63,965,554
Ensembl chr 4:63,878,022...63,965,252
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression decreases activity decreases expression increases secretion decreases secretion affects secretion |
ISO EXP |
geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in decreased expression of PLAT]; Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]; Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of TF]; Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased localization of RELA protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CXCL8 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of MMP9 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [TNF results in increased expression of MMP9 mRNA]; Simvastatin promotes the reaction [TNF results in increased expression of PPARA] Simvastatin results in increased expression of TNF mRNA 1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased secretion of TNF protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Acrolein results in increased secretion of TNF protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of NOS2 mRNA] Simvastatin results in decreased activity of TNF; Simvastatin results in decreased activity of TNF protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Guanidines inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL15 mRNA]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] Simvastatin results in decreased expression of TNF mRNA; Simvastatin results in decreased expression of TNF protein Simvastatin results in increased secretion of TNF protein Simvastatin results in decreased secretion of TNF protein Simvastatin affects the secretion of TNF protein |
CTD |
PMID:10946302 PMID:12117737 PMID:12615677 PMID:12753293 PMID:12829860 PMID:12963647 PMID:15187114 PMID:15234187 PMID:15537504 PMID:15705589 PMID:15883752 PMID:16321392 PMID:16387846 PMID:16443229 PMID:16511915 PMID:16740276 PMID:17075836 PMID:17169357 PMID:17178392 PMID:17277159 PMID:17560598 PMID:17729120 PMID:17901590 PMID:18047562 PMID:18310456 PMID:18504409 PMID:19001041 PMID:19024099 PMID:19080365 PMID:19166837 PMID:20126887 PMID:20191585 PMID:20359552 PMID:20863785 PMID:21910007 PMID:21925249 PMID:21994025 PMID:22305382 PMID:30408459 PMID:33774062 PMID:35762198 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
increases expression |
ISO |
Simvastatin results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:21431270 |
|
NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
decreases expression |
EXP |
Simvastatin results in decreased expression of TNFRSF1A mRNA |
CTD |
PMID:18310456 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tnfrsf1b |
tumor necrosis factor receptor superfamily, member 1b |
decreases expression |
EXP |
Simvastatin results in decreased expression of TNFRSF1B mRNA |
CTD |
PMID:18310456 |
|
NCBI chr 4:144,938,938...144,973,453
Ensembl chr 4:144,940,033...144,973,440
|
|
G |
Tnfrsf4 |
tumor necrosis factor receptor superfamily, member 4 |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein] Simvastatin results in decreased expression of TNFRSF4 mRNA; Simvastatin results in decreased expression of TNFRSF4 protein |
CTD |
PMID:19589242 |
|
NCBI chr 4:156,098,049...156,101,070
Ensembl chr 4:156,098,300...156,101,069
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
multiple interactions increases response to substance |
ISO |
[Simvastatin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein] TNFSF10 protein results in increased susceptibility to Simvastatin |
CTD |
PMID:21910007 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
G |
Tnfsf4 |
tumor necrosis factor (ligand) superfamily, member 4 |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein] Simvastatin results in decreased expression of TNFSF4 mRNA; Simvastatin results in decreased expression of TNFSF4 protein |
CTD |
PMID:19589242 |
|
NCBI chr 1:161,223,009...161,245,777
Ensembl chr 1:161,222,980...161,245,981
|
|
G |
Tnni3 |
troponin I, cardiac 3 |
multiple interactions |
ISO |
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein] |
CTD |
PMID:35762198 |
|
NCBI chr 7:4,521,304...4,526,228
Ensembl chr 7:4,521,304...4,527,228
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of TPT1 protein |
CTD |
PMID:20217863 |
|
NCBI chr14:76,082,771...76,085,743
Ensembl chr14:76,082,533...76,085,965
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
decreases expression |
ISO |
Simvastatin results in decreased expression of TRADD mRNA |
CTD |
PMID:17277159 |
|
NCBI chr 8:105,985,207...105,991,226
Ensembl chr 8:105,984,918...105,991,241
|
|
G |
Traf2 |
TNF receptor-associated factor 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of TRAF2 mRNA |
CTD |
PMID:17277159 |
|
NCBI chr 2:25,407,994...25,436,952
Ensembl chr 2:25,407,994...25,436,952
|
|
G |
Trf |
transferrin |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [TNF results in increased expression of TF] |
CTD |
PMID:12753293 |
|
NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643
|
|
G |
Trim63 |
tripartite motif-containing 63 |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of TRIM63 mRNA Simvastatin results in increased expression of TRIM63 mRNA; Simvastatin results in increased expression of TRIM63 protein FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA] |
CTD |
PMID:19001041 PMID:27734117 PMID:33034787 |
|
NCBI chr 4:134,042,431...134,056,940
Ensembl chr 4:134,042,431...134,056,940
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions increases phosphorylation increases expression |
ISO |
pifithrin inhibits the reaction [Simvastatin results in increased expression of TP53 protein]; Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter]; Simvastatin results in increased expression of and results in increased phosphorylation of TP53 protein Simvastatin results in increased phosphorylation of TP53 protein Simvastatin results in increased expression of TP53 mRNA; Simvastatin results in increased expression of TP53 mutant form; Simvastatin results in increased expression of TP53 protein |
CTD |
PMID:15625077 PMID:18804536 PMID:20045437 PMID:21199873 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of TXNRD1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
|
|
G |
Tyms |
thymidylate synthase |
decreases expression |
ISO |
Simvastatin results in decreased expression of TYMS mRNA; Simvastatin results in decreased expression of TYMS protein |
CTD |
PMID:17428261 |
|
NCBI chr 5:30,243,544...30,279,261
Ensembl chr 5:30,263,200...30,278,615
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
decreases phosphorylation |
EXP |
Simvastatin results in decreased phosphorylation of VASP protein |
CTD |
PMID:19332549 |
|
NCBI chr 7:18,990,854...19,005,779
Ensembl chr 7:18,990,854...19,005,742
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]; Simvastatin promotes the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in decreased expression of VCAM1 protein]; Simvastatin promotes the reaction [ethinyl estradiol-desogestrel combination results in decreased expression of VCAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of VCAM1 protein modified form] Simvastatin results in decreased expression of VCAM1 mRNA; Simvastatin results in decreased expression of VCAM1 protein; Simvastatin results in decreased expression of VCAM1 protein modified form |
CTD |
PMID:10946302 PMID:14602771 PMID:15234187 PMID:17105841 PMID:17169357 PMID:18269829 PMID:18309148 PMID:20863785 PMID:21874229 PMID:22245985 More...
|
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
G |
Vcl |
vinculin |
affects localization |
ISO |
Simvastatin affects the localization of VCL protein |
CTD |
PMID:22306966 |
|
NCBI chr14:20,979,436...21,083,744
Ensembl chr14:20,979,466...21,083,744
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of VDAC1 protein |
CTD |
PMID:20217863 |
|
NCBI chr11:52,251,905...52,280,224
Ensembl chr11:52,251,687...52,280,224
|
|
G |
Vdr |
vitamin D (1,25-dihydroxyvitamin D3) receptor |
increases expression |
EXP |
Simvastatin results in increased expression of VDR mRNA |
CTD |
PMID:19262002 |
|
NCBI chr15:97,752,308...97,806,177
Ensembl chr15:97,752,306...97,808,511
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases expression increases expression increases secretion |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of VEGFA protein] Simvastatin results in decreased expression of VEGFA protein Simvastatin results in increased expression of VEGFA; Simvastatin results in increased expression of VEGFA mRNA Simvastatin results in increased secretion of VEGFA protein Simvastatin results in increased expression of VEGFA mRNA; Simvastatin results in increased expression of VEGFA protein Simvastatin inhibits the reaction [Glucose results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of VEGFA protein] |
CTD |
PMID:15572054 PMID:16424782 PMID:17277159 PMID:18316203 PMID:18356691 PMID:18569938 PMID:20381859 PMID:20687301 PMID:20821229 PMID:21211366 More...
|
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vim |
vimentin |
decreases expression |
EXP ISO |
Simvastatin results in decreased expression of VIM protein |
CTD |
PMID:14973129 PMID:15855201 |
|
NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637
|
|
G |
Vwf |
Von Willebrand factor |
increases expression |
ISO |
Simvastatin results in increased expression of VWF mRNA; Simvastatin results in increased expression of VWF protein |
CTD |
PMID:19109527 |
|
NCBI chr 6:125,529,911...125,663,642
Ensembl chr 6:125,523,737...125,663,642
|
|
G |
Wnt4 |
wingless-type MMTV integration site family, member 4 |
multiple interactions increases expression |
ISO |
Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT4 mRNA] Simvastatin results in increased expression of WNT4 protein |
CTD |
PMID:18004065 |
|
NCBI chr 4:137,004,946...137,026,812
Ensembl chr 4:137,004,800...137,027,037
|
|
G |
Wnt5a |
wingless-type MMTV integration site family, member 5A |
multiple interactions increases expression |
ISO |
Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT5A mRNA] Simvastatin results in increased expression of WNT5A mRNA; Simvastatin results in increased expression of WNT5A protein |
CTD |
PMID:18004065 PMID:19968183 |
|
NCBI chr14:28,224,962...28,249,405
Ensembl chr14:28,226,707...28,249,405
|
|
G |
Xbp1 |
X-box binding protein 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of XBP1 protein |
CTD |
PMID:18807172 |
|
NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
EXP |
Simvastatin results in decreased expression of XIAP mRNA; Simvastatin results in decreased expression of XIAP protein |
CTD |
PMID:19262002 |
|
NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533
|
|
G |
Zfp810 |
zinc finger protein 810 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ZFP810 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 9:22,188,044...22,218,973
Ensembl chr 9:22,188,044...22,218,944
|
|
G |
Zfp997 |
zinc finger protein 997 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCL5 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr13:66,258,188...66,271,523
Ensembl chr13:66,261,294...66,271,953
|
|